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Summary 
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality 
worldwide. Because current treatment options for HCC are capable of providing good survival 
rates to only a small subset of patients, innovative therapeutic strategies are urgently required. 
The endoplasmic reticulum (ER) is responsible for protein translocation, folding mediated by a 
machinery of molecular chaperones, and post-translational modifications that allow further 
transport of proteins to the Golgi apparatus. Protein folding and modification in the ER is highly 
sensitive to disturbances of homeostasis. Accumulation of unfolded proteins in the ER lumen, 
termed ER stress, activates intracellular signalling pathways to resolve the protein-folding 
defects. This unfolded protein response (UPR) increases the protein-folding capacity, reduces 
global protein synthesis and stimulates the ER-associated protein degradation. Three major ER 
stress transducers regulating the UPR have been identified: PKR-like endoplasmic reticulum 
kinase (PERK), inositol-requiring enzyme-1 (IRE1) and activating transcription factor 6 
(ATF6). Paradoxically, if ER stress is too severe or persistent, numerous apoptotic signalling 
pathways are activated. The UPR has been implicated in a variety of diseases including 
metabolic diseases, neurodegenerative diseases, inflammatory diseases and cancer. Recently, 
UPR activation was shown in human HCC samples. Given the dichotomy in outcomes of UPR 
activation, it remains unclear whether a window exists in which manipulation of the UPR can 
be harnessed therapeutically. Thus, it is crucial to develop a precise understanding of the signal 
transduction in the UPR. 
The present work focused on the exact role and therapeutic potential of ER stress and the UPR 
in hepatocarcinogenesis, which starts from the initial genotoxic insult, through the clonal 
expansion from a premalignant to a tumoural lesion (promotion) and finally to tumour 
progression. 
First, we sequentially monitored the UPR over time in a commonly used orthotopic mouse 
model for HCC induced by 30 weeks of the carcinogen diethylnitrosamine and explored the 
effects of UPR modulation on cell viability and proliferation in vitro and in the mouse model. 
We observed that the expression of ER-resident chaperones peaked during tumour initiation 
and increased further during tumour progression, predominantly within the nodules. A peak in 
Ire1 signalling was observed early during tumour initiation. The Perk pathway was activated 
during tumour progression. The Atf6 pathway was modestly activated only after tumour 
initiation. Consistent with the UPR activation, electron microscopy demonstrated ER expansion 
and reorganization in isolated HCC cells in vivo.  
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Strikingly, under ER stress or hypoxia, the Perk inhibitor and not the Ire1 inhibitor reduced cell 
viability via escalating proteotoxic stress. Importantly, the Perk inhibitor significantly 
decreased tumour burden in the mouse model. Thus, we provided the first evaluation of the 
UPR dynamics in a long-term cancer model and identified a small molecule Perk inhibitor as a 
new strategy for HCC therapy. However, the antitumour effect of this inhibitor was modest and 
we found induction of hyperglycaemia in the mice treated with the Perk inhibitor, confirming 
the essential role of Perk in insulin biosynthesis. 
Secondly, we assessed the impact of ER stress in tumour initiation and progression by applying 
tauroursodeoxycholic acid (TUDCA), a bile acid with chaperone properties reducing ER stress, 
in the diethylnitrosamine-induced HCC model in preventive and therapeutic settings. 
Administration of TUDCA in the preventive setting reduced carcinogen-induced elevation of 
liver enzyme levels, apoptosis of hepatocytes and tumour burden. TUDCA also suppressed 
carcinogen-induced pro-apoptotic UPR. Furthermore, TUDCA administration after tumour 
development did not alter orthotopic tumour or HepG2 xenograft growth. Thus, these results 
identified the UPR as a key pathway in hepatocarcinogenesis and showed that TUDCA 
attenuates hepatocarcinogenesis by suppressing carcinogen-induced ER stress-mediated cell 
death without stimulating tumour progression. Therefore, this chemical chaperone could 
represent a novel chemopreventive agent. 
Thirdly, we assessed the effect of established or potential HCC treatments possibly modulating 
the UPR, including sorafenib, artesunate, PlGF inhibition and proteasome inhibition, on the 
tumour growth and UPR signature in HCC. Sorafenib, a multi-kinase inhibitor, is currently the 
only drug available for the treatment of advanced HCC, but effects are limited. Given the 
importance of the UPR and UPR-induced autophagy in HCC, we questioned whether the use 
of rationally designed combinations of sorafenib with clinically applicable modulators of the 
UPR and autophagy would be more effective than sorafenib monotherapy. We found that 
sorafenib activated the UPR and autophagy in HCC cells. Furthermore, sorafenib-mediated 
reduction in tumour cell proliferation was dependent on proteotoxicity and IRE1 RNase 
activity. Targeting of the UPR or autophagy separately did not enhance the antitumour efficacy 
of sorafenib. However, the combination with an ER stress inducer and an inhibitor of adaptive 
protein refolding or autophagy potentiated the efficacy. Thus, triple therapies of sorafenib with 
inducers of ER stress and inhibitors of autophagy seem to enhance the antitumour potential of 
sorafenib. 
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Artemisinins are antimalarial drugs that exert anticancer activity, possibly by inducing ER 
stress. We evaluated the effects of artesunate, a semisynthetic derivative of artemisinin, on 
tumour growth, angiogenesis and the UPR in HCC. We found that artesunate dose dependently 
reduced cell viability in different HCC cells. These effects were enhanced by hypoxia. In mice, 
artesunate decreased vessel density and tumour burden. These in-vivo effects were enhanced 
by combination with sorafenib. Furthermore, artesunate modulated the UPR in vitro and in vivo, 
increasing proapoptotic signalling. Thus, clinical trials with artesunate as monotherapy or in 
combination with current hypoxia-inducing approaches are necessary. Therefore, we initiated 
a phase I dose-escalation study evaluating the safety and pharmacokinetics of oral artesunate in 
patients with advanced HCC (DESPARTH trial). 
We previously showed that the inhibition of placental growth factor (PlGF) exerts antitumour 
effects and induces vessel normalisation, possibly reducing hypoxia. However, the exact 
mechanism underlying these effects remains unclear. Because hypoxia and ER stress have been 
implicated in HCC progression, we assessed the interactions between PlGF and these 
microenvironmental stresses. Both the genetic and pharmacological inhibitions of PlGF 
reduced the chaperone levels and the activation of the PERK pathway in experimental HCC. 
We identified that tumour hypoxia was attenuated. Furthermore, hypoxic exposure activated 
the PERK pathway in vitro, suggesting PlGF inhibition may diminish PERK activation by 
improving oxygen delivery via vessel normalisation. 
The first-in-class proteasome inhibitor bortezomib has been approved in clinical use against 
hematologic malignancies and has shown modest activity in a variety of solid tumours. 
However, a considerable proportion of subjects fail to respond to bortezomib and have adverse 
events. Recently, the next-generation orally bioavailable proteasome inhibitor oprozomib was 
developed. Oprozomib dose dependently reduced viability and proliferation of human HCC 
cells. The effect of oprozomib on the UPR pattern was dual: oprozomib inhibited the 
cytoprotective transcriptional program of ATF6 but increased the pro-apoptotic UPR-mediated 
protein levels by prolonging protein half-life. Oral oprozomib displayed antitumour effects in 
the HCC models. Importantly, combination of oprozomib with PERK activators stimulating 
CHOP induction improved the antitumour efficacy compared to oprozomib monotherapy 
without cumulative toxicity. 
In conclusion, the UPR seems to be involved in the different steps of hepatocarcinogenesis and 
HCC survival under tumour microenvironmental stress. Consequently, chemopreventive and 
therapeutic targeting of the UPR holds significant potential in HCC. 
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Samenvatting 
Hepatocellulair carcinoom (HCC) is wereldwijd de 2de belangrijkste oorzaak van kanker-
gerelateerde mortaliteit. Aangezien de huidige behandelingsopties slechts voor een klein deel 
van de patiënten goede overlevingskansen bieden is er een dringende nood aan innovatieve 
behandelingen. 
Het endoplasmatisch reticulum (ER) is verantwoordelijk voor eiwittranslocatie, opvouwing en 
post-translationele modificaties. Vervolgens worden de mature eiwitten na een 
kwaliteitscontrole verder getransporteerd naar het Golgi apparaat. Eiwitopvouwing is gevoelig 
aan stress in de cellulaire micro-omgeving en accumulatie van ongevouwen eiwitten in het ER 
lumen, een status die ER stress wordt genoemd, activeert intracellulaire signaalwegen die 
trachten de eiwithomeostase in het ER te herstellen. Deze “unfolded protein response” (UPR) 
verhoogt de eiwitopvouwingscapaciteit, vermindert de globale eiwitsynthese en stimuleert de 
ER-geassocieerde eiwitafbraak. Binnen de UPR zijn er drie voorname ER stress transducers 
geïdentificeerd: inositol-requiring enzyme-1 (IRE1), PKR-like endoplasmic reticulum kinase 
(PERK) en activating transcription factor 6 (ATF6). Echter, als de ER stress te ernstig of 
persistent is, wordt apoptose geïnitieerd. De UPR is betrokken bij diverse pathologieën, 
waaronder metabole, neurodegeneratieve en inflammatoire pathologieën, maar ook bij kanker. 
Zo werd recent UPR activatie in humane HCC stalen aangetoond. Aangezien de UPR kan leiden 
tot paradoxale effecten op celoverleving is het onduidelijk of er een therapeutisch venster 
bestaat waarbij UPR manipulatie kan worden aangewend in kankerbehandeling of -preventie. 
Hiervoor is een adequaat inzicht van de UPR signaaltransductie tijdens de verschillende stappen 
van de carcinogenese van essentieel belang. 
Hepatocarcinogenese begint met de eerste genotoxische schade, gevolgd door klonale expansie 
van een premaligne naar een maligne laesie (tumorpromotie) en finaal tot tumorprogressie. 
Deze studie focust op de rol en het therapeutisch potentieel van ER stress en de UPR in de 
hepatocarcinogenese. 
Vooreerst hebben we de UPR dynamiek gemonitord in de tijd in een orthotoop muismodel 
geïnduceerd door toediening van het carcinogeen diethylnitrosamine. Vervolgens hebben we 
de effecten van UPR-modulatie op de viabiliteit en proliferatie van HCC cellen in vitro en in 
het desbetreffende muismodel onderzocht. Hierbij stelden we vast dat de expressie van ER-
residente chaperones piekte tijdens tumorinitiatie en verder toenam tijdens tumorprogressie. 
Tijdens tumorinitiatie werd eveneens een piek in het Ire1 signaal waargenomen.  
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De Perk pathway werd geactiveerd tijdens tumorprogressie. De Atf6 pathway werd mild 
geactiveerd na tumorinitiatie. Elektronenmicroscopie identificeerde ER expansie en 
reorganisatie, ultrastructurele kenmerken van ER stress, in HCC cellen in vivo. Verder werd er 
vastgesteld dat bij ER stress of hypoxie, de Perk inhibitor en niet de Ire1 inhibitor de 
celviabiliteit via escalerende proteotoxiciteit verminderde. Toediening van de Perk inhibitor 
reduceerde de tumorgroei. Kortom, deze studie leidde tot de eerste evaluatie van de UPR 
dynamiek in een kankermodel geïnduceerd door chronische carcinogeenexpositie en 
identificeerde de Perk inhibitor als een potentiële therapeutische strategie. Echter, het 
antitumoraal effect van deze inhibitor was beperkt en we detecteerden inductie van diabetes 
door de Perk inhibitor. 
Ten tweede hebben we de impact van ER stress op tumorinitiatie en -progressie geanalyseerd 
door het toepassen van tauroursodeoxycholic acid of kortweg TUDCA, een galzuur met 
chaperone eigenschappen die ER stress antagoneert, in het HCC model in de preventieve en 
therapeutische setting. TUDCA toediening in de preventieve setting reduceerde de carcinogeen-
geïnduceerde leverenzymen, incidentie van apoptotische hepatocyten, pro-apoptotische UPR 
signalisatie en tumorlast. TUDCA toediening na tumorontwikkeling daarentegen had geen 
effect op de tumorgroei. Deze resultaten identificeerden de UPR als een belangrijke as in 
hepatocarcinogenese en toonden aan dat TUDCA hepatocarcinogenese reduceert door 
onderdrukking van carcinogeen-geïnduceerd UPR-gemedieerde apoptose zonder stimulatie van 
tumorprogressie. Hierdoor kan dit chemisch chaperone als een nieuw chemopreventief agens 
worden beschouwd. 
Ten derde onderzochten we het effect van erkende of potentiële HCC behandelingen die 
mogelijks de UPR moduleren. Hierbij includeerden we sorafenib, artesunaat, PlGF inhibitie en 
proteasoom inhibitie en onderzochten we het effect van deze op de tumorgroei en het UPR 
patroon in HCC. Sorafenib, een multi-kinase inhibitor, is momenteel het enige geneesmiddel 
beschikbaar voor gevorderd HCC. Echter is het overlevingsvoordeel door sorafenib beperkt tot 
enkele maanden. Gezien het belang van de UPR en autofagie, een katabool proces waarbij 
subcellulaire componenten via lysosomale enzymen worden afgebroken, vroegen we ons af of 
het gebruik van rationeel gedesignde combinaties van sorafenib met klinisch toepasbare 
modulators van de UPR en/of autofagie effectiever zou zijn dan sorafenib monotherapie. We 
stelden vast dat sorafenib de UPR en UPR-geïnduceerde autofagie activeert in HCC cellen en 
dat de sorafenib-gemedieerde reductie in cellulaire proliferatie afhankelijk is van 
proteotoxiciteit en IRE1. Inhibitie van de UPR of autofagie afzonderlijk verbeterde het anti-
tumor effect van sorafenib echter niet. 
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Maar combinatie van een ER stress inductor samen met een remmer van adaptieve 
heropvouwing of autofagie versterkte het effect van sorafenib. 
Artemisinines zijn antimalariamiddelen die een antitumoraal effect blijken te hebben in 
verschillende kankertypes, eventueel door inductie van ER stress. We evalueerden de effecten 
van artesunaat, een semi-synthetisch derivaat van artemisinine, op tumorgroei, angiogenese en 
de UPR in HCC. We vonden dat artesunaat dosisafhankelijk de viabiliteit van HCC cellen 
verminderde en dat deze effecten bovendien werden versterkt door hypoxie. Artesunaat 
verminderde tevens de bloedvatdensiteit en tumorlast in vivo. Hetgeen werd versterkt in 
combinatie met sorafenib. Verder moduleerde artesunaat de UPR waardoor pro-apoptotische 
UPR signalering optrad. Bijgevolg lijken klinische studies met artesunaat als monotherapie of 
in combinatie met huidige hypoxie-inducerende behandelingen aangewezen. Daarom zijn we 
gestart met een fase I dosisescalatie studie ter evaluatie van de veiligheid en farmacokinetiek 
van oraal artesunaat bij HCC patiënten (DESPARTH trial). 
We toonden eerder aan dat inhibitie van de placentale groeifactor (PlGF) bloedvatnormalisatie 
en antitumorale effecten induceert. Het onderliggend mechanisme is echter onduidelijk. Omdat 
hypoxie en ER stress betrokken blijken bij HCC, onderzochten we de interacties tussen PlGF 
en deze stressoren. Zowel genetische als farmacologische PlGF inhibitie onderdrukte de 
chaperones en Perk pathway in HCC. We identificeerden dat PlGF inhibitie tumorhypoxie 
tempert en dat hypoxie de PERK pathway activeert, wat erop wijst dat PlGF inhibitie de Perk 
activatie reduceert door verbeterde zuurstofvoorziening via bloedvatnormalisatie. 
De first-in-class proteasoominhibitor bortezomib is in klinisch gebruik bij hematologische 
maligniteiten en heeft een bescheiden activiteit aangetoond in verschillende solide tumoren. 
Echter, een aanzienlijk deel van patiënten reageren niet op bortezomib en hebben majeure 
bijwerkingen. Recent werd de next-generation proteasoominhibitor oprozomib ontwikkeld.  
Oprozomib verminderde de proliferatie van HCC cellen op een dosisafhankelijke manier. Het 
effect van oprozomib op het UPR patroon was tweeledig: oprozomib remde het cytoprotectief 
transcriptioneel programma van ATF6, maar verhoogde de pro-apoptotische UPR-gemedieerde 
eiwitniveaus door verlengde halfwaardetijd. Oraal oprozomib reduceerde de tumorgroei in vivo. 
Combinatie van oprozomib met PERK activatoren verbeterde de werkzaamheid in vergelijking 
met oprozomib monotherapie zonder cumulatieve toxiciteit. 
We besluiten dat de UPR betrokken is bij verschillende stappen van hepatocarcinogenese en de 
overleving van HCC cellen in de stressvolle tumor micro-omgeving. Bijgevolg heeft het 
chemopreventief en therapeutisch manipuleren van de UPR een belangrijk potentieel in HCC.
  
  
General introduction 
Chapter 1 
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 Hepatocellular carcinoma 
1.1. Introduction 
Tumours of the liver are classified as being either primary (originating from the liver) or 
metastatic (spread from another organ to the liver). Primary liver tumours may be further 
divided into those that are benign, which are not cancerous and remain in the liver, or malignant, 
which progress with local expansion, intrahepatic spread and distant metastases [1]. The most 
common primary malignant tumour of the liver is a hepatocellular carcinoma (HCC). HCC 
occurs predominantly in patients with underlying chronic liver disease and cirrhosis [1], [2]. 
 
Figure 1. Large hepatocellular carcinoma. Note the 
heterogeneity within the nodule. Image courtesy of Arief 
Suriawinata, Department of Pathology, Dartmouth 
Medical School, USA. 
1.2. Pathophysiology of hepatocellular carcinoma 
The ratio of cell growth and death is precisely balanced through developmental and homeostatic 
processes in multi-cellular organisms [3]. Sensu stricto, cancer is a genetic disease and the 
genetic alterations that lead to most cancers arise in the DNA of a somatic cell [4]. Because of 
these genetic changes, cancer cells proliferate irrepressibly, producing malignant cells that 
invade surrounding healthy tissue and tend to metastase, that is, to spawn cells that break away 
from the parent mass, enter the lymphatic or vascular circulation, and spread to distant sites in 
the body where they establish metastases that are no longer amenable to surgical resection [2]. 
Chapter 1 
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The hallmarks of cancer comprise biological capabilities acquired during multistep 
carcinogenesis [3]. They include sustaining proliferative signalling, evading growth 
suppressors, resisting cell death, enabling replicative immortality, inducing angiogenesis, 
reprogramming of energy metabolism, evading immune destruction and activating invasion and 
metastasis. Underlying these hallmarks are genome instability, which generates the genetic 
diversity that expedites their acquisition, and inflammation, which fosters multiple hallmarks. 
In addition to cancer cells, tumours exhibit another dimension of complexity: they contain a 
repertoire of recruited, ostensibly normal cells that create the tumour microenvironment. Recent 
evidence suggests that pathophysiologic conditions unique to the tumour microenvironment 
initiate tumour cell stress signals that converge upon the endoplasmic reticulum (ER), resulting 
in a condition termed “ER stress” (see section 2.2) [5]. 
Also hepatocarcinogenesis is a multistep process: the presence of specific risk factors (see 
section 1.4) promotes genotoxicity leading to a cascade of molecular and cellular deregulations 
that ultimately result in malignant transformation of hepatocytes and generally develops within 
liver cirrhosis related to various aetiologies [1], [2]. In cirrhosis, precancerous dysplastic 
macronodules transform into early HCCs that evolve into small and progressed HCCs, and 
finally lead to advanced HCC [6], [7]. In rare cases, HCC develops in a normal liver, with some 
of these tumours potentially resulting from malignant transformation of hepatocellular 
adenomas [8]. 
High-resolution analyses have depicted the molecular heterogeneity of HCC [9]. A broad 
variety of pathways activated in HCC have been reported including the Wnt/β-catenin, 
Ras/MAPK, insulin-like growth factor, PI3K/Akt/mammalian target of rapamycin (mTOR), 
vascular endothelial growth factor (VEGF), hepatocyte growth factor/cMET signalling among 
many others [4]. Depending on the specific alterations, distinct molecular subclasses have been 
defined (see section 1.6) [10]. 
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Furthermore, several structural alterations have been characterized. Recent studies identiﬁed 
an average of 30-40 mutations per tumour, among which 6–8 are considered oncogenic drivers 
[11]. Mutations in TERT (60%, telomere stability), TP53 (30%, genome integrity guardian), 
CTNNB1 (25%, Wnt signalling), NFE2L2 (6-10%, oxidative stress) and ARID1A (10-16%, 
chromatin remodelling) and high-level amplifications in 11q13 (7%) and 6p21 (5%, contains 
VEGF) are the most relevant ones [4], [10]. Another study identified 161 putative driver genes 
associated with 11 recurrently altered pathways [9]. Associations of mutations defined 3 groups 
of genes related to aetiology. However, no oncogenic addiction loop for any driver has been 
deﬁned in HCC. Intriguingly, well-known genes commonly mutated in other solid tumours such 
as EGFR, PIK3CA or KRAS are rarely mutated in HCC [11]. 
Next to the structural alterations, several prognostic mRNA-based molecular signatures from 
tumour tissue have been reported [12], [13]. Signatures identifying progenitor cell-like and/or 
cholangiocyte proﬁle (EPCAM signature3, CK19 signature) show worse prognosis [13]. 
Likewise, a 5-gene score signature (TAF9, RAN, RAMP3, KRT19, HN1) predicted overall 
survival in four independent cohorts [14]. However, there is significant intratumour 
heterogeneity (Figure 1) leading to an underestimation of the tumour genomics landscape 
portrayed from single tumour biopsy [15]. 
In conclusion, the interindividual and intratumour heterogeneity, biological redundancies and 
presence of several growth factors and cytokines potentially involved in HCC progression make 
it extremely difficult to select the best genetic target for therapy and stimulated us to target other 
hallmarks of cancer, such as angiogenesis or effect of peritumoural microenvironmental stress. 
1.3. Epidemiology of hepatocellular carcinoma 
HCC is the fifth most common cancer in men (554,000 cases, 7.5% of total cancer incidence) 
and the ninth in women (228,000 cases, 3.4%) [16]. HCC has a strong male preponderance with 
a male to female ratio estimated to be 2.4, which is partially explained by the protective role of 
oestrogens and HCC-promoting effects of androgens [17]. It is mainly a problem of the less 
developed regions where 83% of the estimated 782,000 new cases worldwide occurred in 2012. 
In men, high incidence regions are Eastern and South-Eastern Asia (age-standardised rates: 31.9 
and 22.2 resp.). Intermediate rates occur in Southern Europe (9.5) and Northern America (9.3) 
and the lowest rates are in Northern Europe (4.6). 
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HCC is the second leading cause of cancer-related mortality worldwide, estimated to be 
responsible for nearly 746,000 deaths in 2012 (9.1% of total cancer-related mortality) [16]. 
The prognosis is very poor (overall ratio of mortality to incidence of 0.95). The incidence 
increases progressively with advancing age in all populations, reaching a peak at 70 years. 
Unfortunately, HCC is one of the cancers with a still increasing incidence rate [18], [19]. 
 
 
Figure 2. Estimated liver cancer incidence worldwide in 2012: men. Estimated age-
standardised rates per 100,000 [16]. 
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1.4. Aetiology of hepatocellular carcinoma 
Hepatitis viral infection (hepatitis B (HBV) and C (HCV)), chronic alcohol abuse and non-
alcoholic steatohepatitis (NASH) are the major risk factors of liver cirrhosis and cancer [1]. 
Other risk factors include fungal aflatoxin B1 exposure, hemochromatosis, α-1-antitrypsin 
deficiency and tyrosinaemia [2]. Worldwide, 54% of HCC cases can be attributed to HBV 
infection (which affects 400 million people globally), while 31% can be attributed to HCV 
infection (which affects 170 million people), leaving 15% to other aetiologies. In Africa and 
East Asia, the largest attributable fraction is due to HBV (60%) whereas in the Western world, 
only 20% of cases can be attributed to HBV, while chronic HCV and alcohol consumption 
appear to be the major risk factors (Table 1) [20]. Recently, great advances in HCV therapies 
were made. For more information, please see our review concerning ‘New therapies for 
hepatitis C’ (YP. Vandewynckel et al., Tijdschr. voor Geneeskunde, 2014). Long-term follow-
up studies have demonstrated that 1-8% of cirrhotic patients per year develop HCC [21]. 
Ultimately, one-third of cirrhotic patients will develop HCC during their lifetime [22]. In 
general, liver disease severity, age and male gender correlate with HCC development among 
cirrhotic patients [23]. Since risk factors are well known, prevention by risk factor reduction is 
an achievable objective. Control of HBV and HCV, as well as reduction in alcohol consumption 
is recommended [24]. While health plans are implemented to achieve this goal, the epidemic of 
overweight and metabolic syndrome leading to NASH-induced HCC has emerged as a 
significant risk factor [25]. Alternatively, development of chemopreventive agents could 
drastically reduce HCC mortality [26]. However, randomized controlled chemoprevention trials 
are logistically and ethically challenging. 
Table 1. Geographical distribution of main risk factors 
for hepatocellular carcinoma worldwide. 
 
AAIR, age-adjusted incidence rate. Adapted from [1]. 
Chapter 1 
20 
1.5. Diagnosis of hepatocellular carcinoma 
Diagnosis of HCC is based on the diagnostic algorithm in Figure 4 [1]. In cirrhotic patients, 
nodules less than 1 cm in diameter detected by ultrasound should be followed every 4 months 
the first year and every 6 months thereafter. In cirrhotic patients, diagnosis of HCC for nodules 
of 1-2 cm should be based on non-invasive criteria or biopsy-proven pathological confirmation. 
In cirrhotic patients, nodules more than 2 cm can be diagnosed for HCC based on typical 
features on one imaging technique. In case of uncertainty or atypical radiological findings, 
diagnosis should be confirmed by biopsy. 
Pathological diagnosis is based on the recommendations of the International Consensus Panel 
[6]. Non-invasive criteria can only be applied to cirrhotic patients and are based on imaging 
techniques obtained by 4-phase multidetector CT or dynamic contrast-enhanced MRI [1]. 
Diagnosis is based on the typical hallmark of HCC, i.e. hypervascular in the arterial phase 
with washout in the portal venous or late phases (see section 4.1). 
 
Figure 4. Diagnostic algorithm for hepatocellular carcinoma. **HCC radiological hallmark: 
arterial hypervascularity and venous/late phase wash-out. Adapted from [1]. 
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1.6. Treatment of hepatocellular carcinoma 
The Barcelona-Clinic Liver Cancer (BCLC) staging system is recommended for prognostic 
prediction and treatment allocation [1]. The BCLC classification divides HCC patients in 5 
stages (0, A, B, C and D) according to pre-established prognostic variables and allocates 
therapies according to treatment-related status (Fig. 5). Prognosis prediction is defined by 
variables related to tumour status (size, number, vascular invasion, N1, M1), liver function 
(Child–Pugh's) and performance status of the patient (ECOG). Treatment allocation 
incorporates treatment dependant variables, which have been shown to influence therapeutic 
outcome, such as bilirubin, portal hypertension or presence of symptoms. 
 
Figure 5. BCLC staging system and treatment strategy. Adapted from [1]. 
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Resection is the treatment option for patients with solitary tumours and well-preserved liver 
function, as normal bilirubin with either hepatic venous pressure gradient ≤10 mmHg or platelet 
count ≥100,000. Large tumours are not well served by ablation because long lasting complete 
response in HCC >3 cm is less frequent and recurrence rate is high [27]. However, resection 
may be successful and this is why tumour size does not constitute a contraindication by itself 
[1]. Additional indications for patients with multifocal tumours meeting Milan criteria (≤3 
nodules ≤3 cm) or with mild portal hypertension not suitable for liver transplantation require 
prospective comparisons with loco-regional treatments. Peri-operative mortality of resection in 
cirrhotic patients is expected to be 2-3%. Tumour recurrence represents the major 
complication of resection [28]. In case of recurrence, the patient will be re-assessed by BCLC 
staging and re-treated accordingly [1]. 
If patients present hepatic decompensation, the expected outcome offered by liver 
transplantation, if the Milan criteria are not exceeded, is superior to resection and ablation 
[18]. Peri-operative mortality and one-year mortality are expected to be approximately 3% and 
≤10%, respectively [1]. Modest expansion of the Milan criteria applying the “up-to-seven” in 
patients without microvascular invasion achieves competitive outcomes. 
Local ablation with radiofrequency or percutaneous ethanol injection is considered the 
standard of care for patients with BCLC 0-A tumours not suitable for surgery [1]. 
Chemoembolization is recommended for patients with BCLC B, multinodular asymptomatic 
tumours without vascular invasion or extra-hepatic spread. However, although severe events 
are infrequent, chemoembolization is associated with transient post-embolization syndrome in 
most cases and there is still no standardized protocol for chemoembolization in terms of 
treatment schedule, type and dosage of anti-cancer drug [18]. 
Multiple guidelines have been developed to assist clinicians in HCC management. Though, we 
reported that the methodological quality of guidelines on chemoembolization in HCC 
management is poor [29]. This results in important discrepancies between guideline 
recommendations, creating confusion in clinical practice. Incorporation of the Appraisal of 
Guidelines Research and Evaluation II (AGREE II) instrument in guideline development may 
improve quality of future guidelines by increasing focus on methodological aspects [30]. 
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Conventional chemotherapy, either alone or in combination, administered intravenously or 
intra-arterially, never reached positive results [2]. Based on the positive phase III SHARP trial 
demonstrating a median overall survival of 10.7 months for sorafenib-treated vs. 7.9 months 
for placebo-treated HCC patients [31], sorafenib is the standard systemic therapy for advanced 
HCC. In terms of toxicity, there were more cases of diarrhoea, weight loss, hand-foot skin 
reaction and hypophosphatemia among the patients receiving sorafenib [31]. In addition, we 
reported (YP. Vandewynckel et al. Cerebellar stroke in a low cardiovascular risk patient 
associated with sorafenib treatment for fibrolamellar hepatocellular carcinoma. Clin Case 
Rep. 2014,2,4-6) a case of a 26-year-old man with fibrolamellar HCC, who had a 
cerebrovascular accident while being treated with sorafenib, illustrating a probable relationship 
between the use of sorafenib and vascular adverse effects in low cardiovascular risk patients. 
Sorafenib acts by inhibiting the serine threonine kinases Raf-1 and B-Raf and the receptor 
tyrosine kinase activity of VEGF and platelet-derived growth factor (PDGF) receptors, among 
others [32] and is indicated for patients with well-preserved liver function (Child-Pugh A) and 
with advanced tumours (BCLC C) or those progressing upon loco-regional therapies [1]. To 
date, there are no biomarkers available to identify the best responders and no second-line 
treatment for patients with intolerance or failure to sorafenib. 
Molecular classiﬁcation should aid in understanding the biological subclasses and oncogenic 
drivers and optimize beneﬁts from targeted therapies and enrich trial populations [1], [32]. 
Different molecular classes have been characterized including a Wnt class (25% of cases; 
enriched with CTNNB1 mutations and HCV aetiology), a proliferation/progenitor class (50% 
of cases; worse prognosis; with two subclasses: S1-TGF-β and S2-EpCAM positive) and an 
inﬂammation/interferon class [10], [12]. Nonetheless, no molecular subclass has been reported 
to respond to a speciﬁc targeted therapy. 
Several therapies targeting signalling cascades involved in hepatocarcinogenesis have been 
explored in phase III trials [32]. However, none of the drugs tested have shown positive results 
in the first-line (tyrosine kinase inhibitors (TKI): brivanib, sunitinib, erlotinib and linifanib) or 
second-line (TKI: brivanib and mTOR inhibitor: everolimus) setting after sorafenib progression 
(Table 2). Regorafenib, lenvatinib, cabozantinib and tivantinib are currently being evaluated in 
phase III trials [18]. 
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Reasons for failure are diverse and include lack of understanding of critical drivers of tumour 
progression, liver toxicity or marginal antitumour potency [32]. If targeted therapy is aimed to 
act on speciﬁc targets it would make sense to select patients according to the recognition of the 
pathway to be modulated. This enrichment policy is sound but the challenge is how to properly 
proﬁle the biomarker status. As indicated earlier, HCCs present a marked heterogeneity within 
the same nodule (Figure 1) and across nodules making a single biopsy unlikely to provide an 
accurate proﬁling of the tumour. 
 
Table 2. Randomized phase III clinical trials completed in HCC in ﬁrst and second line (2007–2014). 
(Modiﬁed from [18]) 
 
n.s., not signiﬁcant; TTP, time to progression; OS, overall survival. 
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 Endoplasmic reticulum stress and the unfolded protein response 
2.1. The endoplasmic reticulum: a biosynthetic factory 
The endoplasmic reticulum (ER; Figure 6) is the central organelle in the secretory pathway and 
provides a specialized environment for protein translocation, protein folding by a machinery 
of molecular chaperones and post-translational modifications that allow further transport of 
proteins to the Golgi and ultimately to vesicles for secretion or display on the membrane [33], 
[34]. The rates of protein synthesis, folding and trafficking are precisely coordinated by an 
efficient system termed quality control to ensure that only properly folded proteins exit the 
ER. Misfolded proteins are either retained within the ER or subject to degradation by the 
proteasome-dependent ER-associated protein degradation (ERAD) pathway or by autophagy 
(see section 3). 
Furthermore, the ER is the major site for the synthesis of sterols and phospholipids that 
constitute the bulk of the lipid components of all membranes. The ER, therefore, plays an 
essential role in regulating the lipid composition of membranes, which, in turn, determines the 
biophysical properties and functions of cell membranes [35]. ER membrane expansion 
generally reflects the increased secretory capacity or the accumulation of unfolded proteins in 
the ER [35], [36]. 
Finally, the ER is the main site for storage of intracellular Ca2+. The concentration of Ca2+ in 
the ER lumen can reach ∼5 mM [37]. The majority of ER-luminal Ca2+ is bound to molecular 
chaperones and is essential for their function. 
 
  
Figure 6. Transmission electron microscopy showing the normal morphology of the endoplasmic 
reticulum of a hepatocyte (left) versus the expanded morphology of a hepatocellular carcinoma cell 
(right). 
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2.2. Endoplasmic reticulum stress 
The ER is a highly dynamic organelle and responds to perturbations in its function, a process 
named ER stress, through a series of signalling cascades known as the unfolded protein 
response (UPR) [38]. The UPR is a tightly orchestrated collection of intracellular signal 
transduction reactions designed to cope with misfolded proteins and restore ER proteostasis 
[33], [34]. However, chronic or irremediable ER stress results in cell apoptosis [39]. 
The UPR regulates the size, the shape and the components of the ER machinery to 
accommodate the fluctuating demands on protein folding, as well as other ER functions in 
coordination with different physiological and pathological conditions [40].  
Recent studies on the integration of the UPR with metabolic stress, oxidative stress and 
inflammatory signalling highlight new insights into the diverse cellular processes regulated by 
the UPR [41], [42]. For example, UPR signalling was shown to intersect at many levels with 
the innate and adaptive immune responses [42]. 
Three canonical UPR branches have been identified: inositol-requiring protein-1α (IRE1), 
protein kinase RNA (PKR)-like ER kinase (PERK) and activating transcription factor 6 
(ATF6). Next to the canonical UPR, the OASIS family represents a group of additional ER 
stress transducers and UPR regulators [43]. These ER membrane-bound sensors operate in 
parallel and use unique mechanisms of signal transduction. The IRE1 branch is the most 
conserved and sole branch of the UPR in lower eukaryotes [44]. Evolution later added the 
PERK and ATF6 branches to metazoan cells. 
Under physiological conditions, the luminal domains of PERK and ATF6 are bound to the ER-
resident chaperone Binding immunoglobulin Protein or glucose-regulated protein, 78 kDa (BiP 
or GRP78), which keeps them inactive [34]. When unfolded proteins accumulate in the ER, 
GRP78 binds with high affinity to the exposed hydrophobic regions of the unfolded proteins 
and is thereby released from these complexes to assist with the folding of accumulated proteins. 
Upon activation, PERK, IRE1 and ATF6 induce signal transduction that alleviate the 
accumulation of misfolded proteins by increasing expression of ER chaperones, inhibiting 
protein entry into the ER by arresting global mRNA translation and stimulating retrograde 
transport of misfolded proteins from the ER into the cytosol for ubiquitination and destruction 
by ERAD [45]. Under conditions when ER stress is chronically prolonged and the protein load 
on the ER greatly exceeds its folding capacity, cellular dysfunction and UPR-mediated 
apoptosis occur [33]. 
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Among the UPR pathways IRE1 is a key molecule that functions as a rheostat regulating cell 
fate upon ER stress [38]. The alternative outputs from IRE1-mediated downstream signalling 
dictate opposing cell fates (survival versus death) during ER stress, which are critically 
influenced by the intensity and longevity of ER stress [34]. IRE1 is a transmembrane protein 
that consists of an N-terminal luminal sensor domain, a transmembrane domain and a C-
terminal cytosolic effector that is responsible for both protein kinase and endoribonuclease 
activities [38]. Accumulation of unfolded proteins in the ER triggers oligomerization and 
autophosphorylation. The RNase mediates splicing of an intron from the X-box-binding 
protein-1 (XBP1) mRNA to allow production of the spliced XBP1 (XBP1s) protein, which is a 
stronger transcription factor compared to unspliced XBP1 (XBP1u) protein. Notably, XBP1u 
is not the only mRNA targeted by the IRE1 RNase [46]. For example, IRE1 also controls its 
own expression by cleaving its own mRNA. The XBP1s protein binds to promoters of several 
genes involved in the UPR and ERAD to restore proteostasis [47]. In addition to its 
cytoprotective function, IRE1 also stimulates activation of the apoptotic-signalling kinase-1 
(ASK1), which causes activation downstream of stress kinases Jun-N-terminal kinase (JNK) 
and p38 MAPK that promote apoptosis. Among the apoptosis-inducing substrates of JNK are 
Bcl-2 and Bim, which are inhibited and activated, respectively, by JNK [33]. Also, p38 MAPK 
phosphorylates and activates the transcription factor C/EBP homologous protein (CHOP), 
which leads to major changes in gene expression that favour cell apoptosis, including increasing 
expression of Bim and DR5, while decreasing expression of Bcl-2 [48]. Recently, regulated 
IRE1-dependent decay of mRNA (RIDD) was shown to reduce ER localized mRNAs [46]. 
RIDD selectively targets and degrades mRNAs encoding proteins involved in protein folding. 
Prolonged RIDD can promote cell death, but its exact role is currently not well understood. 
ATF6 is a transcriptional factor that upon ER stress translocates to the Golgi where it is cleaved 
by the action of two proteases: the serine protease site-1 (S1P) cleaves ATF6 in the luminal 
domain, while the N-terminal portion is subsequently cleaved by the site-2 protease (S2P) [34]. 
The cleaved N-terminal cytosolic domain of ATF6 subsequently translocates into the nucleus 
where it binds to ATF/cAMP-response elements and ER stress-response elements to activate 
target genes, such as chaperones GRP78, PDIA4, GRP94 but also CHOP [49]. 
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When activated upon sensing ER stress, PERK oligomerizes and phosphorylates itself and the 
α subunit of eukaryotic translation initiation factor 2 (eIF2α), inactivating eIF2α and inhibiting 
global mRNA translation. Phosphorylation of eIF2α inhibits the recycling of eIF2α to its active 
GTP-bound form, which is required for the initiation of polypeptide chain synthesis [33]. 
Thereby, PERK prevents influx of de novo synthesized proteins into the stressed ER providing 
a time frame to restore ER function [50]. However, some mRNAs containing short open reading 
frames in their 5’-untranslated regions are preferentially translated when eIF2α is limiting. One 
of these encodes the activating transcription factor 4 (ATF4), whose translation is thus induced 
upon eIF2α phosphorylation. Two important target genes driven by ATF4 are the proapoptotic 
CHOP and growth arrest and DNA damage–inducible 34 (GADD34) [51]. Thus, the PERK 
pathway is strongly protective at modest levels of signalling but, paradoxically, can contribute 
signals to apoptosis [33]. This dualism is likely played out at the level of eIF2α. GADD34 
encodes a regulatory subunit of protein phosphatase 1C that dephosphorylates eIF2α. Selective 
inhibition of the GADD34-PP1c complex, either by salubrinal or GADD34 deletion, protects 
cells against ER stress by prolonging low-level eIF2α phosphorylation. Besides elF2α, PERK 
can phosphorylate nuclear erythroid 2-related factor 2 (NRF2), which contributes to 
dissociation of the NRF2-Keap1 complex and thereby promotes expression of genes containing 
antioxidant response elements, preventing oxidative stress [52]. 
2.3. Endoplasmic reticulum stress in disease 
The UPR has been implicated in a variety of diseases including metabolic such as diabetes and 
atherosclerosis, neurodegenerative such as Alzheimer's and Parkinson's diseases, amyotrophic 
lateral sclerosis, as well as rare prion disorders, and inflammatory diseases, and cancer 
[53],[54]. Signalling components of the UPR are rapidly emerging as targets for treatment of 
human diseases [41]. Many extracellular stimuli and fluctuations in intracellular homeostasis 
disrupt protein folding. Consequently, the cell uses its ER protein-folding status as an exquisite 
sensor to monitor intracellular homeostasis. Pharmacological insults were used to elucidate how 
cells cope with immediate and severe challenges to the protein-folding quality control. It is now 
evident that intracellular signalling, such as insulin anabolic responses, as well as 
pathophysiological conditions including hypoxia, oxidative stress, high or low glucose levels, 
acidosis, hyperlipidaemia, hyperhomocysteinaemia and inflammatory cytokines all disrupt 
protein folding and activate the UPR [33]. In solid tumours, the UPR mediates adaptation to 
various micro-environmental stressors [55]. 
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2.4. Endoplasmic reticulum stress in cancer 
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 Abstract 
The endoplasmic reticulum (ER) is an elaborate organelle that is essential for cellular function 
and survival. Conditions that interfere with ER functioning can lead to the accumulation of 
unfolded proteins, which are detected by transmembrane sensors that then initiate the unfolded 
protein response (UPR) to restore ER proteostasis. If the adaptive response fails, apoptotic cell 
death ensues. Many studies have focused on how this failure initiates apoptosis, particularly 
because ER stress-induced apoptosis is implicated in the pathophysiology of several diseases, 
including cancer. Whether the UPR inhibits tumour growth or protects tumour cells by 
facilitating their adaptation to stressful conditions within the tumour microenvironment is 
unknown, and dissection of the UPR network will likely provide answers to this question. In 
this review, we aim to elucidate the paradoxical role of the UPR in apoptosis and cancer. 
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 Introduction 
The endoplasmic reticulum (ER) consists of a membranous network that extends throughout 
the cytosol; here, proteins are synthesized, post-translationally modified and folded into correct 
conformations. Unlike the cytosol, the ER luminal environment is sufficiently oxidised to 
permit for cysteine oxidation and subsequent formation of the disulfide bonds that are critical 
to the correct conformations of many mature proteins (1). The ER contains stringent quality 
control systems that selectively export correctly-folded proteins and extract terminally-
misfolded proteins for ubiquitin-dependent proteolytic degradation, a process known as ER-
associated protein degradation (2) (Figure 1). However, if degradation is insufficient, misfolded 
proteins can accumulate. This phenomenon is called ER stress, and it activates the unfolded 
protein response (UPR). The UPR is generally considered to be the transcriptional induction of 
molecular chaperones in response to ER stress (3). However, gene expression profiling has 
demonstrated that, parallel to the chaperones, the UPR regulates genes involved in protein entry 
into the ER, calcium and redox homeostasis, ER quality control, autophagy, lipid biogenesis 
and vesicular trafficking. Additionally, ER stress attenuates global protein synthesis, a process 
that subsequently reduces the protein load to help re-establish equilibrium and is associated 
with cell-cycle arrest and tumour dormancy. Three ER stress transducers have been identified: 
protein kinase RNA-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme-1 
(IRE1) and activating transcription factor-6 (ATF6; Figure 2) (4, 5). Most targets are co-
regulated by IRE1, PERK and ATF6 to ensure the redundancy and robustness of this adaptive 
response (6). 
Following initiation of malignancy, rapid tumour growth and inadequate vascularization result 
in microenvironmental stress. This condition activates a range of stress response pathways, 
including the UPR, which meticulously coordinate adaptive and apoptotic responses to ER 
stress. During tumourigenesis, the UPR enhances the ER protein-folding capacity and maintains 
ER protein homeostasis (or proteostasis), thereby counteracting apoptosis. The UPR, when 
coupled with induced tumour dormancy, dually protects neoplastic cells from apoptosis and 
permits recurrence once favourable growth conditions have been restored (7, 8). However, if 
ER stress is prolonged and the UPR fails to restore ER proteostasis, tumour cell apoptosis 
ensues. This review addresses this paradoxical role in cancer. 
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Figure 1. Cellular stress as the cause of protein misfolding. Molecular chaperones stabilise and (un)fold 
newly-synthesised proteins into their proper conformations. During tumour formation, continuous 
endoplasmic reticulum (ER) stress eventually causes damage that the chaperones cannot correct. These 
proteins might then be recognised and degraded by the ubiquitin-proteasome system (UPS). However, if this 
process is insufficient to counter the accumulation of misfolded proteins, the unfolded protein response (UPR) 
is activated to induce chaperones, protein quality control and degradation. 
 Extrinsic and Intrinsic Stressors that Activate the UPR During Tumourigenesis 
Although tumours secrete angiogenic factors to promote angiogenesis, this is often insufficient 
to meet the elevated tumour metabolic requirements. Therefore, in addition to hypoxia (9), cells 
in developing tumours are subject to glucose deprivation, lactic acidosis, oxidative stress and 
decreased amino acid supplies (Figure 1). In addition to these extrinsic stressors, tumour-
intrinsic stressors, such as errors in glycoprotein and lipid biosynthesis that result from an 
increased mutation rate, might also contribute to the induction of ER stress (10). 
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Hypoxia-mediated UPR activation is essential for tumour cell survival. The major UPR-
inducing pathway in tumours is mediated by hypoxia. Human fibrosarcoma and lung carcinoma 
cells up-regulate 78-kDa glucose-regulated protein (GRP78) and X-box-binding protein 1 
(XBP1) splicing under hypoxic conditions in vitro, whereas in human colon cancer cells, 
hypoxia induces the PERK-dependent phosphorylation of eukaryotic initiation factor-2α 
(eIF2α) and the translation of activating transcription factor-4 (ATF4; Figure 2) (8). A strong 
positive correlation was demonstrated between spliced XBP1 (XBP1s)-induced 
bioluminescence and tumour hypoxia in transgenic mice that developed spontaneous mammary 
carcinomas and exhibited luciferase reporter coupled XBP1 splicing (11). Additionally, the 
exposure of transformed mouse embryonic fibroblasts (MEFs) to hypoxia led to increased 
GRP78 and XBP1 expression, as well as increased ATF4 and C/EBP homologous protein 
transcription factor (CHOP) expression. A potential UPR trigger in hypoxic conditions is ER 
oxidase 1α (ERO1α), an oxidoreductase that catalyses disulfide bond formation in nascent 
proteins in an oxygen-dependent manner. Although hypoxia transcriptionally induces ERO1α, 
reduced oxygen tension impairs ERO1α activity and subsequent protein folding. Another UPR-
inducing mechanism is the upregulation of glycogen synthase kinase 3B, which activates the 
PERK branch (12). 
The UPR is required for tumour cell growth under hypoxic conditions (13). Cells are sensitised 
to hypoxia in vitro by antisense-mediated GRP78 inhibition (14). PERK inactivation due to the 
generation of mutations in its kinase domain impairs cell survival under extreme hypoxia (15). 
PERK promotes cancer cell proliferation by limiting oxidative DNA damage through ATF4 
(16). 
Additionally, XBP1-deficient tumour cell survival was reduced during severe hypoxia in vitro, 
and these cells were unable to grow as tumours in vivo. Spliced XBP1 expression restored 
tumour growth, suggesting that the IRE1 branch is also required for tumour cell survival during 
hypoxia (17). 
Thus, tumour formation with aberrant microcirculation leads to hypoxia, which induces the 
UPR. In turn, the UPR increases cellular survival and proliferation, which further enlarges the 
tumour and thereby increases hypoxia in the tumour core (Figure 3). 
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Activation of the UPR by glucose deprivation and subsequent acidosis. Tumour cells adapt to 
low glucose levels by switching to a high rate of aerobic glycolysis, which is known as the 
Warburg effect (18). The resulting lactic acid production reduces the pH, leading to aggravated 
local distress. Acidosis is a prominent feature of the tumour microenvironment that surprisingly 
promotes tumour survival and progression by regulating several B-cell leukaemia/lymphoma-
2 (BCL-2) family members and CHOP (see below) (19). The glucose-regulated protein family, 
which includes the master UPR regulator GRP78, was originally discovered due to the up-
regulation of its members in response to glucose deprivation (20). In the XBP1s reporter mouse 
model, which develops spontaneous mammary tumours, XBP1 splicing was found to increase 
upon exposure to a non-metabolizable glucose analog that simulates glucose deprivation (11).  
CHOP deletion in a mouse model of Kirsten rat sarcoma viral oncogene homolog-induced lung 
cancer increases tumour incidence and thus supports the notion that ER stress serves as a barrier 
to malignancy. UPR activation and the subsequent p58IPK expression control the fates of 
malignant cells that face glucose deprivation. Overcoming this barrier requires for selective 
attenuation of the PERK-CHOP branch by p58IPK. Furthermore, this p58IPK-mediated fine-
tuning enables cells to benefit from the protective features of chronic UPR (21). 
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Figure 2. Endoplasmic reticulum (ER) stress induces the unfolded protein response (UPR) through a triple 
transcription factor system. Misfolded proteins sequestrate 78-kDa glucose-regulated protein (GRP78), thus 
allowing the activation of three ER membrane-associated proteins. Activating transcription factor-6 (ATF6) 
translocates to the Golgi for cleavage, and the cleaved fragment subsequently regulates UPR gene expression. 
Inositol requiring enzyme 1 (IRE1) cleaves X-box-binding protein 1 (XBP1) mRNA to a spliced form (XBP1s) 
that is translated to a strong transcription factor. Along with selective XBP1 mRNA splicing, other mRNAs are 
degraded by the IRE1 RNase activity (RIDD). IRE1 promotes c-Jun N-terminal kinase (JNK) and p38 
phosphorylation through direct interactions. Caspase-12 (murine) or -4 (human) activation is ER stress-
dependent. Protein kinase RNA-like endoplasmic reticulum kinase (PERK) phosphorylates eukaryotic initiation 
factor 2α (eIF2α) to attenuate global translation. Phosphorylated eIF2α favours activating transcription factor 
4 (ATF4) translation. The latter induces growth arrest and DNA damage-inducible protein (GADD34), which 
dephosphorylates eIF2α. PERK also phosphorylates nuclear factor erythroid 2-related factor 2 (NRF2), which 
induces an anti-oxidative response. ASK1: apoptosis signal-regulating kinase; CHOP: C/EBP homologous 
protein transcription factor; ERAD: ER-associated protein degradation; ERO1α: ER oxidase 1α; JIK: jun kinase-
inhibitory kinase; ROS: reactive oxygen species; TRAF2: tumour necrosis factor receptor-associated factor-2. 
 Dual Role of GRP78 in and on Surface of Tumour and Endothelial Cells 
GRP78 is a key player in tumourigenesis and is involved in the three major hallmarks of cancer, 
namely the enhancement of cell proliferation, protection against apoptosis and promotion of 
tumour angiogenesis (22). The phosphoinositide-3 kinase (PI3K)/phosphatase and tensin 
homolog (PTEN)/protein kinase B (PKB) pathways play central roles in these hallmark 
processes. In mice, PKB activation in PTEN-null prostate epithelium was potently suppressed 
in a GRP78-knockout model, and a similar suppression of PKB activation was observed in 
human prostate cancer cells that had been transfected with small interfering RNA (siRNA) 
targeted against GRP78 (23, 24). As PTEN mutations and PKB activation are major drivers of 
tumourigenesis, GRP78 inactivation might represent a novel approach to reducing 
tumourigenesis that results from loss of PTEN tumour suppression or oncogenic PKB activation 
(1). Apart from its abundant expression in the ER, GRP78 can localise at the cell surface, within 
the cytoplasm, in the mitochondria and in the nucleus, as well as in secretions from tumour and 
endothelial cells, and this protein is implicated in processes beyond protein folding. 
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Figure 3. The paradoxical role of the unfolded protein response (UPR) in cancer. During 
tumourigenesis, specific stressors activate the UPR in both cancer and endothelial cells 
(EC). In cancer cells, both apoptosis and survival can be induced by UPR components. 
Furthermore, cell-cycle progression or arrest (e.g. by reduced cyclin D1 translation) can 
occur in response to protein kinase RNA-like endoplasmic reticulum kinase (PERK) 
activation. This arrest can be temporary during stressful conditions such as chemotherapy. 
After the induced dormancy, tumour re-growth can occur upon the restoration of more 
favourable conditions. A positive feedback loop increases ER stress via cellular adaptation 
during tumour formation. Due to its effects on endothelial and cancer cell survival and 
function, the UPR also modulates metastasis and angiogenesis, which, if functional, reduces 
ER stress. ROS: Reactive oxygen species. 
 
GRP78 in tumour cells. The first causal correlation between GRP78 and in vivo carcinogenesis 
was reported in fibrosarcoma cells. GRP78 silencing in these cells inhibited their ability to form 
tumours upon xenografting into mice (25). The essential role of GRP78 was confirmed in a 
transgenic mouse mammary tumour model. Mice that lacked one GRP78 allele exhibited 
decreased breast adenocarcinoma growth and angiogenesis as well and showed survival 
compared to wild-type mice (26). Likewise, in glioma cells, high GRP78 levels were found to 
correlate with increased proliferation, and siRNA-mediated GRP78 suppression reduced the 
cell proliferation rate (27). 
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GRP78 levels are known to be increased in various solid tumour types, including prostate, head 
and neck, melanoma, breast, lung, brain, gastric, colon, and hepatocellular carcinoma (HCC) 
(14, 28). Furthermore, elevated GRP78 levels correlate with gastric, breast, and liver cancer 
metastasis (7). In contrast, a recent report suggested that GRP78 is downregulated in mouse 
prostate cancer models (29). Thus, although GRP78 and malignancy appear to be positively 
correlated, exceptions might occur. However, these unexpected results might be due to time-
dependent alterations. Additionally, GRP78 plays a dual role in tumour cells. GRP78 controls 
early tumour development through tumour suppressive mechanisms such as the induction of 
dormancy (30). On the other hand, at more advanced stages of progression, during which 
tumours are exposed to more severe stress, GRP78 has been shown to promote tumour 
progression through its pro-survival (26) and pro-metastatic functions (7). 
GRP78 on the tumour cell surface. Severe ER stress promotes GRP78 cell surface localization 
in various types of neoplastic and endothelial cells (14). The cell surface form of GRP78 affects 
cell membrane signalling pathways that regulate proliferation, apoptosis and tumour immunity 
(31). A growing number of cell surface GRP78-binding partners have been identified (1, 14). 
In prostate cancer cells, cell surface GRP78 binds the activated form of the proteinase inhibitor 
α2macroglobulin. This interaction promotes cell proliferation by activating p38 and PI3K (32). 
In addition to α2-macroglobulin, cell surface GRP78 can interact with Cripto, a small tumour 
cell surface protein that regulates tumour progression by blocking the growth-inhibitory 
transforming growth factor β and activating c-SRC and PKB. Interestingly, antibody-mediated 
blockade of this interaction with cell surface GRP78 is sufficient to inhibit its oncogenic 
signalling (14, 33). Finally, neovascularization, together with the formation of cell surface 
GRP78/T-cadherin complexes, was accelerated by ER stress (34), whereas cell surface GRP78 
might also serve as a receptor for the angiogenesis inhibitor Kringle 5; the binding of Kringle 
5 to GRP78 is required to exert its anti-angiogenic and pro-apoptotic activities in stressed 
tumour and endothelial cells (14). Thus, the dual effects of cell surface GRP78 signalling 
depend on the availability of binding partners in the tumour microenvironment. 
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GRP78 in endothelial cells. The importance of GRP78 in tumour angiogenesis is reflected by 
its constitutively high expression within the glioblastoma vasculature, which is suggestive of 
the sustained stress experienced by tumour-associated endothelial cells (31). In a mammary 
tumour model, conditional heterozygous GRP78 knockout in endothelial cells led to a dramatic 
reduction in tumour angiogenesis and metastatic growth, with minimal effects on normal tissue 
microvascular densities. GRP78 knockdown in immortalised human endothelial cells revealed 
that GRP78 regulated endothelial cell proliferation, survival and migration (7). Vascular 
endothelial growth factor (VEGF) is a major driver of endothelial proliferation, and all three 
UPR pathways directly regulate VEGF expression (35). However, the downstream target 
GRP78 also plays an active role in VEGF regulation. GRP78-knockdown suppresses VEGF 
receptor-2, as well as VEGF-induced endothelial cell proliferation (14). 
 Three Proximal UPR Sensors in Cancer: An Integrated View 
After the sequestration of GRP78 by unfolded proteins, ATF6, IRE1, and PERK are activated 
to transduce the ER stress signal to the cytosol and nucleus (Figure 2). 
ATF6: Fine-tuning of the UPR. Although the ATF6 branch in cancer is the least investigated, 
its potential as an effector of clinical outcomes should not be underestimated. Activated ATF6 
translocates to the Golgi, where proteases cleave it and release a fragment into the cytosol. 
Indeed, enhanced nuclear translocation of the ATF6 fragment is observed in various types of 
cancer, including HCC (28) and Hodgkin’s lymphoma (36), and its expression has been linked 
to metastasis and relapse (37). Additionally, whereas XBP1s is required for organismal 
development, the functional roles of ATF6 in ER proteostasis remodelling are adaptive and can 
adjust the ER capacity to match demand. Therefore, ATF6 modulation might sensitively tune 
proteostasis without globally influencing proteome folding, trafficking, or degradation (38). 
In contrast to PERK and IRE1, ATF6 activation has no obvious paradoxical outcomes. The 
latter primarily induces cytoprotective responses, such as ER biogenesis, chaperone up-
regulation and protein degradation (38, 39). Moreover, ATF6 induces transcription of XBP1 
mRNA, the major splicing target of the IRE1 endonuclease. 
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 Recently, ATF6 was identified as a survival factor for quiescent, but not proliferative, 
squamous carcinoma cells and as essential for the adaptation of dormant tumour cells to 
chemotherapy, a process that is mediated by Ras homolog enriched in brain (RHEB) and 
mammalian target of rapamycin (mTOR) activation (37). ATF6 or RHEB down-regulation was 
able to reverse dormant cell resistance in vivo. Therefore, targeting survival signalling in 
dormant tumour cells after chemotherapy by abrogating the adaptive ATF6-RHEB-mTOR 
pathway might reduce the metastatic cancer relapse rate. 
IRE1: The conserved core branch. After oligomerisation, IRE1 has at least three established 
outputs: XBP1 mRNA splicing, regulation of IRE1-dependent decay (RIDD) of other mRNAs 
and direct interactions with downstream mediators (40) (Figure 2).  
Increased XBP1 splicing has been demonstrated in numerous haematological and solid types 
of cancer and has been associated with more malignant phenotypes and poor survival (41-43). 
IRE1 has been shown to promote cell proliferation by regulating cyclin A1 expression through 
XBP1 splicing in prostate cancer cell lines (44). Notably, XBP1s enhances catalase expression, 
and the loss of XBP1s sensitizes cells to oxidative stress-induced apoptosis. Indeed, XBP1-
deficient cells produce less catalase, which is associated with reactive oxygen species (ROS) 
generation and p38 activation (45). Moreover, XBP1 splicing itself might directly lead to 
tumourigenesis, as was evidenced by the observation that the maintenance of elevated XBP1s 
levels in B and plasma cells could drive multiple myeloma pathogenesis and promote hallmark 
myeloma characteristics, including bone lytic lesions and sub-endothelial immunoglobulin 
deposition (46). Moreover, a putative inhibitor of IRE1 RNase exhibited anti-myeloma activity 
in xenograft mice, suggesting that the IRE1-XBP1 pathway is an appealing target for anticancer 
therapies (47). 
Xenograft glioma cells that expressed dominant-negative IRE1 exhibited reduced proliferation. 
In this model, wildtype gliomas were characterised by an angiogenic/massive phenotype, 
whereas tumours that expressed dominant-negative IRE1 exhibited an avascular/diffuse 
phenotype, suggesting that IRE1 is required for angiogenesis and functions as a switch between 
angiogenesis and invasion (48). The requirement for IRE1 in tumour angiogenesis during stress 
conditions in vitro could be attributed to its role in VEGF expression regulation (49). 
Additionally, the loss of XBP1 was shown to inhibit both tumour growth and blood vessel 
formation. However, these effects appeared to be VEGF-independent, indicating that the IRE1-
XBP1s-VEGF axis only partially regulates the angiogenic functions of IRE1 (50). On the other 
hand, VEGF induces internalization of the VEGF receptor, which subsequently interacts with 
IRE1 to enhance XBP1 splicing (51). 
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The role of RIDD and the interactions of IRE1 with several downstream mediators during 
tumour growth and angiogenesis are not currently understood. Prolonged RIDD activation has 
been reported to increase apoptosis (40). Activated IRE1 recruits the adaptor protein tumour 
necrosis factor receptor associated factor-2 (TRAF2) to the ER membrane, which has been 
reported to further activate c-Jun N-terminal kinase (JNK) (see below), resulting in caspase-12 
activation and apoptosis in a mouse model (52). The JNK pathway is a member of the mitogen-
activated protein kinase superfamily, which also includes p38 (53), and this activated pathway 
is involved in ER stress-mediated apoptotic cascades. 
XBP1s overexpression in breast cancer cells increased BCL-2 levels after antiestrogen 
stimulation, thereby suppressing apoptosis (54); however, JNK phosphorylates and 
paradoxically inhibits BCL-2. Thus, the effects of IRE1 on the BCL-2 family vary according to 
the output, which is anti-apoptotic when mediated by XBP1 splicing versus proapoptotic when 
mediated by JNK. 
PERK and protein translation in cancer. PERK phosphorylates eIF2α, leading to a translation 
blockade and cap-independent ATF4 translation, as well as nuclear factor erythroid 2-related 
factor-2 (NRF2), leading to the upregulation of antioxidative enzymes (6) (Figure 2). PERK 
has been implicated in tumour progression and angiogenesis. PERK inactivation in mouse 
fibroblasts and human colon cancer cells, using targeted mutagenesis or a dominant-negative 
PERK, resulted in smaller tumours that demonstrated impaired angiogenic abilities upon 
grafting into immunodeficient mice (13, 55). PERK deletion in a mammary tumour mouse 
model was found to modestly increase tumour latency while profoundly inhibiting metastatic 
spread (16). 
Similar observations were made in a colorectal carcinoma xenograft model that expressed a 
dominant-negative PERK. PERK-knockdown in human esophageal and breast carcinomas 
resulted in cell-cycle arrest at the G2/M phase (16). This G2/M arrest could likely be attributed 
to reduced NRF2 activity in these PERK-deficient cells, resulting in ROS accumulation that 
causes oxidative DNA damage and subsequently triggers cell-cycle arrest via the DNA double 
strand-break checkpoint (31). Similar to IRE1 deficiency, PERK-deficient tumours exhibited 
reduced viability and impaired angiogenic ability during hypoxia; these effects were attributed 
to the losses of phosphorylated eIF2α and ATF4. The requirement for PERK in tumour 
angiogenesis was further confirmed with a mouse PERK–/– insulinoma model in which PERK–
/– tumours exhibited reduced vascularity (56). Thus, both downstream transcription factors of 
PERK, namely ATF4 and NRF2, contribute to cellular adaptation and tumour promotion. 
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In contrast to the previous results, p38-induced dormancy in squamous cell carcinoma cells was 
associated with increased PERK activation. Accordingly, pharmacologically activated PERK 
was found to induce growth arrest in vitro and to suppress tumour growth in vivo, indicating an 
additional role for PERK in tumour growth suppression (57). Indeed, eIF2α phosphorylation-
induced translational arrest down-regulates cell-cycle regulators such as cyclin D1, resulting in 
cell-cycle arrest in the G1 phase. Accordingly, a non-phosphorylatable eIF2α mutant was 
sufficient to drive the malignant transformation of human kidney cells or fibroblasts, and 
conditional PERK deletion was found to deregulate mammary acinar morphogenesis and to 
cause hyperplastic growth in vivo (58, 59).  
Taken together, activation of the PERK axis induces tumour suppression (by G1/S arrest) and 
dormancy, whereas inactivation appears to induce paradoxical effects on specific hallmarks of 
carcinogenesis (22), such as tumourigenesis, angiogenesis and metastasis. 
Recently, a context-dependent impact of PERK on cell fate has been indicated. Downstream of 
PERK, CHOP directly transactivates the growth arrest and DNA damage inducible protein 
(GADD34). The latter promotes eIF2α dephosphorylation, thereby creating a negative feedback 
loop that leads to translational recovery (60). Additionally, both ATF4 and CHOP induce 
protein synthesis (61). This finding could explain the time-dependent balance in protein 
synthesis. After acute ER stress, protein synthesis is inhibited by eIF2α phosphorylation. 
However, downstream induction of ATF4, CHOP, and GADD34 leads to protein synthesis 
recovery. If acute ER stress is addressed, survival is promoted by the restoration of translation. 
Conversely, if chronic ER stress continues or the acute ER stress was too severe to be addressed 
during a transient reduction of translation, protein synthesis leads to ROS formation and 
ultimately triggers apoptosis. Accordingly, salubrinal, an eIF2α dephosphorylation inhibitor, 
protects cells from ER stress-associated apoptosis (62). 
 The UPR and Apoptosis: Adaptation or Suicide – A Double-edged Sword 
During ER stress, cells either survive by inducing adaptation mechanisms or commit suicide by 
apoptosis. The intrinsic apoptosis pathway is closely related to factors anchored on the 
mitochondria. The membrane insertion of pro-apoptotic proteins changes mitochondrial 
membrane permeability, resulting in cytochrome c release and caspase activation (53, 63). 
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CHOP: A key mediator of ER stress-induced apoptosis. Notably, CHOP induction strongly 
correlates with the onset of ER stress-associated apoptosis, and CHOP silencing protects cells 
(53). However, mouse embryonic fibroblasts (MEFs) derived from CHOP-knockout mice 
exhibit only partial resistance to ER stress-driven apoptosis, indicating that CHOP is not the 
only death pathway in this context (64). Precisely how CHOP mediates ER stress-induced 
apoptosis remains controversial because CHOP regulates numerous genes, the majority of 
which are involved in hallmarks of cancer, such as cell migration, proliferation, and survival 
(22, 65). 
The down-regulation of anti-apoptotic BCL-2 and the induction of the proapoptotic BCL-2 
interacting mediator of cell death (BIM), p53 up-regulated modulator of apoptosis (PUMA) and 
BCL-2-associated X protein (BAX) are believed to contribute to CHOP-mediated apoptosis 
(63). In vivo data from breast carcinoma-derived cells corroborate these findings (66). 
CHOP transcriptionally induces ERO1α (see above), which promotes disulfide bond formation 
but also generates hydrogen peroxide leakage into the cytoplasm (60). In vivo, partial ERO1α 
silencing was shown to protect against ER stress-induced death, and CHOP deficiency 
suppressed pancreatic β-cell apoptosis, which was associated with decreased ERO1α 
expression and oxidative stress markers. ERO1α activates the ER calcium channel inositol-
1,4,5trisphosphate receptor 1 (IP3R1) (67). Upon release from the ER, calcium triggers 
apoptosis by activating calcium/calmodulin-dependent kinase II (CaMKII), which subsequently 
induces four apoptotic pathways. Firstly, CaMKII triggers JNK-mediated Fas antigen 
induction. Secondly, CaMKII promotes mitochondrial calcium uptake, thereby activating 
intrinsic apoptosis. Thirdly, CaMKII activates signal transducer and activator of transcription-
1 (STAT1), a pro-apoptotic signal transducer (68). Finally, the CHOP-ERO1α-IP3R1-CaMKII 
axis induces NADPH oxidase subunit 2 and generates ROS to possibly amplify CaMKII 
activation as part of a positive feedback loop because ROS induces CHOP expression. 
Surprisingly, NADPH oxidase-induced ROS are also part of a second positive feedback loop 
that activates dsRNA-dependent protein kinase to subsequently phosphorylate eIF2α, thereby 
amplifying CHOP expression. For example, CHOP-induced hepatocyte death in a mouse 
protein-misfolding model was associated with oxidative stress and was relieved by an 
antioxidant. Because CHOP-induced apoptosis can be blocked by buffering cytosolic calcium, 
the ERO1α-IP3R1 pathway appears to comprise its main signalling axis (69). 
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Furthermore, CHOP activity is increased in response to phosphorylation by p38. p38 is a 
substrate of apoptosis signal-regulating kinase (ASK1, see below), which is recruited to the 
IRE1-TRAF2 complex upon ER stress. Thus, during prolonged stress, the PERK and IRE1 
pathways might converge on CHOP, with IRE1-mediated ASK1 activation potentiating CHOP 
activity (4). 
The JNK pathway in ER stress-mediated apoptosis. Several studies indicate a pivotal role for 
JNK in the mediation of ER stress-induced apoptosis (70). JNK recruitment by IRE1 is 
regulated by c-Jun NH2-terminal inhibitory kinase (JIK), which has been reported to interact 
with both IRE1 and TRAF2. The IRE1-TRAF2 complex then recruits ASK1, causing ASK1 
activation and regulating the JNK pathway that leads to cell death. In a mouse HCC model, 
ASK1 deficiency promoted HCC, whereas the reintroduction of ASK1 suppressed tumour 
development (71). Furthermore, cells from ASK1-knockout mice were found to be resistant to 
ER stress-associated apoptosis and exhibited reduced JNK and p38 activity (72). JIK 
overexpression was shown to promote the interaction between IRE1 and TRAF2 and JNK 
activation in response to ER stress, whereas the overexpression of an inactive JIK mutant 
inhibited JNK activation (52). Thus, the IRE1-TRAF2-JIK-ASK1-JNK pathway exerts an 
opposite effect on cell survival than that of the cytoprotective IRE1-XBP1s pathway. The 
regulation of these paradoxical IRE1 outputs requires further investigation. As described 
previously, JNK is a downstream effector of the CHOP-CaMKII pathway. Therefore, in 
conditions where both proapoptotic IRE1 activation and CHOP expression are prolonged, 
additive JNK activation might play a crucial role in apoptosis regulation. 
Downstream apoptosis-related targets of JNK include antiapoptotic BCL-2, B-cell lymphoma-
extra-large (BCLXL) and myeloid cell leukaemia sequence 1 (MCL-1), all of which are 
inhibited by JNK, and proapoptotic BID and BIM, which are activated by JNK-mediated 
phosphorylation (63, 73). During non-stress conditions, BIM is sequestered by dynein motor 
complexes. ER stress increases BIM levels by reducing BIM degradation and by CHOP-
mediated gene induction. Phosphorylation by JNK releases BIM from its inhibitory association 
with the motor complexes, thus permitting its translocation to the mitochondrial outer 
membrane where it promotes cytochrome c release and caspase activation. Interestingly, a 
positive feedback loop exists between BIM and caspase-3. Phosphorylated BIM is a caspase-3 
target and, once cleaved, becomes a more potent inducer of cytochrome c release (74, 75). 
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The mitochondria and the BCL-2 family. The proapoptotic BCL-2 family members trigger 
mitochondrial dysfunction and are sub-divided into the multi-BCL-2 homology (BH) domain 
proteins, such as BAX and BAK, and the BH3-only proteins, such as BAD. Of the 11 BH3-
only protein subfamily members, PUMA, NOXA, BID, HARAKIRI and BIM have been 
reported to mediate ER stress-induced apoptosis (74, 75). 
Additionally, the BCL-2 family also regulates ER stress through physical interactions with 
certain UPR components. For example, BAX and BAK directly interact with the IRE1 cytosolic 
domain upon ER stress; this interaction is essential for IRE1 activation (76). In cells that 
exclusively express ER-localised BAK, BIM and PUMA selectively activate the TRAF2-JNK 
arm of IRE1 in the absence of XBP1 splicing (77). In BAX/BAK double-knockout mice, ER 
stress failed to induce XBP1s, IRE1 or JNK. Moreover, BAX/BAK double-knockout MEFs are 
resistant to apoptosis mediated by various ER stressors, and the reconstitution of BAK 
expression in these MEFs restored JNK phosphorylation, suggesting a direct connection 
between the UPR and the apoptotic machinery (76). Thus, BAX and BAK are required for IRE1 
signalling, although both are also involved in ER stress-induced apoptosis. This response could 
represent a switch toward pro-apoptotic signalling by IRE1. The association of IRE1 with BAX 
and BAK is influenced by BAX inhibitor-1 (BI-1), an ER transmembrane protein. BI-1 directly 
interacts with the IRE1 cytosolic domain to inhibit its endoribonuclease activity. BI-1-deficient 
cells were found to exhibit enhanced IRE1 activity and sustained XBP1 splicing, whereas BI-1 
overexpression disrupted the interaction between IRE1 and BAX or BAK (78). Similar to ER-
localised BAX/BAK oligomers (see below), BI-1 also modulates ER calcium homeostasis by 
forming a calcium-permeable channel pore (79). 
BCL-2, BAX and BAK associate with both mitochondrial and ER membranes. During ER 
stress, ER-targeted BAX and BAK undergo conformational changes and oligomerisation, 
which leads to calcium release from the ER to the cytosol to activate m-calpain and, 
subsequently, procaspase-12 (see below) (81, 82). In contrast, mitochondria-targeted BAK 
enhances caspase-7 cleavage to create parallel pathways of caspase activation by BAX and 
BAK (80). 
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Each branch acts on different levels to tightly modulate the BCL-2 family. During hypoxia, 
ATF4 induces the BH3only proteins HARAKIRI, PUMA and NOXA following PERK 
activation (75). Additionally, CHOP transactivates BIM and down-regulates BCL-2 and MCL-
1. The less studied ATF6 has been linked to ER stress-induced apoptosis in a myoblast cell line 
through the indirect inhibition of MCL-1 expression (83). The IRE1 branch can affect BH3only 
proteins such as PUMA or BID. Functional integration likely occurs because BAX/BAK acts 
through mitochondrial permeabilisation, a key pro-apoptotic effect of the CHOPERO1α-
CaMKII pathway.  
Caspases. The processing of caspases-2 to -9 and caspase-12 has been observed in various 
models of ER stress-induced apoptosis (84, 85). In mouse models, caspase-12 was proposed as 
a key mediator of ER stress-induced apoptosis. Caspase-12knockout MEFs exhibited partial 
resistance, specifically against ER stressors. However, another study that used different 
caspase-12-knockout MEFs did not show any resistance to apoptosis (86). Procaspase-12 is 
localised on the cytosolic ER surface and is activated by ER stress via IRE1-TRAF2dependent 
mechanisms. TRAF2 promotes procaspase-12 clustering at the ER membrane (52). The 
interaction between TRAF2 and procaspase-12 is inhibited by ER stress, and IRE1 
overexpression. Therefore, caspase-12 activation might require for the dissociation of 
procaspase-12 from TRAF2, which is subsequently recruited to IRE1. Calpains, a family of 
calcium-dependent proteases, also play a role in caspase-12 activation, and calpain-deficient 
MEFs exhibit reduced ER stress-mediated caspase-12 activation and apoptosis (85). Therefore, 
it is plausible that a CHOP-ERO1α-IP3R-calcium-calpain pathway contributes to caspase-12 
activation. Surprisingly, human caspase-12 has no similar function because its gene has been 
disrupted by a frame shift. Instead, human caspase-4 is specifically cleaved under ER stress, 
suggesting that it might be a functional mouse caspase-12 ortholog. Transmembrane protein 
214 (TMEM214) mediates stress-induced apoptosis by acting as an anchor for the ER 
recruitment and subsequent activation of procaspase-4 (87). 
Caspase-7, which also translocates from the cytosol to the cytosolic ER surface in response to 
ER stress, cleaves procaspase-12. A dominant-negative catalytic caspase-7 mutant was shown 
to inhibit caspase-12 activation. Caspase-7 is also a downstream executioner of caspase-12, a 
fact that suggests an amplification loop in the ER stress-induced apoptotic cascade (53). 
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 Future Perspectives and Remaining Conundrums 
Recently, ER stress research has received unprecedented attention. A basic PubMed search 
revealed that more than 830 ER stress investigational studies have so far been published in 
2013. However, to integrate these links with hypoxia-inducible factor 1(HIF1)-VEGF or 
inflammatory pathways in a comprehensive network, the focus should be placed on elucidating 
the downstream mediators and crosstalk for all three UPR pathways. The observed paradox of 
the UPR in cancer (Figure 3) is likely due to functional redundancy and time-dependent 
outcomes of the UPR, although there are also some methodological issues. 
ER stress-induced apoptosis is not completely suppressed when a single UPR effector is 
experimentally silenced. The fact that CHOP is a transcriptional target of both PERK and IRE, 
and even ATF6 provides an obvious link among all three branches. One caveat is that the IRE1 
and ATF6 branches have weaker activities, compared to the PERK-CHOP branch, during 
prolonged ER stress (63). Most targets can be regulated separately by each pathway; moreover, 
each pathway possesses its own transcriptional activity for a certain target that determines its 
effect on cell fate. Some targets even require the concomitant activation of two pathways, for 
example, p58IPK requires ATF6/IRE1 cooperation (38). Additionally, a single downstream 
effector can exhibit different mechanisms of action. For example, the anti-apoptotic 
mechanisms of GRP78 include the prevention of UPR sensor activation, and the preservation 
of ER calcium homeostasis and its chaperone activity by limiting misfolded protein aggregation 
(1, 26). 
The majority of studies measured the expression of only two or three ER stress markers such 
as GRP78 or CHOP; only a minority included target genes from each branch. Future therapeutic 
targeting of the UPR will likely affect one branch. The pleiotropic effects and acute toxicities 
of global 
UPR inducers, including the most commonly used thapsigargin (an ER calcium pump inhibitor) 
and tunicamycin (an N-linked glycosylation inhibitor), complicate studies that focus on an 
understanding of how the UPR remodels ER proteostasis in the absence of acute ER stress or 
how partitioning between ER client protein folding and trafficking versus degradation can be 
influenced by arm-selective UPR modulation. Moreover, UPR research that includes a variety 
of acute ER stress inducers introduces difficulties when comparing data from different studies. 
The recent development of targeted inhibition [e.g. PERK inhibitors (88)] or activation [e.g. 
PERK activators (89)] approaches, as opposed to the concomitant activation of all three 
branches, will lead to a new era in UPR research.  
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The duration and severity of ER stress determine the survival/apoptosis switch. The three 
branches provide opposing signals, and the timing of their induction shifts the balance between 
cytoprotection and apoptosis in response to unmitigated ER stress. For example, IRE1 
signalling is an early event that is attenuated upon prolonged ER stress (90), and likewise, 
PERK induces its own de-activation via the upregulation of GADD34 (Figure 2). Both 
pathways thus contain intrinsic ‘timers’ that likely contribute to cellular lifeor-death decisions. 
Because CHOP mRNA and protein half-lives were found to be short, compared to those of 
prosurvival UPR outputs such as GRP78, sustained PERK activity (which is primarily 
responsible for CHOP upregulation) might therefore be necessary to accumulate CHOP levels 
sufficiently to stimulate the pro-apoptotic BCL-2 family proteins. Additionally, despite ATF4, 
CHOP, and GADD34 being able to restore protein synthesis, sustained PERK activity results 
in a protracted translational block that is incompatible with cell survival (38, 61). Similarly, 
sustained IRE1-mediated mRNA degradation might deplete ER cargo and protein-folding 
activities (40). Currently, it is unclear how tumour cells adapt to chronic ER stress in vivo. 
Although the UPR components are clearly activated in several types of tumours, the long-term 
evolution of this activity is unknown. Therefore, the use of experimental models with which to 
monitor temporal dynamics is required. For example, under hypoxia, there is a bi-phasic 
response to eIF2α phosphorylation. Phosphorylation is increased after 8 h but reduced after 24 
h (possibly by PERK-ATF4-CHOPGADD34) and is again enhanced after 48 h. Thus, following 
the initial attenuation in protein translation, there might be a transient period in which additional 
protein synthesis is permitted before a more permanent reduction occurs (15). Consequently, 
the effects of future drug interventions might be time-dependent, and whether cancer incidence 
might be reduced through the enhancement of protein-folding capacities during carcinogen 
exposure remains unknown. For example, the development of molecules that protect the liver 
by reducing alcohol-induced ER stress might dramatically reduce the incidence of HCC because 
chronic alcohol use increases HCC risk (91). 
Deciphering this paradox could permit for the development of novel therapeutic modalities. In 
cancer, the UPR could be targeted to promote apoptosis by inhibiting UPR components and 
thus abrogating cellular adaptation (e.g. the use of versipelostatin, a repressor of GRP78 
expression) or overloading the UPR (e.g. the use of proteasomal inhibitors). Overall, an ideal 
approach would integrate both targets without any toxicity.  
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In principle, UPR inhibitors should specifically target the tumour tissue. However, certain 
normal cell types place high demands on ER function, such as antibody-producing B-cells or 
insulin-secreting β-cells, and the potential toxicities against these cell types would require close 
monitoring during future drug discovery efforts (92). Notably, tissue-specific UPR patterns 
might help to differentiate target tissues. However, current molecular insights into the 
adaptation/apoptosis switch during ER stress are insufficient, and UPR drugs might block ER 
stress-mediated apoptosis and might unintentionally promote tumour progression. In general, 
protein kinases such as PERK represent favourable targets for the development of small-
molecule inhibitors. However, as described above, PERK exhibits both pro- and anti-tumour 
properties. PERK-targeted therapies might facilitate the proliferation of dormant tumour cells 
or might drive cancer cells into dormancy, thereby protecting them from chemotherapy. 
Additionally, the inhibition of one branch might result in altered signalling through the other 
branches. Indeed, HEK293 cells that overexpressed a kinase-dead PERK mutant were found to 
exhibit increased XBP1 splicing and ATF6 activation in response to ER stress. Despite delayed 
dynamics, these cells still induced CHOP expression, which partially accounts for the increased 
susceptibility of these cells to ER stress-induced apoptosis (93). 
In conclusion, the ability of the UPR to regulate cell fate has been highlighted as a primary 
pathophysiology research focus and represents a potential cancer therapeutic axis. However, its 
paradoxical effects on survival and proliferation of neoplastic and endothelial cells complicate 
the clinical applications of UPR modulators. This paradox is primarily due to our incomplete 
understanding of redundancy, the opposing effects of the separate outputs of each pathway, the 
interplay between the UPR and other pathways and the temporal UPR dynamics in cancer, as 
well as other confounding factors, including the absence of a standardized definition of ER 
stress, and a lack of branch-specific research. 
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2.5. Endoplasmic reticulum stress in hepatocellular carcinoma 
Rapid tumour growth creates hypoxia, glucose deprivation and oxidative stress, activating the 
UPR in various solid tumour types [33]. In human HCC, Shuda et al. (2003) showed that 
elevated expression of GRP78 and ATF6 and splicing of XBP1 mRNA occurred in HCC tissues 
with increased histological grading [56]. Higher accumulation of the GRP78 product in the 
cytoplasm, concomitantly with marked nuclear localization of the activated ATF6 fragment, 
was observed in moderately to poorly differentiated HCC tissues. In addition, Al-Rawashdeh 
et al. (2010) showed that 100% of the 86 investigated human HCC samples exhibited increased 
expression of ER stress marker GRP78 [57]. Proteomic profiling of 146 HCC samples revealed 
that in response to the stressful microenvironment, tumour cells strived to increase the 
expression of chaperone proteins including GRP78 for cytoprotective function [58]. Moreover, 
upregulation of GRP78 was significantly associated with tumour venous infiltration. Also 
CHOP expression was shown to be upregulated in human HCC [59]. In contrast, unaffected 
liver tissue from HCC patients showed significantly less CHOP staining and control liver 
samples showed less still. In summary, the UPR was shown to be activated in human HCC 
[56]–[58]. However, the dynamics and the role of these pathways in hepatocarcinogenesis is 
currently unknown. 
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 Autophagy 
3.1. Autophagy: a lysosomal degradation pathway 
Autophagy or "self-eating" digests proteins and organelles to reuse. Autophagy is an 
evolutionary highly conserved mechanism involved in cellular homeostasis under basal 
conditions and is upregulated during cellular stress [60]. During autophagy, cytoplasmic 
content is delivered to lysosomes for degradation to macronutrients and energy. As shown in 
Figure 7 , there are three isoforms: 1) micro-autophagy, i.e. direct engulfment of cytoplasmic 
content by a lysosome, 2) chaperone-mediated autophagy (CMA), i.e. delivery of cytoplasmic 
proteins by specific chaperones to the lysosome and 3) macro-autophagy, i.e. isolation of 
cytoplasmic material in a double membrane structure, which will subsequently fuse with the 
lysosome [61], [62]. Macro-autophagy is thought to play the most significant role under 
pathophysiological conditions and we refer to this isoform through this thesis [62]. Autophagy 
is a context-dependent tumour-suppressing mechanism that can also promote tumour cell 
survival upon stress and treatment resistance [63]. Because of this ambiguity, autophagy is 
considered as a double-edged sword, making therapeutic approaches highly challenging. 
 
 
Figure 7. The three forms of autophagy: macroautophagy, microautophagy and chaperone-mediated 
autophagy. Macroautophagy starts with the de novo formation of a cup-shaped double membrane that 
engulfs a portion of cytoplasm. Microautophagy involves the engulfment of cytoplasm instantly at the 
lysosomal membrane by invagination, protrusion and separation. Chaperone-mediated autophagy is a 
process of direct transport of unfolded proteins via the lysosomal chaperonin hsc70 and LAMP-2A. All 
forms of autophagy subsequently lead to the degradation of intra-autophagosomal components by lysosomal 
hydrolases. PE, phosphatidylethanolamine. [64] 
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3.2. Autophagy and endoplasmic reticulum stress: integration of two double-
edged swords 
ER stress induces autophagy directly through upregulation of GRP78 and through mechanisms 
downstream of the three UPR signal transducers [65]. A critical role for GRP78 in autophagy 
was demonstrated with GRP78 knockdown in normal and cancer cells, which prevented 
autophagosome formation in response to starvation or in response to tunicamycin, an inhibitor 
of N-linked glycosylation required for proper protein folding. The massively dilated and 
disrupted ER and deficient autophagosome formation induced by GRP78 knockdown were both 
alleviated by simultaneous knockdown of the IRE1-regulated XBP1 [66], suggesting that intact 
ER is maintained by and required for autophagy. 
The link between the IRE1 branch and autophagy is mediated by IRE1-activated JNK. A study 
conducted in neuroblastoma cells using siRNA knockdown of IRE1, PERK or ATF6 or using 
a JNK inhibitor, demonstrated that ER stress upregulated autophagy through a mechanism 
dependent on IRE1, but independently of PERK and ATF6 [67]. ER stress was induced with 
ER stress inducers tunicamycin or thapsigargin, an agent that blocks ER Ca2+ uptake by 
inhibiting ER Ca2+-ATPase. In this model, autophagy protected against cell death as 
demonstrated by the increased cell death when autophagy was inhibited by chemical (3-
methyladenine) or genetic manipulation (ATG7 siRNA) and suppressed cell death when 
autophagy was induced by chemical stimulation by the mTOR inhibitor rapamycin. The 
mechanism of autophagy induction downstream of JNK is a result of JNK phosphorylation of 
Bcl-2, which releases Bcl-2 repression of the autophagy factor Beclin1 [68]. 
The link between the PERK arm and autophagy is mediated by ATF4-driven upregulation of 
the ATG genes [69]. Treatment of embryonic carcinoma cells with misfolded polyglutamine 
repeats caused accumulation of polyubiquitinated protein aggregates and induced LC3 
conversion through a PERK-dependent mechanism and resulting in autophagic elimination of 
the aggregates [70]. When proteasomal inhibitor bortezomib was used in pancreatic cancer 
cells, phospho-eIF2α led to ATF4-driven transcription of ATG5 and ATG7 [71]. 
All three of the UPR arms were involved in the induction of autophagy in breast cancer cells 
caused by accumulation of sphingosine-1-phosphate [72]. The resulting autophagy was 
prevented by silencing of PERK, IRE1 or ATF6. In conclusion, multiple levels of integration 
between autophagy and the UPR can maintain cellular homeostasis or default into apoptosis. 
Upon stress, the ultimate consequence of cell survival or apoptosis depends on the balance of 
events linked at multiple network connections between the UPR and autophagy.  
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 Angiogenesis and endoplasmic reticulum stress 
4.1. Angiogenesis 
Angiogenesis refers to the sprouting, migration and remodelling of existing blood vessels and 
plays a crucial role in several physiological processes as well as in a number of diseases 
including liver diseases and cancer [73], [74]. Endothelial cells exhibit the ability to divide 
rapidly in response to physiological stimuli, such as hypoxia, inflammation and shear stress. 
However, when these stimuli become too pronounced, angiogenesis becomes a key 
pathophysiological process, for example, in tumour growth. HCC cells exhibit rapid growth 
and consequently require high oxygen and nutrient supply [75]. Hence, these tumour cells 
induce the formation of new blood vessels to counteract hypoxia. As mentioned previously, 
HCC lesions are characterised by arterial hypervascularity to provide the tumour with 
oxygenated blood [1]. However, these neo-vessels are marked by a disorganised vasculature, 
consisting of leaky and tortuous vessels, resulting in a chaotic and dysfunctional blood flow 
[75]. 
Angiogenesis is tightly regulated by pro- and anti-angiogenic factors that are produced in 
steady-state. Pro-angiogenic factors such as VEGF, fibroblast growth factor (FGF), PDGF and 
interleukin-8 (IL-8), bind to their receptors on endothelial cells causing proliferation, release of 
matrix metalloproteinases and migration towards the angiogenic stimuli, and finally inducing 
the formation of new blood vessels [76]. The best characterized pathway regulating VEGF is 
the hypoxia inducible factor (HIF) pathway activated by hypoxia [77]. HIF1 and HIF2 are 
heterodimeric transcription factors composed of an α and β subunit. The β subunit is 
constitutively expressed but the α subunit is labile in an oxygen rich setting. When hypoxia 
occurs the α subunit is stabilized, thereby activating the HIF-complex, which induces 
transcription of pro-angiogenic factors such as VEGF and leads to angiogenesis restoring the 
oxygen levels [77], [78]. 
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4.2. Angiogenesis and endoplasmic reticulum stress 
It is well established that hypoxia and glucose deprivation induce angiogenesis in tumours, 
triggering the growth of new capillaries from pre-existing vessels [79]. Importantly, ER stress 
was shown to stimulate angiogenesis in tumour cells, where the UPR shifts the balance from 
anti-angiogenic to pro-angiogenic events through modulating the expression of different factors 
including VEGF, FGF, interleukin (IL)-1β, IL-6 and IL-8 [79], [80]. In fact, hypoxia causes 
upregulation of VEGF through the HIF pathway as well as via the UPR [73].  
Glucose or amino acid deprivation, as well as chemical ER stress inducers thapsigargin and 
tunicamycin also induce VEGF upregulation, but only via the UPR [81]. The PERK target 
ATF4 directly binds to the VEGF promoter [73]. The IRE1/XBP1 axis also increases 
angiogenesis in cancer models, including VEGF and IL-6 expression [73]. Moreover, GRP78 
expression accelerates cancer progression also through induction of tumour angiogenesis [82]. 
Recently, Karali et al. (2014) revealed that VEGF signalling engages UPR sensors in an 
unconventional manner independently of ER stress, mediated by mTOR signalling, to promote 
endothelial cell survival and angiogenesis [81]. This finding extends the role of the UPR sensors 
beyond adaptation to ER stress. 
4.3. The placental growth factor 
Another member of the VEGF family which contributes to pathological angiogenesis is the 
placental growth factor (PlGF) [83], [84]. The PlGF gene is highly expressed in the placenta at 
all stages of human gestation. Unlike VEGF, the role of PlGF during embryogenesis and 
physiological angiogenesis is redundant. PlGF-deficient mice are viable and fertile and do not 
have any visible abnormalities [85]. Recently, HIF-1α and chromatin remodelling were shown 
to be involved in the hypoxia-mediated upregulation of PlGF [86]. Studies in transgenic mice 
revealed that the angiogenic activity of PlGF is restricted to pathological conditions. Loss of 
PlGF impairs angiogenesis in wounded skin, ischemic retina, limb or heart and in cancer, 
whereas administration of recombinant PlGF promotes collateral vessel growth in models of 
limb and myocardial ischemia [85], [87]. 
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The effect of PlGF is mediated by binding to VEGFR-1 and neuropilin-1 [88]. VEGFR1 is 
minimally expressed in adult quiescent vessels but membranous localization is upregulated 
during pathological conditions, stimulating PlGF-dependent angiogenesis. Different direct and 
indirect effects after PlGF-receptor interaction can lead to increased angiogenesis [89]. PlGF 
has been proposed to stimulate angiogenesis by displacing VEGF from VEGFR-1, thereby 
increasing the fraction of VEGF available to activate its main receptor, VEGFR-2. Activation 
of VEGFR-1 can also induce a crosstalk with VEGFR-2 resulting in transphosphorylation of 
VEGFR-2, which becomes more active in signalling VEGF-driven angiogenesis. Alternatively, 
PlGF might stimulate angiogenesis by direct signalling via VEGFR-1 or by forming 
heterodimers with VEGF [89]. 
As the role of PlGF is mainly restricted to pathological conditions, blocking PlGF signalling 
may be an attractive target to avoid potential side-effects related to VEGF inhibition such as 
thrombosis, hypertension and proteinuria [90]. In contrast to VEGF inhibitors, a monoclonal 
anti-PlGF antibody (aPlGF) has been shown to reduce pathological angiogenesis in various 
spontaneous cancer and other disease models without affecting healthy blood vessels, resulting 
in no major side effects [91]–[93]. We previously showed that PlGF inhibition exerts 
antitumour effects and induces vessel normalization in experimental HCC (Fig. 8) [91], [93]. 
However, the exact role of PlGF in tumoural UPR activation remains elusive. 
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Figure 8. PlGF inhibition induces vessel normalization and antitumour effects in 
experimental HCC. (A) Mean tumour burden is reduced in placental growth factor knockout 
(PlGFKO) compared to wild type mice following 20, 25 and 30 weeks of diethylnitrosamine 
(DEN). *p<0.05, **p<0.01, ***p<0.001. (B) Scanning electron microscope images showing 
the microvasculature of IgG (chaotic) and anti-PlGF (αPlGF) (normalised) treated 
peritumoural vessels. Adapted from [91]. 
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 Artemisinins, cancer and endoplasmic reticulum stress 
5.1. Artemisinins 
Artemisinins are a family of sesquiterpene trioxane lactone anti-malarial agents originally 
derived from sweet wormwood Artemisia annua L. [94]. With its established safety record in 
millions of malarial patients, Artemisinins are also being investigated in cancer [95]. The active 
moiety is dihydroartemisinin (DHA), which is the reduced form of Artemisinin. Since DHA 
has unfavourable thermal stability, it is more convenient for pharmaceutical applications to use 
DHA prodrugs, including the stable succinate-ester derivative, Artesunate [96]. The latter 
confers substantial water-solubility and high oral bioavailability, resulting in a more favourable 
pharmacological proﬁle. Artesunate is recommended by the World Health Organization in 
preference to quinidine for the treatment of malaria and has been used worldwide for many 
years. In 2007, the Food and Drug Administration made intravenous Artesunate available for 
treatment of malaria in the United States. 
5.2. Artesunate and cancer: old drug, new tricks? 
Artesunate has demonstrated remarkable cytotoxicity against a wide range of human tumour 
cell lines and showed anticancer activity in different animal models, including HCC [97], [98]. 
The multi-faceted mechanism of action of Artesunate involves the formation of free radicals 
via cleavage of the endoperoxide bond in its structure, protein alkylation, induction of 
apoptosis, angiogenesis inhibition, cell cycle regulation and abrogating cancer invasion and 
metastasis [99]. Importantly, the anti-cancer activity of DHA is also associated with induction 
of iron-dependent ER stress [100]. These preclinical results led to the development of clinical 
trials with Artesunate in cervical [101] and lung [102] cancer, which showed promising results. 
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 Experimental mouse models for hepatocellular carcinoma 
6.1.  Carcinogen-induced mouse model 
When selecting a model for HCC research, one must first understand the limitations and 
advantages that the specific model possesses. The advantage of chemically-induced models is 
the similarity with the injury-fibrosis-malignancy cycle observed in humans [103]. 
Diethylnitrosamine (DEN) is often used as a carcinogen and the target organ in which DEN 
induces tumours is species-dependent. Mice mostly develop liver tumours [104]. The 
carcinogenic capacity of DEN is situated in its capability of alkylating DNA-structures. In the 
first step DEN is hydroxylated to hydroxylnitrosamine. This bioactivation step is oxygen- and 
NADPH-dependent and mediated by cytochrome P450, an enzyme that has its highest activity 
in the centrilobular hepatocytes [105]. After cleavage of acetaldehyde, an electrophilic 
ethyldiazonium ion is formed and causes DNA-damage by reacting with nucleophiles such as 
DNA-bases. Furthermore, oxidative stress caused by DEN can contribute to the 
hepatocarcinogenesis [106]. Reactive oxygen species (ROS) generated by cytochrome P450 
induce oxidative stress due to the formation of hydrogen peroxide and superoxide anions [106]. 
Production of ROS is known to cause DNA, protein and lipid damage; consequently oxidative 
stress has been known to play a significant role in DEN-elicited carcinogenesis.  
Chronic DEN exposure for 25 weeks, in contrast to single DEN injection, induces small cell 
dysplasia, ductular hyperplasia and readily distinguishable HCC nodules occurring in a 
background of liver inflammation and mild fibrosis [104]. Additionally, we reported (YP. 
Vandewynckel, R. De Rycke, E. Bogaerts, H. Van Vlierberghe. Intestinal metaplasia in an 
orthotopic mouse model for hepatocellular carcinoma. Dig Liver Dis. 2014;46,e17) the rare 
occurrence of intestinal metaplastic cells in the liver parenchyma of DEN-treated mice. 
Intestinal metaplasia is the transformation of epithelium, usually of the stomach or the 
oesophagus but here of the hepatocytes, to an intestinal type. The existence of this phenotype 
is evidence of the multipotency of hepatic stem/progenitor cells involved in the hepatic healing 
response to DEN. 
Limitations of this model include the high variability in tumour burden and high mortality (i.e. 
mean survival of 70% in our hands). In conclusion, DEN has been shown to induce tumours 
which are histologically similar to human HCC with poor prognosis. 
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6.2. Xenograft mouse model 
In xenograft models, injecting human cancer cells from a cell culture in immune-deficient mice 
creates the tumours. Athymic (nude) or severe combined immune deficient mice are often used 
as hosts [103]. In the ectopic xenograft model, human tumour cells are subcutaneously injected 
in these mice and tumour volume is followed over time. The advantages of xenograft mouse 
models is the short time span needed for tumour development, low mortality and the low 
variability in tumour burden. However, the histological resemblance between xenograft and 
human tumours is rather poor [107].  
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 Aims of the work 
A role for ER stress signalling in cancer was initially proposed in 1996, introducing the concept 
that it could either be beneficial for tumour growth or play a guardian role to prevent cell 
transformation [108], [109]. Accumulating evidence in the course of the last decade indicated 
that all branches of the UPR contribute to the tumourigenesis, affecting diverse aspects of the 
disease including angiogenesis, cell differentiation, cell migration, tumour growth and the 
inflammatory microenvironment [41]. Also in human HCC, the UPR was shown to be activated 
[56]. 
 
 First, we aimed to determine the presence of ER stress and the temporal dynamics of 
UPR activation in the well-known diethylnitrosamine-induced mouse model for HCC. 
Additionally, we aimed to validate innovative imaging techniques for the functional 
assessment of experimental HCC burden (in collaboration with Infinity Lab, Ghent 
University). 
 
 Secondly, we aimed to explore the effects of rational UPR modulation on HCC cell 
viability and proliferation in vitro and in the mouse model. 
 
These objectives were assessed in the following manuscript: 
Y.-P. Vandewynckel, D. Laukens, E. Bogaerts, A. Paridaens, A. Van den Bussche, X. Verhelst, C. Van Steenkiste, 
B. Descamps, C. Vanhove, L. Libbrecht, R. De Rycke, B. N. Lambrecht, A. Geerts, S. Janssens, H. Van 
Vlierberghe. Modulation of the unfolded protein response impedes tumor cell adaptation to proteotoxic 
stress: a PERK for hepatocellular carcinoma therapy. Hepatol. Int. 2014,9:93-104. 
 
 Thirdly, we assessed the impact of ER stress in tumour initiation and progression by 
applying tauroursodeoxycholic acid (TUDCA), a bile acid with chaperone properties 
reducing ER stress, in the diethylnitrosamine-induced HCC model in preventive and 
therapeutic settings. 
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This objective was assessed in the following manuscript: 
Y.-P. Vandewynckel, D. Laukens, L. Devisscher, A. Paridaens, E. Bogaerts, X. Verhelst, A. Van den Bussche, S. 
Raevens, C. Van Steenkiste, M. Van Troys, C. Ampe, B. Descamps, C. Vanhove, O. Govaere, A. Geerts, H. Van 
Vlierberghe. Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic reticulum 
stress during hepatocarcinogen exposure. Oncotarget 2015,6:X. Accepted. 
 
 Finally, we assessed the effect of established or potential HCC treatments possibly 
modulating the UPR, including sorafenib, artesunate, PlGF inhibition and proteasome 
inhibition, on the tumour growth and UPR signature in HCC and subsequently aimed to 
enhance the antitumour efficacy of these treatments by UPR modulation subverting ER 
stress towards apoptosis of the tumour cells.  
 
These objectives were assessed in the following manuscripts: 
Y.-P. Vandewynckel, I. Desaegher, D. Laukens, L. Devisscher, E. Bogaerts, A. Paridaens, S. Raevens, A. Van den 
Bussche, X. Verhelst, C. Van Steenkiste, B. Descamps, C. Vanhove, L. Libbrecht, A. Geerts, B. N. Lambrecht, S. 
Janssens, H. Van Vlierberghe. Antitumor efficacy of sorafenib is potentiated by modulation of the interplay 
between the unfolded protein response and autophagy in hepatocellular carcinoma. Manuscript in 
preparation, patent application filed. 
Y.-P. Vandewynckel, D. Laukens, A. Geerts, C. Vanhove, B. Descamps, L. Devisscher, E. Bogaerts, A. Paridaens, 
X. Verhelst, C. Van Steenkiste, L. Libbrecht, I. Colle, B. Lambrecht, S. Janssens, H. Van Vlierberghe. 
Therapeutic Effects of Artesunate in Hepatocellular Carcinoma: Repurposing an Ancient Antimalarial 
Agent. Eur. J. Gastroenterol. Hepatol. 2014, 26:861-70. 
Y.-P. Vandewynckel, D. Laukens, L. Devisscher, E. Bogaerts, A. Paridaens, A. Van den Bussche, S. Raevens, X. 
Verhelst, C. Van Steenkiste, B. Jonckx, L. Libbrecht, A. Geerts, P. Carmeliet, H. Van Vlierberghe. Placental 
growth factor inhibition modulates the interplay between hypoxia and the unfolded protein response in 
hepatocellular carcinoma. Submitted for publication in BMC cancer. 
Y.-P. Vandewynckel, C. Coucke, D. Laukens, L. Devisscher, A. Paridaens, E. Bogaerts, A. Van den Bussche, S. 
Raevens, X. Verhelst, C. Van Steenkiste, L. Libbrecht, A. Geerts1, H. Van Vlierberghe. Next-generation 
proteasome inhibitor oprozomib synergizes with modulators of endoplasmic reticulum stress in 
hepatocellular carcinoma. Manuscript in preparation, patent application filed. 
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 Identification and modulation of the ER stress phenotype in experimental 
hepatocellular carcinoma 
1.1. Modulation of the unfolded protein response impedes tumor cell 
adaptation to proteotoxic stress: a PERK for hepatocellular carcinoma therapy 
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Modulation of the unfolded protein response impedes tumor cell adaptation to 
proteotoxic stress: a PERK for hepatocellular carcinoma therapy 
 Abstract 
Background 
Functional disturbances of the endoplasmic reticulum (ER) lead to activation of the unfolded 
protein response (UPR), which is involved in the consecutive steps of carcinogenesis. In human 
hepatocellular carcinoma (HCC), the UPR is shown to be activated; however, little is known 
about the UPR kinetics and effects of UPR modulation in HCC. 
Methods 
We sequentially monitored the UPR over time in an orthotopic mouse model for HCC and 
explored the effects of UPR modulation on cell viability and proliferation in vitro and in the 
mouse model. 
Results 
The expression of ER-resident chaperones peaked during tumor initiation and increased further 
during tumor progression, predominantly within the nodules. A peak in Ire1 signaling was 
observed during tumor initiation. The Perk pathway was activated during tumor progression, 
and the proapoptotic target Chop was upregulated from week 5 and continued to rise, especially 
in the tumors. The Atf6 pathway was modestly activated only after tumor initiation. Consistent 
with the UPR activation, electron microscopy demonstrated ER expansion and reorganization 
in HCC cells in vivo. Strikingly, under ER stress or hypoxia, the Perk inhibitor and not the Ire1 
inhibitor reduced cell viability and proliferation via escalating proteotoxic stress in vitro. 
Notably, the Perk inhibitor significantly decreased tumor burden in the mouse model. 
Conclusion 
We provide the first evaluation of the UPR dynamics in a long-term cancer model and identified 
a small molecule inhibitor of Perk as a promising strategy for HCC therapy.
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 Abbreviations 
HCC Hepatocellular carcinoma 
ER Endoplasmic reticulum 
GRP78 Glucose-regulated protein, 78 kDa 
GRP94 Glucose-regulated protein, 94 kDa 
PDIA4 Protein disulfide-isomerase A4 
CANX Calnexin 
ERAD ER-associated protein degradation 
EDEM1 Degradation-enhancing a-mannosidase-like protein 
UPR Unfolded protein response 
PKR dsRNA-dependent protein kinase 
PERK PKR-like endoplasmic reticulum kinase 
IRE1 Inositol requiring enzyme 1 
ATF6 Activating transcription factor 6 
eIF2a Eukaryotic initiation factor 2a 
ATF4 Activating transcription factor 4 
CHOP CCAAT/enhancer-binding protein homologous protein 
NRF2 Nuclear factor erythroid 2-related factor 2 
GCLC Glutamate-cysteine ligase, catalytic subunit 
GPX3 Glutathione peroxidase 3 
ERDJ4 Endoplasmic reticulum DnaJ homolog 4 
ERO1L Endoplasmic oxidoreductin-1-like protein 
XBP1u Unspliced X-box-binding protein 1 
HERPUD1 Homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like 
domain member 1 protein 
XBP1s Spliced X-box-binding protein 1 
DEN Diethylnitrosamine 
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W Week 
PERKi PERK inhibitor 
GADD34 Growth arrest and DNA damage-inducible protein 
TUDCA Tauroursodeoxycholic acid 
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 Introduction 
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality 
worldwide [1]. Conventional chemotherapy is ineffective, and targeted therapy for advanced 
HCC with sorafenib shows only a limited survival benefit [2]. 
The endoplasmic reticulum (ER) consists of a membranous network in which proteins are 
synthesized, posttranslationally modified and folded. Therefore, the ER lumen houses a large 
array of chaperones, including glucose-regulated protein-78 (GRP78) and -94 (GRP94), and 
protein disulfide-isomerase A4 (PDIA4), and contains stringent quality-control systems that 
selectively extract terminally misfolded proteins for degradation, a process known as ER-
associated protein degradation (ERAD), which is accelerated by ER degradation-enhancing 
amannosidase-like 1 (EDEM1) [3]. Several perturbations in protein folding lead to the 
accumulation of unfolded proteins that trigger the unfolded protein response (UPR). The UPR 
engages a transcriptional response involved in protein quality control, ERAD, redox 
homeostasis and ER expansion. Paradoxically, the UPR also coordinates proapoptotic 
responses to ER stress [3, 4]. 
Three major ER stress sensors have been identified: PKR-like endoplasmic reticulum kinase 
(PERK), inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6) [3]. 
Upon irremediable ER stress, the effect of ATF6 on cell fate is primarily cytoprotective, 
whereas the effect of IRE1 and PERK is presumed to be both proadaptive and proapoptotic [4, 
5]. 
Following the release of GRP78, PERK phosphorylates eukaryotic initiation factor 2a (eIF2a), 
leading to the attenuation of global translation. However, the translation of certain transcripts, 
such as activating transcription factor 4 (ATF4), is favored. ATF4 induces genes involved in 
protein quality control, amino acid biosynthesis and the induction of apoptosis via 
CCAAT/enhancer-binding protein homologous protein (CHOP) [3]. PERK-regulated nuclear 
factor-(erythroid-derived-2)-like-2 (NRF2) promotes cell survival via antioxidant enzymes, 
such as glutamate-cysteine ligase, catalytic (GCLC) and glutathione peroxidase-3 (GPX3) [6]. 
IRE1 activation results in XBP1 mRNA splicing to generate a more active spliced XBP1 
(XBP1s), which induces genes involved in protein folding, such as ERDJ4 and CANX, ERAD 
and redox homeostasis [7].  
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ATF6 is mobilized to the Golgi where it is cleaved, releasing a transcriptionally active fragment, 
which in turn induces the expression of chaperones, such as PDIA4 and endoplasmic 
oxidoreductin-1-like protein (ERO1L), unspliced XBP1 (XBP1u) and ERAD components, such 
as homocysteine-responsive endoplasmic reticulum-resident ubiquitin-like domain member 1 
(HERPUD1) [3, 7]. Although each UPR pathway targets a specific set of genes, certain targets 
require the concomitant activation of two pathways, e.g., P58IPK and EDEM1 transcription 
require the cooperation of ATF6 and XBP1s [7]. 
Rapid tumor growth creates hypoxia, glucose deprivation and oxidative stress, activating the 
UPR in various solid tumor types [3]. In human HCC, elevated GRP78, ATF6 and IRE1 
activation was observed [8–10]. The UPR demonstrates a specific time-dependent pattern of 
activation that determines its cytoprotective versus proapoptotic outcome [11]. However, these 
alterations have only been investigated in vitro during acute ER stress in a maximum time 
period of 48 h [3, 11], and it is unknown how tumor cells adapt to chronic ER stress in vivo. In 
the present study, we monitored the kinetics of the UPR, a potential tumoral Achilles’ heel, in 
an orthotopic mouse model for hepatocarcinogenesis [12, 13]. Our data showed IRE1 signaling 
during tumor initiation and robust PERK activation once the tumors had been established. 
Furthermore, we explored the therapeutic potential of UPR modulation in vitro and in vivo. We 
observed that in contrast to the dogma stating that PERK induces apoptosis via CHOP 
accumulation, a small molecule inhibitor of PERK actually reduces HCC burden via 
proteotoxicity. 
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 Materials and methods 
Cell culture 
HepG2, BWTG3 and Hepa1-6 (ATCC, Manassas, VA, USA) cells were cultured with DMEM 
supplemented with 10 % fetal bovine serum (Life Technologies, Ghent, Belgium). Cells were 
incubated for 48 h with tunicamycin (1.25 µg/ml), a PERK inhibitor (0.3 µM; GSK2656157, 
NoVi Biotechnology, Shandong, China), an IRE1 inhibitor (8 µM; 4µ8C, Calbiochem, 
Cambridge, MA, USA), salubrinal (50 µM; Tocris, Bristol, UK), tauroursodeoxycholic acid (1 
µM), cycloheximide (5 µM), ascorbic acid (50 µM) or pretreated with N-acetylcysteine (2 h; 5 
µM), SP600125 and SB203580 (30 min; 10 µM), and compared to equal volumes of solvent in 
normoxic and hypoxic (1 % oxygen; AnaeroGen, Oxoid, Hampshire, UK) conditions. All 
reagents were from Sigma (Diegem, Belgium) unless stated otherwise. Each experiment was 
performed in quadruplicate. 
 
Animals 
Wild-type 129S2/SvPasCrl mice (Charles River, Brussels, Belgium) were maintained as 
previously described [12]. Five-week-old males received weekly intraperitoneal saline or 
diethylnitrosamine (DEN; 35 mg/kg). Every 5 weeks (W) until W30 (12 groups with n = 12), a 
group of mice was euthanized. The mice were killed 1 week after the last DEN injection. By 
macroscopic and microscopic assessments, three liver tissue areas, non-HCC (no nodules in the 
close proximity), surrounding (perinodular ring of altered hepatic tissue) and HCC (nodules), 
were isolated by microdissection (Carl Zeiss, Bernreid, Germany) from W25 because at this 
time, nodules could be clearly distinguished from the surrounding tissue. The number of tumors 
with a minimum diameter of 2 mm was counted. In addition, 30 µg of tunicamycin was injected 
intraperitoneally in four untreated 30-week-old male mice 72 h before sacrifice. After 
randomizing mice treated for 25 W with DEN or saline, GSK2656157 (100 mg/kg bid) was 
administered intraperitoneally for 4 W and compared with the vehicle (4 groups with n = 12).  
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Blood was collected from the ophthalmic artery. All organs were fixed in 4 % phosphate-
buffered formaldehyde and embedded in paraffin or snap frozen in liquid nitrogen. 
Hematoxylin & eosin and reticulin stainings were performed to assess the tumor burden as 
shown by the mean total tumor surface of six slides per liver and blindly evaluated by two 
independent observers. Interobserver reliability was substantial (intraclass correlation 
coefficient = 0.74). Mean intercapillary distance was measured on CD105-stained slides as 
previously described [12]. Sirius Red staining enabled fibrosis assessment by Metavir scoring. 
Serum alanine aminotransferase and glycemia were measured at Ghent University Hospital. All 
protocols were approved by the Ethics Committee of experimental animals, Ghent University 
(ECD 11/52). 
 
Detailed information regarding RNA extraction, quantitative real-time PCR, Western blot 
analysis, immunohistochemistry, TUNEL immunofluorescence, WST-1 and caspase-3 activity 
assays, electron microscopy and positron emission tomography is provided in the 
Supplementary Materials and Methods. 
 
Statistics 
Statistical analysis was performed using SPSS 21 (SPSS, Chicago, IL, USA). Data are 
presented as the mean ± SD or as the fold change relative to the expression in the controls. 
Normally distributed data were subjected to unpaired Student’s t test. Multiple groups were 
compared by one-way ANOVA with Bonferroni correction. Non-normally distributed data 
were tested using the Mann-Whitney U test. The Friedman test with Bonferroni correction was 
applied to compare non-HCC, surrounding and tumor tissues of the same liver. The chi-squared 
test was used to compare mortality. Reported p values were two sided and considered 
significant when lower than 0.05. 
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 Results 
Kinetics of chaperone expression in the HCC model 
Every 5 weeks (W) after DEN administration, mice were killed for the analysis of tumor 
progression and the expression of the (co-)chaperones Grp78, Grp94 and P58IPK (Fig. 1a). At 
W25, tumor nodules were observed in a background of fibrosis (Fig. S1). The expression of 
Grp78 was upregulated at W10 (mRNA: p<0.05; protein: Fig. 1b) but reduced again at W15 
(mRNA: p<0.05), and once tumors were established, Grp78 mRNA was elevated in the nodules 
compared to the surrounding (p<0.05) and non-HCC tissue (p<0.01). By 
immunohistochemistry, we demonstrated an inhomogeneous pattern of Grp78-positive HCC 
cells within the nodules, but only a few Grp78-positive cells in the surrounding tissue (Fig. 1c). 
Grp94 mRNA followed a similar temporal pattern, i.e., increased from W25 only in the 
surrounding and tumor tissue (p<0.05, Fig. 1a). Accordingly, in addition to a tendency to 
increase at W10, co-chaperone P58IPK exhibited upregulation in the surrounding tissue and 
nodules from W25 (Fig. 1a). 
The Ire1 pathway is activated before tumor promotion 
At W10, phospho-Ire1 levels (Fig. 1b), detected by the use of a phosphate-binding tag, and 
Xbp1 splicing (p<0.05, Fig. 1d) were increased. Two targets of Xbp1s (7), Canx mRNA and 
Erdj4 mRNA showed a similar evolution until W20, but in contrast to the Xbp1 splicing, they 
continued to rise in the tumor tissue (p<0.05, Fig. 1d). Additionally, Edem1 mRNA peaked at 
W5 (p<0.05) but not during tumor growth. Although splicing activity was not significantly 
altered in the DEN- compared with saline-treated mice at W30 (Fig. 1d), phospho-Ire1 levels 
were increased in the tumors (Fig. 1b), suggesting additional regulation of the Ire1 
endoribonuclease, possibly by reduced oligomerization [3, 14]. 
The Perk pathway is robustly activated in HCC 
At W25, during tumor progression, Atf4 mRNA upregulation was observed and limited to the 
nodules (Fig. 2a). At W30, expression expanded to the surrounding tissues (Fig. 2a, b).  
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Phosphorylation of eIf2a was increased in both surrounding and tumor tissue at W30 (Fig. 2b). 
Immunostaining for phospho-eIf2a showed a diffuse distribution in the surrounding tissue, 
intensifying toward the core of the nodules at W30. The expression of Chop, a presumed 
proapoptotic target of Perk [4], was increased from the beginning, then stable between W5 and 
W20 and from W25 continued to increase. Although expression was higher in HCC compared 
to non-HCC tissue (p<0.05), both Chop mRNA (Fig. 2a) and protein (Fig. 1b, 2b) levels were 
increased in all three isolated areas. Furthermore, caspase-3 activity, an indicator of apoptosis, 
was increased at W30 in the surrounding tissue and nodules (p<0.01, Fig. 2c). Growth arrest 
and DNA damage-inducible protein (Gadd34) demonstrated a similar pattern as Atf4, with a 
marked increase from W25, especially in the nodules (p<0.05; Fig. 2a, b), suggesting Perk 
activation in HCC. Concerning the Perk/Nrf2 axis, we observed the upregulation of Gpx3 
mRNA at W5, W10 and W20, and Gclc mRNA showed a tendency to upregulation at these 
time points (Fig. S2). Surprisingly, in the tumors both these transcripts showed a tendency to 
downregulation compared to the non-tumor liver. 
The Atf6 pathway is modestly activated after tumor initiation 
To examine the Atf6 pathway, Pdia4, Herpud1 and Ero1L expressions were monitored [7]. The 
expression of Pdia4 mRNA (p<0.05; Fig. 2d) and protein (Fig. 1b) was modestly increased 
from W30 in the tumors compared with the surrounding tissue. In accordance, Ero1L and 
Herpud1 mRNA was upregulated in the nodules from W30 compared with saline-treated livers 
(p<0.05; Fig. 2d). 
Murine HCC cells exhibit ultrastructural hallmarks of ER stress  
Electron microscopy of the tumors in the mouse model at W30 revealed an extensive expanded 
ribosome-bound ER in a lamellar pattern (Fig. 3a, middle panel) in the HCC cells compared 
with the ER in the hepatocytes of saline-treated mice (Fig. 3a, left panel). The liver of mice 
treated with the ER stress inducer tunicamycin showed extremely dilated ER in the hepatocytes 
(Fig. 3a, right panel).  
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Interestingly, some HCC cells demonstrated a remarkable ER reorganization with disruption of 
ribosome-bound ER and extension of smooth ER (Fig. 3b). These observations provide 
structural evidence for the hypothesis that DEN-induced hepatocarcinogenesis leads to ER 
stress. Consistent with histological Metavir scoring of fibrosis (Fig. S1C), we observed the 
increased presence of collagen fibers in the extracellular matrix (data not shown). 
PERK inhibition but not IRE1 inhibition diminishes the viability and proliferation of 
HCC cells under stressed conditions 
To address whether interfering with the UPR affects tumor growth, we first validated the effect 
of the PERK inhibitor (PERKi) and IRE1 inhibitor on HepG2 cells under hypoxia and in the 
presence of tunicamycin-induced ER stress. The expression of ER stress markers was induced 
by tunicamycin and hypoxia (Fig. 4b). 
PERKi induced no alterations in basal XBP1 splicing or on the basal expression of PERK 
targets (Fig. 4a, b). However, under hypoxia or ER stress, PERKi diminished the expression of 
chaperones GRP78 and PDIA4, the adaptive factor ATF4 and the proapoptotic factor CHOP 
and elevated IRE1 splicing activity (both p<0.05) compared with vehicle-treated cells (Fig. 4a, 
b). Under these conditions, PERKi decreased eIF2a phosphorylation, suggesting the unblocking 
of protein synthesis. Indeed, PERKi restored the tunicamycin-attenuated protein synthesis rate 
(Fig. S3A). The IRE1 inhibitor abolished basal and induced XBP1 splicing (p<0.001; Fig. 4a) 
and attenuated the induction of PDIA4 and GRP78, although to a lesser extent than in the 
presence of PERKi. ATF4 and CHOP were unchanged at the mRNA level but slightly increased 
at the protein level. We next defined the effect of these small molecules on the cell viability and 
proliferation rate in different HCC cell lines. Here, we also tested salubrinal, which is known 
to prevent eIF2a dephosphorylation, thus prolonging PERK activation. 
Neither hypoxia nor tunicamycin affected cell viability (Fig. 4c), and under normal conditions, 
UPR modulation did not alter cell viability in HepG2 cells. However, following ER stress 
induction, PERKi, but not the IRE1 inhibitor, strikingly reduced cell viability (p<0.001), while 
salubrinal increased cell viability (p<0.05). PERKi also impaired cell viability under hypoxia 
(p<0.01). Accordingly, PERKi elevated caspase-3 activity under these stressed conditions 
(p<0.001, Fig. 4d). 
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To further confirm the potential of PERKi-induced cell death, cell proliferation was assessed 
by the incorporation of the thymidine analog bromodeoxyuridine into DNA. Under ER stress, 
PERKi (p<0.01) and the IRE1 inhibitor (p<0.05) reduced the cell proliferation rate. Hypoxia 
increased the proliferation rate (p<0.001; Fig. S3B), and only PERKi was able to temper the 
hypoxia-stimulated proliferation (p<0.001). Viability experiments were repeated in BWTG3 
and Hepa1-6 cells with comparable results (Fig. S3C). These data suggest that PERKi is able 
to suppress HCC cell growth under conditions comparable to the tumor microenvironment. 
Antitumor effect of the PERK inhibitor is mediated by proteotoxic stress and not 
oxidative stress 
Because the PERK/NRF2 pathway is known to upregulate antioxidant enzymes [6], which were 
increased in our mouse model (Fig. S2), we examined whether the killing of HepG2 cells by 
PERKi depends on oxidative stress. Under ER stress, the co-incubation of PERKi with N-
acetylcysteine (NAC) or ascorbic acid, which attenuate oxidative stress by directly scavenging 
ROS, was unable to counteract the PERKi-mediated reduction of cell viability (Fig. S3D) or 
the IRE1 hyperactivation (data not shown). 
To examine whether the compensatory hyperactivation of the proapoptotic IRE1/JNK/p38 
pathway [4] is involved in the antitumor effect of PERKi, cells were pretreated with the JNK 
inhibitor SP600125 or the p38 inhibitor SB203580 (validation not shown). Both compounds 
did not affect the PERKi-mediated reduction of cell viability (Fig. S3D).  
Additionally, the combination of PERKi with the IRE1 inhibitor did not modify cell viability 
under ER stress compared with PERKi alone. These findings suggest that neither oxidative 
stress nor the observed IRE1 hyperactivation contribute to PERKi-induced cell death. In 
addition, we tested whether the PERKi-induced cell death was due to autophagy modulation by 
using inhibitors (3-methyladenine and chloroquine) or activators (rapamycin); however, despite 
validation by LC3 and P62 blotting, the effect of PERKi on viability was unaltered (data not 
shown). 
PERK is known to inhibit protein synthesis in response to accumulation of misfolded proteins 
[3]. To check whether the cellular stress caused by PERKi was due to proteotoxicity, 
cycloheximide was used to inhibit protein synthesis.  
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Additionally, the chemical chaperone tauroursodeoxycholic acid (TUDCA) was applied to 
reduce the load of misfolded proteins. Both cycloheximide and TUDCA decreased PERKi-
induced cell death under ER stress (p<0.001; Fig. S3D). These findings highlight a key role of 
proteotoxic stress in PERKi-induced cell death. 
The PERK inhibitor disrupts the UPR and reduces tumor growth in vivo 
Based on the in vitro data, we investigated the effects of PERKi in an orthotopic model of HCC. 
While the administration of PERKi in saline- or DEN-treated mice did not significantly alter 
weight or survival (Table 1), a tendency to increase the survival of the PERKi-treated HCC-
bearing mice was observed (83 vs. 66 % in the vehicle-treated group). No other clinical signs 
of toxicity were observed in any of the PERKi-treated groups. Furthermore, PERKi induced no 
inherent hepatotoxicity, as the serum alanine aminotransferase levels were similar to those in 
the vehicle-treated control mice (35.6 ± 11 vs. 41.3 ± 14 U/l). 
PERKi reduced PERK autophosphorylation in DEN-induced HCC, validating the in vivo 
activity of the small molecule used. Atf4 expression and eIf2a phosphorylation were only 
slightly reduced (Fig. 5a). The quantification analysis of HCC burden, characterized by the loss 
of normal reticulin staining, revealed that PERKi reduced the mean tumor number (10.5 ± 2.4 
vs. 7.8 ± 3.4; p<0.05) and burden (p<0.001; Fig. 5b) of the DEN-treated mice and rendered the 
tumors more spongiform with increased intercellular spaces. Choline positron emission 
tomography, used to visualize cellular membrane biosynthesis, demonstrated a decreased 
number of loci with high mean standardized uptake values after PERKi compared with vehicle 
administration (p<0.05; Fig. 5c). In addition, TUNEL immunofluorescence showed that DEN 
administration significantly increased the hepatic apoptosis rate compared with saline-treated 
livers (p<0.01) and that the PERK inhibitor induced a tendency to further elevate the apoptosis 
rate (Fig. S4). 
No abnormalities were found during the pathologic examinations of the heart, spleen and 
kidney. Because PERK is known to play an essential role in insulin biosynthesis [15], we 
examined the fasting blood sugar levels. Hyperglycemia was observed in the PERKi-treated 
mice (174 ± 43 vs. 118 ± 31 mg/dl, p<0.01). Taken together, PERKi decreased the tumor burden 
without inducing significant toxicity. 
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 Discussion 
HCC is the second leading cause of cancer-related mortality [1]. Hepatocarcinogenesis starts 
from the initial genotoxic insult, through the clonal expansion from a premalignant to a tumoral 
lesion (promotion) and finally to tumor progression [16]. In the present study, we monitored 
the UPR during hepatocarcinogenesis. We observed a differential induction of the UPR 
pathways with a strong activation of the PERK pathway in HCC. Initially, PERK induces eIF2a 
phosphorylation to globally attenuate translation, thus reducing the load of unfolded proteins 
entering the ER. Under irremediable ER stress, PERK induces CHOP accumulation and 
subsequently apoptosis. Interestingly, we found that a small molecule inhibitor of PERK leads 
to ER-stress-driven cell death and HCC regression via proteotoxicity. 
The chaperones, which assist protein folding, were elevated early during tumor initiation and 
even more so later on in the tumors. In contrast, the Atf6 pathway, a cytoprotective fine-tuner 
of the UPR [7], was not activated until W30, suggesting that Atf6-mediated adaptation is not a 
prerequisite for HCC initiation. Interestingly, the increased expression of Grp78 and Pdia4 
mRNA in the tumor nodules compared with the perinodular ring of hepatic tissue suggests that 
these targets are additionally upregulated by tumoral UPR fine-tuning. 
Ire1 signaling peaked before tumor development at W5-15, indicating a possible modulatory 
role for the Ire1 pathway during tumor initiation. The rise in Xbp1s could be an adaptation to 
the environment created by DEN-mediated inflammation [4, 12]. Surprisingly, Edem1 and 
P58IPK, both requiring the co-activation of Atf6 and Ire1, followed a different pattern. P58IPK 
was upregulated in the tumors, while Edem1, an ERAD accelerator [17], showed an early peak 
that faded thereafter. 
In C57Bl/6J models of HCC induced by a single DEN injection, Chop expression was only 
found in the tumors and, in contrast to our model with repeated DEN injections, not in the 
surrounding tissue [18, 19]. Because Chop expression was increased from the first time point 
in the liver parenchyma without canonical UPR activation, Chop may be upregulated by an 
integrated stress response induced by DEN-mediated oxidative stress [20, 21]. 
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To inhibit PERK, a recently developed small molecule (PERKi) was used and had no effect 
under normal conditions but potently diminished the viability of HCC cells under ER stress or 
hypoxia. In contrast, salubrinal treatment improved viability, suggesting a cytoprotective role 
of persistent eIF2a phosphorylation for attenuating protein synthesis [22]. In the mouse model, 
PERKi reduced the tumor burden. Collectively, these findings highlight the importance of the 
proadaptive outputs of PERK in HCC biology. Recently, the dogma of the proapoptotic PERK/ 
CHOP pathway was challenged by the observation that PERK-mediated eIF2a-
phosphorylation-attenuated protein synthesis is crucial for cell survival [5] and that CHOP 
promotes inflammation-mediated hepatocarcinogenesis [18, 19]. Accordingly, in the present 
study, PERKi augmented UPR-mediated cell death despite reduced expression of CHOP. 
PERKi decreased the expression of UPR-induced chaperones and the phospho-eIF2a/ATF4 
pathway, which protect tumor cells from UPR-induced apoptosis [3, 23]. Furthermore, PERKi 
elevated global protein synthesis during ER stress, possibly escalating the unfolded protein load 
and ROS formation. Moreover, a protein synthesis inhibitor and a chemical chaperone were 
each able to hamper the cytotoxic effect of PERKi. Intriguingly, eIf2a phosphorylation was 
only modestly reduced in vivo, suggesting that other eIf2a kinases are able to bypass PERK 
inhibition [3]. Importantly, antioxidants were unable to limit PERKi-mediated cell death, 
suggesting that oxidative stress is not required for its cytotoxicity and that the inhibition of the 
PERK/NRF2 pathway, which promotes the antioxidant defense, is not the dominant antitumor 
action. Notably, PERKi enhanced IRE1 activation under ER stress, indicating a compensatory 
adaptation, consistent with the hyperactivity of the IRE1/XBP1 system in embryonic stem cells 
with defective PERK signaling [24]. However, because the inhibition of the IRE1/p38/JNK 
pathway did not affect cell death by PERKi, this pathway seems to be redundant for its 
antitumor effect. These findings reveal a pivotal survival role for the PERK pathway under 
stressed conditions as present in the tumor microenvironment. 
PERK deficiency during development leads to Wolcott-Rallison syndrome [25]. However, in 
the therapeutic study with PERKi in adult mice, we observed no increased mortality or apparent 
toxicity with the exception of hyperglycemia, possibly due to reduced pancreatic b-cell mass 
[15]. In conclusion, our study sheds light on the UPR fine-tuning during hepatocarcinogenesis. 
Furthermore, our in vitro and in vivo results identified PERK inhibition as a novel approach to 
modulate the UPR in order to selectively kill ER-stressed HCC cells.  
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 Figures 
 
Fig. 1 Temporal dynamics of chaperones and the Ire1 pathway in the HCC model. a Real-time PCR 
of Grp78, Grp94 and P58IPK during hepatocarcinogenesis. Orange line compares DEN-treated groups at 
different time points. From W25, different tissue compartments were isolated: green, non-HCC; blue, 
surrounding; red, tumors. Dashed lines compare these compartments at W30. Relative fold change was 
calculated using the DDCT method. b Immunoblotting for UPR-mediated proteins. Results are 
representative of two independent experiments. Densitometric analysis of the p-Ire1:Ire1 ratio is 
indicated. c Immunostaining for Grp78 in livers treated for 30 W. Arrows indicate tumor. Positive control 
received a single injection with tunicamycin. Scale bar 100 lm. d Real-time PCR of Ire1mediated splicing 
activity, Erdj4, Canx and Edem1. The Ire1mediated splicing of Xbp1 mRNA is calculated as the relative 
ratio of spliced Xbp1 mRNA over total Xbp1 mRNA. Horizontal axis in (a) and (d) indicates the number 
of weeks of DEN treatment. *p<0.05, **p<0.01. 
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Fig. 2 Temporal dynamics of genes regulated by Perk or Atf6 in the HCC model. a Real-time PCR 
analysis of Perk-regulated genes. b Immunoblotting and immunostaining for Perk-regulated genes in 
livers treated for 30 W with DEN or saline. Positive control received tunicamycin for 72 h. Arrows 
indicate tumors. Scale bar 100 lm. c Caspase-3 activity of liver lysates of the indicated tissue after 30 
weeks of saline or DEN administration. d Real-time PCR analysis of Atf6 target genes. Horizontal axis 
in (a) and (d) indicates the number of weeks of DEN treatment. Data are presented as the mean ± SD. 
One-way ANOVA was applied for statistical analysis. *p<0.05, **p<0.01. 
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Fig. 3 Transmission electron microscopy of saline- and tunicamycin-treated livers and DEN-induced 
tumors of the mouse model. a Expansion of the endoplasmic reticulum (ER; arrows) in HCC cells (middle 
panel) compared with saline-treated livers (left panel). Dilated ER in the liver of mice that received 
tunicamycin for 72 h (right panel). CF, collagen fibers. Tunicamycin-induced lipid droplets are indicated 
by arrowheads. b Reorganization of the endoplasmic reticulum after 30 weeks of DEN administration. 
DEN-induced HCC: hepatocellular carcinoma nodules isolated from the diethylnitrosamine-treated mouse 
liver. 
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Fig. 4 Effect of salubrinal, PERK or IRE1 inhibitor on the UPR and cell viability in HepG2 
cells. Cells were subjected to hypoxia or tunicamycin as indicated for 48 h. a Effect on UPR marker 
mRNA expression by a PERK inhibitor and by an IRE1 inhibitor compared with solvent-treated 
cells under the same condition. b Immunoblotting for UPR markers. c Cell viability of HepG2 cells 
was assessed by a WST-1 assay. d Caspase-3 activity of HepG2 cells treated with the indicated 
compounds. These experiments were repeated six times with similar results. *p<0.05, ***p<0.001. 
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Fig. 5 A PERK inhibitor reduces HCC burden in the orthotopic mouse model. a Immunoblotting for 
phospho-Perk, Atf4 and phospho-eIf2a in the lysates of isolated tumors after 25 weeks of DEN followed by 
treatment with a PERK inhibitor or vehicle. Experiments were repeated twice with similar results. b Reticulin 
staining to quantify the tumor burden as shown by mean total tumor surface. Arrows indicate tumors. c 18F-
Choline positron emission tomography visualizes cell membrane synthesis after the indicated treatments. 
Arrows indicate the left kidney for reference density. Standardized uptake values of the mouse livers are 
presented as the mean ± SD. One-way ANOVA was applied for statistical analysis. *p<0.05, **p<0.01 
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 Tables 
NS not significant compared with vehicle 
*** p<0.001: 25 weeks DEN versus saline 
  
Table 1 Mouse body weights (g) (mean ± SD) and survival rates (%) 
Group Mean body weight 25 
weeks (g) 
Mean body weight 30 
weeks (g) 
Survival 
(%) 
Saline + vehicle 28.22 ± 2.10 27.03 ± 1.93 100 
Saline + PERK inhibitor 27.42 ± 3.09 24.92 ± 3.38 NS 91.67 
DEN + vehicle 21.75 ± 2.59*** 19.41 ± 2.94 66.67 
DEN + PERK inhibitor 20.36 ± 2.57 17.36 ± 3.07 NS 83.33 
NS 
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 Supplementary Figures 
 
Fig. S1 Confirmation of the mouse model (A) Number of macroscopic tumors. (B) Mean tumor burden. 
(C) Fibrosis as shown by mean Metavir-score. Data are presented as the mean±SD of n=12. *p<0.05, 
**p<0.01, ***p<0.001. (D) Representative images of a 25 week saline- or DEN-treated liver. Arrows 
indicate tumors. 
 
 
Fig. S2 Temporal dynamics of Nrf2-mediated genes (A) Real-time PCR analysis of Gpx3 
and (B) Gclc. Data are presented as the mean ± SD of n=12. *p<0.05, **p<0.01. 
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Fig. S3 Effect of UPR modulation on cell viability, proliferation and protein synthesis in HCC cells 
(A) Protein synthesis rate as assessed by puromycin incorporation in HepG2 cells. (B) Proliferation rate 
was assessed by measurement of BrdU incorporation in HepG2 cells. (C) Cell viability of BWTG3 and 
Hepa1-6 cells, as assessed by a WST-1 assay. For cytotoxic control, 1% Triton X-100 was applied. (D) 
Effect of a PERK inhibitor on cell viability of HepG2 cells under ER stress in combination with the 
indicated compounds for 48 hours. Experiments were repeated twice with similar results. Data are 
presented as the mean ± SD. *p<0.05, **p<0.01, ***p<0.001. 
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Fig. S4 The PERK inhibitor induces a tendency to increased hepatic apoptosis rate (A) 
Representative TUNEL immunofluorescence and (B) quantification of the TUNEL-positive 
index. *p< 0.05, **p<0.01. 
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Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by endoplasmic 
reticulum stress during hepatocarcinogen exposure 
 
 Abstract 
Hepatocellular carcinoma (HCC) is characterized by the accumulation of unfolded proteins in 
the endoplasmic reticulum (ER), which activates the unfolded protein response (UPR). 
However, the role of ER stress in tumor initiation and progression is controversial. To determine 
the impact of ER stress, we applied tauroursodeoxycholic acid (TUDCA), a bile acid with 
chaperone properties. The effects of TUDCA were assessed using a diethylnitrosamine-induced 
mouse HCC model in preventive and therapeutic settings. Cell metabolic activity, proliferation 
and invasion were investigated in vitro. Tumor progression was assessed in the HepG2 
xenograft model. Administration of TUDCA in the preventive setting reduced carcinogen-
induced elevation of alanine and aspartate aminotransferase levels, apoptosis of hepatocytes 
and tumor burden. TUDCA also reduced eukaryotic initiation factor 2α (eIf2α) 
phosphorylation, C/EBP homologous protein expression and caspase-12 processing. Thus, 
TUDCA suppresses carcinogen-induced pro-apoptotic UPR. TUDCA alleviated hepatic 
inflammation by increasing NF-κB inhibitor IκBα. Furthermore, TUDCA altered the invasive 
phenotype and enhanced metabolic activity but not proliferation in HCC cells. TUDCA 
administration after tumor development did not alter orthotopic tumor or xenograft growth. 
Taken together, TUDCA attenuates hepatocarcinogenesis by suppressing carcinogen-induced 
ER stress-mediated cell death and inflammation without stimulating tumor progression. 
Therefore, this chemical chaperone could represent a novel chemopreventive agent. 
 
 List of abbreviations 
HCC, hepatocellular carcinoma; TUDCA, tauroursodeoxycholic acid; NFκB, nuclear factor 
kappa-B; ER, endoplasmic reticulum; UPR, unfolded protein response; Grp78, glucose-
regulated protein, 78 kDa; eIf2α, eukaryotic initiation factor 2α; Chop, C/EBP homologous 
protein; DEN, diethylnitrosamine; LDH, lactate dehydrogenase; BrdU, bromodeoxyuridine; 
Gsta1, glutathione-S-transferase A1; Gsta2, glutathione-S-transferase A2; Nfe2l2, nuclear 
factor erythroid-derived 2, like 2; Gclc, glutamate-cysteine ligase 
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 Introduction 
Hepatocellular carcinoma (HCC) ranks as the second leading cause of cancer-related mortality 
worldwide and is frequently associated with liver cirrhosis [1,2]. Resection and transplantation 
are the only potentially curative treatments available following detection of a small HCC [1]. 
For the majority of patients with locally advanced disease, however, the multi-kinase inhibitor 
sorafenib and transarterial embolization are the only approved treatments. Unfortunately, both 
of these treatments provide a limited survival benefit [1]. Given that risk factors for HCC, such 
as liver cirrhosis, are fairly well established, chemopreventive strategies may help combat the 
disease. Ideally, these drugs should be safe for long-term use in the at-risk population. However, 
no chemopreventive drugs are currently available for HCC [3]. 
 
Tauroursodeoxycholic acid (TUDCA) is a hydrophilic bile acid that is produced endogenously 
in humans at very low levels [4]. TUDCA is synthesized in the conjugation pathway of 
ursodeoxycholic acid, which is effectively used for treating cholestatic liver diseases, including 
primary biliary cirrhosis, without major adverse reactions [4]. These hydrophilic bile acids act 
as bile secretagogues and immunomodulators that can prevent apoptosis induced by several 
agents, such as hydrophobic bile acids, alcohol, transforming growth factor β1, and Fas ligand, 
in hepatic and non-hepatic cells [5,6]. In addition, TUDCA protects rat livers during long-term 
ethanol feeding [7] and human livers from ischemia-reperfusion injury during harvesting and 
cold storage [8]. The mechanisms involved in the antiapoptotic properties of TUDCA include 
targeting mitochondrial function and integrity and interactions with the nuclear factor kappa-B 
(NFκB) signaling pathways [9]. 
 
The endoplasmic reticulum (ER) is an important organelle required for cell survival and is 
highly sensitive to homeostatic alterations. Disruption of ER homeostasis leads to the 
accumulation of unfolded proteins, which disturb ER function and result in a state known as 
ER stress [10]. In resting cells, all ER stress receptors are maintained in an inactive state through 
association with the ER chaperone glucose-regulated protein, 78 kDa (Grp78). Upon ER stress, 
Grp78 dissociates and triggers the unfolded protein response (UPR), which orchestrates cellular 
adaptation to stress by inducing transcriptional programs and by repressing global translation 
by eukaryotic initiation factor 2α (eIf2α) phosphorylation [11].  
Chapter 3 
110 
 
However, if the stress is too severe, UPR signaling switches from a pro-survival to a pro-
apoptotic state, leading to increased pro-apoptotic transcription factor C/EBP homologous 
protein (Chop) expression and the cleavage of procaspase-12 to its active caspase-12 form [11]. 
Interestingly, the UPR is activated in several liver diseases, including fatty liver disease, viral 
hepatitis, alcohol-induced liver injury and HCC [12,13]. 
 
Importantly, TUDCA has been shown to act as a chemical chaperone that decreases UPR 
signaling and protects hepatocytes against cytotoxicity caused by the ER stress inducer 
thapsigargin [14,15]. TUDCA has also been shown to abolish ER stress-induced caspase-12 
processing and to subsequently inhibit effector caspases-3/7 activation and apoptosis [15]. 
 
Recent studies have demonstrated that hepatocyte apoptosis is a pathogenic event in several 
liver diseases [13,16]. Chronically increased hepatocyte apoptosis in genetic mouse models is 
carcinogenic and leads to compensatory liver regeneration, oxidative stress and DNA 
hypermethylation [16,17]. In this study, we investigated the preventive and therapeutic 
potential of TUDCA in HCC. Our data demonstrate that TUDCA reduces carcinogen-induced 
liver dysfunction and HCC incidence, likely through the prevention of ER stress-induced 
apoptosis and inflammation. Importantly, once HCC nodules are established, TUDCA does not 
modulate tumor growth. 
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 Results 
Preventive administration of TUDCA reduces HCC burden in an orthotopic mouse model 
The ER stress-inducing hepatocarcinogen diethylnitrosamine (DEN) promotes multifocal HCC 
after 25 weeks of administration [18,19]. To explore the effects of TUDCA on 
hepatocarcinogenesis, we supplemented the animals with low or high dose TUDCA in their 
drinking water. Administration of DEN resulted in reduced body weights and 25% increased 
mortality (p<0.001; Table 1) compared to saline administration. TUDCA treatment did not 
affect the weight loss or mortality of DEN-treated mice, and no clinical signs of toxicity were 
observed in any of the TUDCA-treated groups. 
DEN-treated mice that received low- or high-dose TUDCA developed fewer nodules per liver 
(all sizes: 18.9 ± 5.3 after vehicle versus 11.5 ± 3.9 after low-dose TUDCA [p<0.01] and 12.3 
± 4.1 after high-dose TUDCA [p<0.05]). HCC burden, quantified by the loss of reticulin 
staining, was reduced in DEN-treated mice following the co-administration of low- or high-
dose TUDCA (p<0.01; Fig. 1A-C). Choline positron emission tomography, which visualizes 
cellular membrane biosynthesis, demonstrated that administration of low-dose TUDCA in 
DEN-treated mice resulted in fewer hepatic loci with high mean standardized uptake values 
compared with animals receiving vehicle alone (p<0.05; Fig. 1D-E). Repeated DEN 
administration induces HCC in a background of liver fibrosis [18]. However, no difference in 
grade of fibrosis, as determined by Sirius Red staining, was found between TUDCA- and 
vehicle-treated livers (data not shown). 
DEN administration increased the levels of serum ALT and AST compared to saline 
administration (p<0.001; Fig. 2A). Importantly, serum ALT and AST levels were reduced in 
DEN-treated mice receiving TUDCA-supplemented drinking water compared to those 
receiving regular drinking water (p<0.05; Fig. 2A). This suggests that both low- and high-dose 
TUDCA protect the liver from DEN-induced hepatotoxicity. Collectively, these data indicate 
that TUDCA decreases the susceptibility of mice to DEN-induced hepatocarcinogenesis in a 
preventive setting. 
TUDCA attenuates UPR-induced apoptosis in DEN-treated mice 
Repeated DEN administration results in significant apoptosis and ER stress in hepatocytes 
[18,19]. We measured the activity of effector caspase-3/7 ex vivo and, as expected, observed 
increased levels in DEN-treated mouse livers (p<0.001, Fig. 2B).  
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Interestingly, the hepatic caspase-3/7 activity was lower in DEN/TUDCA-treated mice 
compared to DEN/vehicle-treated mice (Fig. 2B). In agreement with these data, TUNEL 
immunofluorescence demonstrated a significant reduction of TUNEL-positive hepatocytes 
following TUDCA supplementation (p<0.05, Fig. 2C-D), thus confirming reduced hepatocyte 
apoptosis upon DEN challenge. 
Grp78 and Chop expression and eIf2α phosphorylation were increased in the mice treated with 
DEN, reflecting robust UPR activation (Fig. 3A-B). As a positive control, tunicamycin, a 
nucleoside antibiotic that inhibits protein glycosylation and thereby elicits acute ER stress [11], 
was administered to naive mice. These control mice showed significantly increased expression 
of Grp78 and Chop and eIf2α phosphorylation (Fig. 3B). Administration of TUDCA during the 
25 weeks of carcinogen exposure consistently reduced the expression of Grp78 and Chop and 
inhibited eIf2α phosphorylation, thereby possibly restoring global translation (Fig. 3A-B). 
Caspase-12, the central player in ER stress-induced apoptosis [11], was markedly activated by 
both tunicamycin and DEN administration, whereas TUDCA reduced the DEN-induced 
cleavage of procaspase-12 (p<0.05; Fig. 3C). Overall, these data strongly suggest that TUDCA 
decreases carcinogen-induced ER stress and thereby attenuates caspase-12-mediated 
hepatocyte apoptosis. 
TUDCA increases cellular metabolic activity independent of ER stress 
To further explore the effect of TUDCA on cell viability and proliferation, HepG2, BWTG3 
and Hepa1-6 cells were incubated with a dilution series of TUDCA. As shown by lactate 
dehydrogenase (LDH) activity in the cell supernatant, TUDCA at 0.1-1 mM did not induce 
cytotoxicity in HepG2 cells (Fig. S1A). At 10 mM, however, TUDCA increased the LDH 
activity (p<0.001). Next, we examined the effect of TUDCA on the MTT metabolic activity of 
cells under basal conditions. The reduction of tetrazolium salts such as MTT depends on both 
cellular metabolic activity and proliferation rate. Intriguingly, 0.1-1 mM TUDCA increased the 
MTT metabolic activity of HepG2 cells in a dose-dependent manner to supranormal levels of 
up to 150% (p<0.001; Fig. 3D).  
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Incorporation of the thymidine analogue bromodeoxyuridine (BrdU) into the DNA of HepG2 
cells under basal conditions showed that TUDCA modestly decreased the cell proliferation rate 
at 1 mM (p<0.05, Fig. S1B). Furthermore, we directly counted HepG2 cells after 48 h of 
incubation with 0.1-1 mM TUDCA and found no difference in cell number compared to 
controls (data not shown). The MTT metabolic activity and BrdU incorporation experiments 
were repeated in BWTG3 and Hepa1-6 cells with similar results (Fig. S1C-F). These data 
suggest that, under basal conditions, TUDCA dose-dependently enhances cellular metabolic 
activity without increasing the absolute number of cells. 
Next, we examined whether TUDCA would have the same effects in the presence of ER stress 
[11]. Tunicamycin (0.5 μg/ml) did not alter MTT metabolic activity or LDH release in HepG2 
cells, suggesting no inherent cytotoxicity at the concentration used (Fig. 3D and S1A, 
respectively). However, tunicamycin did impair BrdU incorporation (p<0.01; Fig. S1B), 
confirming the well-known ER stress-mediated induction of cell cycle arrest [11]. Finally, 
TUDCA was able to enhance cellular metabolic activity even in the presence of acute ER stress 
(Fig. 3D and S1C-D); however, this had no effect on the antiproliferative effect of ER stress 
(Fig. S1B and S1E-F). 
TUDCA does not reduce oxidative stress-induced cell death or DEN-induced oxidative 
stress 
TUDCA has been shown to exert cytoprotective effects in different models by reducing 
oxidative stress [20], and ER stress is closely connected to the oxidative stress response [10]. 
Thus, we evaluated the effect of TUDCA on the cytotoxicity of H2O2-induced oxidative stress 
in HepG2 cells. Cell viability declined following the addition of 1-5 mM of H2O2 in a dose-
dependent manner (Fig. S2A). In contrast to the established antioxidant properties of N-
acetylcysteine, co-incubation with 0.1 or 1 mM TUDCA did not protect HepG2 cells against 
H2O2-induced cell death (p<0.01; Fig. S2A). 
In the orthotopic HCC model, TUDCA supplementation did not alter the expression levels of 
DEN-induced antioxidant response genes such as glutathione-S-transferase A1 (Gsta1), 
glutathione-S-transferase A2 (Gsta2), nuclear factor erythroid-derived 2 like 2 (Nfe2l2) and 
glutamate-cysteine ligase (Gclc; Fig. S2B). Malondialdehyde (MDA) is a toxic product of 
reactions between reactive oxygen species (ROS) and polyunsaturated lipids that is commonly 
used as a biomarker to quantify oxidative stress.  
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DEN administration resulted in substantial accumulation of MDA protein adducts (p<0.001), 
and this was found to be unaltered by TUDCA supplementation (Fig. S2C). Thus, the 
chemopreventive action of TUDCA seems to be independent of oxidative stress. 
TUDCA does not affect DEN-induced autophagic flux 
ER stress is able to induce autophagy [21], which has been shown to protect against 
hepatocarcinogenesis [22]. We therefore tested whether TUDCA modulates autophagy in vivo 
(Fig. S3). DEN-treated liver tissue exhibited enhanced expression of Beclin-1 and increased 
conversion of LC3B-I to LC3B-II, indicating the activation of autophagic signals. The cellular 
content of p62, a receptor and substrate of selective autophagy, is a critical indicator of 
autophagic flux [23]. Immunoblotting for p62 showed that DEN slightly decreased the hepatic 
p62 content (Fig. S3A). TUDCA administration did not alter the stably elevated LC3 
conversion and reduced p62 content. Thus, TUDCA was unable to alter the enhanced 
autophagic flux. 
TUDCA attenuates DEN-induced hepatic inflammation 
Human HCC usually develops in the background of chronic hepatic inflammation [1]. Repeated 
DEN-induced murine tumors share similar pathogenesis [18], where pro-inflammatory 
cytokines, such as interleukin-6 (IL-6) and tumor necrosis factor-α (Tnf-α), promote tumor 
development [24]. Indeed, accumulating evidence suggests extensive cross-talk between UPR 
and the inflammatory response [25]. Chop-deficient livers have been shown to exhibit reduced 
inflammation and hepatocarcinogenesis [26]. Because TUDCA abolished the DEN-induced 
Chop expression in our study, we hypothesized that TUDCA might alter DEN-induced hepatic 
inflammation.  
Immunohistochemical staining demonstrated robust accumulation of F4/80+ macrophages in 
the livers of animals treated with DEN for 25 weeks (Fig. 4A-B). However, TUDCA 
significantly decreased the number of liver-infiltrating macrophages (p<0.05). Using multiplex 
microbead immunoassays, we observed that hepatic expression of inflammatory cytokines, 
including interleukin-1 beta (IL-1β), IL-6, keratinocyte-derived chemokine (KC), monocyte 
chemoattractant protein-1 (Mcp-1), and Tnf-α, was augmented following DEN administration. 
Importantly, IL-6 (p<0.05), KC (p<0.05) and Tnf-α (p<0.01) levels were reduced following 
TUDCA supplementation (Fig. 4C). 
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Elevated eIf2α phosphorylation leads to translational repression of the NF-κB inhibitor IκBα 
and thereby promotes NF-κB signaling [27], which exerts a pro-carcinogenic role in 
inflammation-related hepatocarcinogenesis [28]. Using salubrinal, which inhibits eIf2α de-
phosphorylation, we confirmed that sustained eIf2α phosphorylation leads to translational 
repression of IκBα in HepG2 cells (data not shown). Because DEN-induced eIf2α 
phosphorylation was abolished by TUDCA supplementation (Fig. 3B), we assessed the effect 
of TUDCA on hepatic IκBα expression and NF-κB activation to investigate this potential 
mechanism of action. Interestingly, TUDCA supplementation restored IκBα expression and 
slightly decreased phospho-NFκB p65 levels, the active form of NF-κB, in the DEN-treated 
livers (Fig. 4D-E). These data indicate that TUDCA suppresses the immune response to DEN-
induced liver injury by reducing phospho-eIf2α-mediated repression of IκBα translation. 
TUDCA alters invasiveness in vitro 
Because ER stress was previously linked to cell invasion [29,30], we questioned whether 
TUDCA could modify HCC cell invasion in vitro. Therefore, we examined the effect of 
TUDCA in a hepatocyte growth factor-induced invasion assay in which spheroids of the Hepa1-
6 HCC cell line embedded in collagen matrix were observed over time (Fig. 5A-C). TUDCA 
decreased the sphere area after 60 h of incubation (p<0.05; Fig. 5A), whereas the perimeter of 
the TUDCA-treated spheres increased compared with controls after 24 (p<0.001) and 48 h 
(p<0.05) of incubation (Fig. 5B). Although TUDCA may have decreased sphere area by 
affecting cell proliferation in this context (e.g., as observed for HepG2 in Fig. 3B), the larger 
perimeter combined with a smaller area suggests an altered invasive phenotype. This result was 
also supported by the more irregular sphere shape observed upon invasion in the presence of 
TUDCA (Fig. 5C). However, in a Boyden chamber assay, addition of 1-2 mM of TUDCA 
induced no significant alterations in the hepatocyte growth factor-stimulated invasion of the 
HCC cells over a 48-hour period (Fig. 5D). 
Degradation of the extracellular matrix is one pivotal step and occurs due to the actions of 
matrix metalloproteinases (MMP). MMP-2, MMP-9 and MMP-14 enzymes play important 
roles in the degradation of the extracellular matrix and exist extensively in HCC tissues. MMP 
profiling showed that addition of TUDCA did not alter the protein levels of MMP-2, -9 and -
14 (Fig. 5E). Accordingly, we observed no changes in the extracellular MMP-2 and -9 activity 
in the concentrated conditioned medium (Fig. 5F). In conclusion, although TUDCA alters the 
invasive phenotype, TUDCA does not induce increased HCC cell invasion. 
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TUDCA did not affect tumor progression 
Given our findings that TUDCA attenuated UPR-induced apoptosis and increased cellular 
metabolic activity, we evaluated whether TUDCA could stimulate tumor progression via its 
cytoprotective effect. To assess the effect of TUDCA on established tumors, we used orthotopic 
and xenograft mouse models of HCC. Following orthotopic HCC induction with 25 weeks of 
DEN, 5 weeks of low- or high-dose TUDCA supplementation had no significant effect on 
mortality (Table 1) or tumor number (all sizes: 17.4 ± 4.9 after vehicle versus 19.7 ± 4.5 after 
low-dose TUDCA and 18.8 ± 5.3 after high-dose TUDCA). Accordingly, microscopic 
quantification confirmed that TUDCA produced no significant effects on HCC burden (Fig. 
6A-C). Next, we investigated the effects of 5 weeks of TUDCA supplementation following 25 
weeks of DEN-induced tumor development on the UPR (Fig. 6D-E). TUDCA did not alter the 
protein levels of Chop or phospho-eIf2α in HCC-bearing livers (Fig. 6E). Moreover, no 
difference in the apoptosis rate was observed (data not shown). These results suggest that 
TUDCA was unable to restore ER function after prolonged hepatocarcinogen exposure. 
In the HepG2 xenograft model, TUDCA supplementation for 5 weeks did not significantly 
modify tumor growth compared to control treatment (Fig. 6F-G), and no mortality occurred in 
any of these groups. Finally, no metastases were detected in any group of the preventive or 
therapeutic settings of the orthotopic or of the HepG2 xenograft model. 
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 Discussion 
There is an urgent need for innovative preventive and therapeutic options for HCC [3]. Previous 
studies have demonstrated that the chemical chaperone TUDCA serves as a cytoprotective 
agent by reducing ER stress and apoptosis [5,7,8,14]. In this study, we evaluated the preventive 
and therapeutic potential of TUDCA and its effect on carcinogen-induced ER stress in HCC. 
Our results reveal that TUDCA supplementation during carcinogen exposure reduces the 
carcinogen-induced apoptosis of hepatocytes and HCC incidence (Fig. 7). Furthermore, it does 
not stimulate the progression and invasion of established tumors. 
A recent double-blind randomized trial demonstrated that daily TUDCA therapy (750 mg) for 
6 months is safe and appears to be an effective liver cirrhosis treatment; in particular, it 
improved several biochemical parameters [31]. In addition, TUDCA therapy in cirrhotic 
patients awaiting liver transplantation supported their functional stability during the wait time 
[32]. Our results suggest that TUDCA therapy in patients with a high HCC risk, such as cirrhotic 
patients with continuous exposure to carcinogens, not only improved liver function but could 
also prevent HCC incidence. 
We selected a low dosage (60 mg/kg/day), which corresponds to dosages administrable and 
tolerable for humans, and a high dosage (300 mg/kg/day) to assess dose-dependent effects and 
potential side effects. Both low- and high-dose TUDCA administration decreased tumor burden 
in our mouse models. However, the trend of reduced weight and survival was only observed in 
the high-dose TUDCA group. This reduction in body weight was also observed in a mouse 
model of retinitis pigmentosa, where animals were treated with high-dose TUDCA (500 
mg/kg/day) [33]. Additionally, TUDCA has been shown to increase energy expenditure by 
promoting intracellular thyroid hormone activation [34]. Therefore, a low dose of TUDCA is 
advisable for chemoprevention.  
Chemically improving the ER folding capacity by TUDCA administration was previously 
shown to protect from UPR signaling and ER stress-induced apoptosis, which are primarily 
regulated by the phospho-eIf2α\Chop cascade [10,15]. Although Chop plays critical pro-
apoptotic roles, it was recently shown to promote carcinogenesis in a DEN-induced model of 
HCC [26]. Accordingly, TUDCA efficiently diminished Chop expression and tumorigenesis 
during carcinogen exposure in our study. 
In hepatocytes, DEN is metabolized by cytochrome P450 2E1 through a ROS-generating 
reaction that induces liver injury and DNA damage [35,36].  
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Subsequently, danger signals released from injured hepatocytes induce liver inflammation. 
Accordingly, certain antioxidants, such as N-acetylcysteine [35] or lycopene [37], have been 
shown to attenuate DEN-induced hepatocarcinogenesis. Of note, N-acetylcysteine was recently 
shown to accelerate lung cancer progression in mice [38]. Because TUDCA did not affect 
oxidative stress-induced cytotoxicity in vitro or hepatic oxidative stress in vivo, we presume 
that the chemopreventive effect of TUDCA was not mediated by directly antagonizing 
oxidative stress but rather by modulating ER stress-induced apoptosis. Therefore, the 
combination of TUDCA with antioxidants could represent a dual-targeting chemopreventive 
strategy for HCC.  
HCC has been characterized as a chronic inflammation-driven cancer, and chemically induced 
models have revealed the crucial roles of inflammatory signaling in disease onset and severity 
[35]. Therefore, we assessed whether TUDCA affected tumor-immune system crosstalk. 
TUDCA administration resulted in a decrease in hepatic macrophage infiltration and IL-6, KC 
and Tnf-α levels. These results suggest that TUDCA attenuates inflammation in response to 
DEN-induced liver injury and thus interrupts positive feedback from inflammation-induced ER 
stress and UPR-induced inflammation [13]. Interestingly, a similar effect of TUDCA on 
macrophage infiltration and Tnf-α expression was also recently observed in a model of ER 
stress-mediated steatohepatitis-induced HCC [39]. However, additional studies are needed to 
uncover the precise mechanism of the interaction between ER stress and inflammation and the 
effects of TUDCA on these signaling pathways. 
Uncontrolled regeneration of hepatocytes, which occurs after repeated cycles of cell death and 
compensatory proliferation in chronic hepatitis, appears to be an important factor in 
hepatocarcinogenesis [16,40]. Apparently, increased hepatocyte apoptosis contributed to the 
development of HCC in our DEN-induced mouse model. TUDCA interrupts the positive 
feedback from UPR-mediated apoptosis-induced hepatocarcinogenesis, leading to UPR 
activation by tumor microenvironmental stresses [11]. 
Finally, an oral treatment option for preventing HCC would be highly beneficial for cirrhotic 
patients with high HCC risk. In this study, we showed that TUDCA could represent a clinically 
applicable chemopreventive agent for HCC. Whether hepatocyte susceptibility to other 
carcinogens, such as viral replication or alcohol, can be limited by chemical chaperones will be 
of great interest.In conclusion, our study demonstrates that supplementation with TUDCA 
diminishes carcinogen-induced hepatotoxicity and prevents tumor induction by, at least 
partially, alleviating positive feedback from ER stress, inflammation and apoptosis in 
carcinogen-injured liver tissue.  
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 Methods 
Animal studies 
Ethics statement. The investigation was conducted in accordance with the ethical standards and 
according to the Declaration of Helsinki as well as the national and international guidelines. 
The investigation was also approved by the institutional review board of Ghent University 
(ECD 11/52). 
 
Orthotopic model. Wild-type 129S2/SvPasCrl mice were purchased from Charles River 
(Belgium) and maintained as previously described [18]. In the preventive arm of the study, 5-
week-old male mice were randomly divided into 4 groups (n=12 in each group). Three groups 
received weekly intraperitoneal DEN (35 mg/kg, in saline) injections for 25 weeks with either 
regular drinking water or drinking water supplemented with varying amounts of TUDCA (low 
dose of 60 mg/kg/day or high dose of 300 mg/kg/day). Mice in the control group received 25 
weeks of saline injections and regular drinking water. In the therapeutic arm of the study, mice 
received DEN for 25 weeks before being treated with saline- or TUDCA-supplemented (low or 
high dose) drinking water for 5 weeks (n=12 in each group). In addition, 30 μg of tunicamycin 
was intraperitoneally injected in four naive 30-week-old male 129S2/SvPasCrl mice 72 h before 
sacrifice. Blood was collected from the retro-orbital sinus under isoflurane anesthesia. After 
macroscopic evaluation and quantification of hepatic tumor number, all organs were fixed in 
4% phosphate-buffered formaldehyde (Klinipath) and embedded in paraffin or snap frozen in 
liquid nitrogen. Hematoxylin/eosin and reticulin staining were performed to assess tumor 
burden, and the results were evaluated by two independent observers. Sirius Red staining 
enabled fibrosis assessment according to Metavir scoring. Serum alanine and aspartate 
aminotransferase (ALT and AST, respectively) levels were measured at the Lab of Clinical 
Biology, Ghent University Hospital. 
Xenograft model. HepG2 cells (6x106) were re-suspended in 100 μl of serum-free media and 
mixed with 100 μl of Matrigel (BD Biosciences, Bedford, MA, USA). The cell preparation was 
injected subcutaneously into the right ﬂank of 8-week-old male athymic nude mice. Tumor 
volumes were calculated using the following formula: volume (mm³) = ab²/2; where b is the 
smaller dimension.  
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When the mean tumor volume reached 150 mm³, animals were randomized into three groups 
(n=6 in each group) as follows: regular drinking water, low-dose (60 mg/kg/day) TUDCA-
supplemented drinking water and high-dose (300 mg/kg/day) TUDCA-supplemented drinking 
water. Tumor dimensions were recorded two times per week with a digital caliper starting on 
the first day of treatment. Tumor weights were recorded at the time of sacrifice. 
 
Cell culture 
HepG2, BWTG3 and Hepa1-6 (ATCC, Virginia, USA) cells were cultured in DMEM 
supplemented with 10% fetal bovine serum (Life Technologies, Ghent, Belgium). Cells were 
incubated for 48 h with tunicamycin (0.5 μg/ml), TUDCA (0.1–10 mM, Calbiochem, MA, 
USA), salubrinal (50 μM, Tocris, Bristol, UK), N-acetylcysteine (5 mM), H2O2 (1-5 mM) or 
equal volumes of solvent. For direct cell counting, cells were trypsinised and counted in trypan 
blue. All reagents were obtained from Sigma (Diegem, Belgium) unless stated otherwise. 
Experiments were performed in quadruplicate and independently repeated three times. 
Detailed information regarding choline positron emission tomography, caspase-3/7 activity, 
TUNEL apoptosis, RNA extraction, quantitative real-time PCR, western blot analysis, LDH, 
MTT, BrdU incorporation, lipid peroxidation, immunohistochemistry, multiplex microbead 
and spheroid invasion assays is provided in the Supporting Information. 
 
Statistics 
Statistical analyses were performed using SPSS version 21 (SPSS, Chicago, USA). Data are 
presented as the mean ± SD or fold change relative to expression in controls. Normally 
distributed data were subjected to unpaired student’s t-tests. Multiple groups were compared by 
one-way analysis of variance (ANOVA) with Bonferroni correction. Non-normally distributed 
data were tested using the Mann-Whitney U test. The chi-squared test was used to compare 
mortality. Student’s paired t-test was used to compare area or perimeter fold change. Reported 
p-values were two-sided and considered significant when less than 0.05. 
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 Figures 
 
Fig. 1. TUDCA prevents the development of HCC during carcinogen exposure. (A) Representative 
images of livers treated for 25 weeks with the indicated treatments. (B) Quantitative analysis of the 
tumor burden as assessed by (C) Reticulin staining. Scale bar: 100 µm. (D) 18F-Choline positron 
emission tomography was performed to visualize cell membrane synthesis after the indicated treatments 
(blue: low, red: high activity). (E) Quantification of 18F-Choline positron emission tomography. 
Standardized uptake values of the mouse livers are presented as the mean ± SD. One-way ANOVA was 
applied for statistical analysis. *p<0.05, **p<0.01. 
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Fig. 2. TUDCA reduces DEN-induced apoptosis of hepatocytes. (A) Liver damage was 
assessed by measuring ALT and AST levels in the serum of mice after the indicated 
treatments. (B) Caspase-3/7 activity ex vivo (n=8). (C) TUNEL immunofluorescence and 
(D) quantification of the TUNEL-positive index. *p<0.05, **p<0.01, ***p<0.001. 
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Fig. 3. Effect of TUDCA on the hepatic UPR pattern in the DEN-induced mouse model of HCC. (A) 
Real-time PCR analysis of the UPR targets Grp78 and Chop. (B) Expression of Grp78, eIf2α, phospho-eIf2α, 
Chop, procaspase-12 and cleaved caspase-12 was detected using Western blotting. Results are representative 
of 2 independent experiments. (C) Cleaved caspase-12/procaspase-12 ratio obtained using densitometric 
analysis of the Western blot shown in B. (D) Effect of TUDCA treatment on the MTT metabolic activity of 
HepG2 cells (treated with tunicamycin (Tunica) or not). *p<0.05, **p<0.01, ***p<0.001. Results are 
representative of 3 independent experiments. 
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Fig. 4. Effect of TUDCA on DEN-induced hepatic inflammation. (A) Immunostaining for F4/80 and (B) 
quantification of F4/80-positive macrophages in the liver after the indicated treatments (n=5). (C) 
Determination of the indicated hepatic cytokine levels by multiplex microbead immunoassay (n=8). Values 
represent the mean ± SD. *p<0.05, **p<0.01, ***p<0.001. (D) Expression of IκBα, phospho-NFκB p65 and 
NFκB p65 was detected using Western blotting. Results are representative of 2 independent experiments. (E) 
Phospho-NFκB p65/ NFκB p65 ratio obtained using densitometric analysis of the Western blot shown in D. 
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Fig. 5. Effects of TUDCA on HCC cell invasion. (A) The area and (B) length of the outside boundary 
(perimeter) of collagen-embedded Hepa1-6 spheroids (n=9) was measured at 0, 24, 48 and 60 h of 
incubation with 2 mM TUDCA or control medium. Results are representative of 2 independent 
experiments. (C) Representative images of invasive capacity of cells present in a collagen-embedded 
multicellular spheroid are shown at different time points. The multicellular spheroids are approx. 150 
µm in diameter at start. At 60 h, the spheroid perimeter is marked. Scale bar is 50 µm. (D) Boyden 
chamber invasion assay with Hepa1-6 cells following 48 h of incubation with control medium, control 
medium with chemoattractant hepatocyte growth factor (HGF) without or with 1 or 2 mM TUDCA. 
Samples were run in quadruplicate. (E) Western blot analysis of MMP-2, -9 and -14 levels in Hepa1-6 
cell lysates of control cells and cells treated with 1 or 2 mM TUDCA (48h), in the presence or absence 
of 50 ng/ml HGF stimulation. Arrows indicate MMP-2 (72 and 63-66 kDa), MMP-9 (78-82 kDa) and 
MMP-14 (66-57 kDa). The β-actin signal is used as loading control. (F) Gelatin zymography of 
concentrated culture medium of Hepa1-6 control cells or cells treated with 1 or 2 mM TUDCA (48 h), 
in the presence or absence of 50 ng/ml HGF stimulation. The white bands indicate MMP-activity; 
arrowheads: signal for MMP-9 (glycosylated, 92 kDa) and MMP-2 (58/62 kDa, active). Values 
represent the mean ± SD. *p<0.05, ***p<0.001. 
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Fig. 6. Effect of TUDCA on the orthotopic and xenograft mouse models of HCC 
progression. (A) Representative images of murine livers treated for 25 weeks with DEN 
injections followed by 5 weeks of TUDCA-supplemented or control drinking water. (B) 
Reticulin staining of the DEN-treated livers for (C) quantification of tumor burden. Scale bar: 
100 µm. (D) Real-time PCR analysis of the UPR targets Grp78 and Chop. (E) Expression of 
Grp78, eIf2α, phospho-eIf2α, Chop, procaspase-12 and cleaved caspase-12 was detected using 
Western blotting. Results are representative of 2 independent experiments. (F) Effect of 
indicated treatments on growth of HepG2 xenografts in athymic nude mice (n=6). The volume 
of each tumor was measured for 33 days. Values represent the mean ± SD. (G) At the end of 
the treatment period, animals were sacrificed and tumor weights were recorded. *p<0.05, 
**p<0.01. 
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Fig. 7. Schematic overview outlining the mechanisms of the chemopreventive effects of TUDCA. 
  
Chapter 3 
131 
 
 Supplementary Figures 
 
Fig. S1. Effect of TUDCA on viability and proliferation of HCC cells. Control cells or cells treated 
with 0.5 microgram/ml tunicamycin were treated with increasing concentrations of TUDCA as indicated. 
(A) LDH release in HepG2 cells. As positive control, TritonX 1% was applied. (B) Proliferation rate as 
assessed by BrdU incorporation in HepG2 cells. (C) MTT metabolic activity and (D) proliferation rate in 
BWTG3 cells. (E) MTT metabolic activity and (F) proliferation rate in Hepa1-6 cells. Data are presented 
as the mean ± SD of n=4. Statistical significance was determined by one-way analysis of variance 
(ANOVA) with Bonferroni correction. *p<0.05, **p<0.01, ***p<0.001. 
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Fig. S2. Effect of TUDCA on oxidative stress-induced cytotoxicity in 
HepG2 cells. (A) MTT assay of HepG2 cells incubated for 48 h. 
Concentrations are indicated in mM. NAC, N-acetylcysteine. (B) Real-
time PCR analysis of the indicated antioxidant genes after indicated cell 
treatments. (C) Malondialdehyde (MDA) levels were quantified as a 
measure of lipid peroxidation in the mouse livers after the indicated 
treatments. All the values are expressed as the mean ± SD, n=5. *p<0.05, 
**p<0.01, ***p<0.001. 
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Fig. S3. Effect of TUDCA on DEN-induced autophagy. (A) The expression level of autophagy-
associated proteins in the livers was analyzed by western blotting, β-actin: loading control. (B) 
Densitometric analysis of LC3 II/actin ratio. 
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 Tables 
Table 1: Mouse body weight (g) (mean ± SD) 
Group 
Average body weight 
25 weeks (g) 
Average body weight 
30 weeks (g) 
Survival 
(%) 
[%] 
Preventive study    
Saline 31.22 ± 1.39  100 
DEN + control 26.75 ± 1.96***  75 
DEN + low dose TUDCA 27.39 ± 1.45#  83 
DEN + high dose TUDCA 24.64 ± 2.17#  67 
Therapeutic study    
DEN => control 25.96 ± 3.65 22.92 ± 3.19 67 
DEN => low dose TUDCA 23.86 ± 2.70 22.13 ± 2.57¥ 75 
DEN => high dose TUDCA 24.53 ± 2.13 23.43 ± 2.61¥ 67 
***p<0.001: 25 weeks DEN vs. saline. #not significant compared to DEN + control. ¥not significant compared to 
DEN => control. DEN, diethylnitrosamine. 
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 Sorafenib and the unfolded protein response in hepatocellular carcinoma 
2.1. Antitumor efficacy of sorafenib is potentiated by modulation of the 
interplay between the unfolded protein response and autophagy in 
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 Patent application: P2014-060 
 
Abstract of the patent 
 
The present invention relates to compositions which can be used for the treatment of 
hepatocellular carcinoma. More in particular, the present invention discloses that the addition 
of both an endoplasmic reticulum stress inducer and an inhibitor of autophagy significantly 
improve the antitumoral efficacy of the kinase inhibitor sorafenib in a synergistic manner. 
Hence, the present invention relates to compositions comprising the kinase inhibitor sorafenib, 
an endoplasmic reticulum stress inducer -such as nelfinavir- and an inhibitor of autophagy -
such as clarithromycin-. The present invention also discloses the combination of an 
endoplasmic reticulum stress inducer and an inhibitor of autophagy –without sorafenib- for the 
treatment of hepatocellular carcinoma. 
Claims of the patent 
 
1. A composition comprising the kinase inhibitor sorafenib, an endoplasmic reticulum stress 
inducer and an inhibitor of autophagy. 
2. A composition according to claim 1 for use as a medicament. 
3. A composition according to claim 1-2 for use to treat hepatocellular carcinoma. 
4. A composition comprising an endoplasmic reticulum stress inducer and an inhibitor of 
autophagy for use to treat hepatocellular carcinoma. 
5. A composition according to claims 3-4 wherein said hepatocellular carcinoma is advanced 
hepatocellular carcinoma.  
6. A composition according to claims 1-5 wherein said endoplasmic reticulum stress inducer is 
a) the HIV protease inhibitor nelfinavir, saquinavir, fosamprenavir, atazanavir, darunavir, 
tipranavir, indinavir or liponavir, or b) the proteasome inhibitor bortezomib, carfilzomib or 
oprozomib, or c) quercetin, or any combination of said endoplasmic reticulum stress inducers. 
7. A composition according to claims 1-6 wherein said inhibitor of autophagy is a) the 
neomacrolide clarithromycin, azithromycin or roxithromycin, or b) chloroquine or 
hydroxychloroquine, or, any combination of said inhibitors of autophagy. 
8. A composition according to claims 1-2 and 4-7 comprising the kinase inhibitor sorafenib, the 
endoplasmic reticulum stress inducer nelfinavir and the inhibitor of autophagy clarithromycin. 
9. A composition according to claims 1- and 4-7 comprising the kinase inhibitor sorafenib, the 
endoplasmic reticulum stress inducer nelfinavir and the inhibitor of autophagy chloroquine.  
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10. A composition according to claims 1-7 wherein said endoplasmic reticulum stress inducer 
is nelfinavir and wherein said inhibitor of autophagy is clarithromycin.  
11. A pharmaceutical composition comprising a composition according to claims 1-10. 
12. A process to treat hepatocellular carcinoma comprising administering a therapeutically 
effective amount of a pharmaceutical composition according to claim 11 to a person in need 
thereof. 
13. A composition comprising the inhibitor of autophagy clarithromycin and the endoplasmic 
reticulum stress inducer nelfinavir for use to treat hepatocellular carcinoma wherein said 
nelfinavir is given at a dose of maximally 89,3 mg/kg. 
 
Full patent application is provided in the Supplemental information. 
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Antitumor efficacy of sorafenib is potentiated by modulation of the interplay between 
the unfolded protein response and autophagy in hepatocellular carcinoma 
 Abstract 
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality and is 
resistant to cytotoxic and targeted therapies. Although sorafenib, a multi-kinase inhibitor, is the 
standard therapy, the antitumor effect is limited and average survival benefit is less than 3 
months. Given the emerging importance of the unfolded protein response (UPR) and autophagy 
in HCC, we questioned whether the use of rationally designed combinations of sorafenib with 
clinically applicable modulators of the UPR and autophagy would be more effective than 
current sorafenib monotherapy. The UPR and autophagy and their relevance in cell viability 
and proliferation in vitro and in orthotopic and xenograft mouse models were assessed. 
Sorafenib activated the UPR and autophagy in HCC cells. Importantly, sorafenib induced 
inositol-requiring enzyme 1 (IRE1) RNase-mediated mRNA cleavage, a pro-apoptotic process 
called regulated IRE1-dependent decay. Moreover, sorafenib-mediated reduction in tumor cell 
proliferation was dependent on proteotoxicity and IRE1 RNase activity. Also autophagy 
induction by sorafenib was in part mediated by IRE1 activation. Targeting of the UPR or 
autophagy separately did not synergistically enhance the antitumor efficacy of sorafenib. 
However, combination with an UPR inducer and an inhibitor of adaptive protein refolding or 
autophagy potentiated the efficacy synergistically in vitro and in the used mouse models 
without significant toxicity. 
Conclusion: Clinically applicable triple therapies of sorafenib with modulators of the UPR and 
autophagy seem to suppress intrinsic sorafenib resistance and open new avenues for a multi-
target approach that may produce durable responses against HCC. 
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 List of abbreviations 
HCC, hepatocellular carcinoma; ER, endoplasmic reticulum; GRP78, glucose-regulated 
protein, 78 kDa; PDI, protein disulfide isomerases; ERAD, ER-associated protein degradation; 
UPR, unfolded protein response; PERK, PKR-like endoplasmic reticulum kinase; IRE1, 
inositol-requiring enzyme 1; ATF6, activating transcription factor 6; eIF2α, eukaryotic 
initiation factor 2α; ATF4, activating transcription factor 4; CHOP, CCAAT/enhancer-binding 
homologous protein; XBP1u, unspliced X-box-binding protein 1; XBP1s, spliced X-box-
binding protein 1; RIDD, regulated IRE1-dependent decay; IP, intraperitoneal; IG, intragastric; 
ERDJ4, endoplasmic reticulum DnaJ homolog 4; DEN, diethylnitrosamine; GADD34, growth 
arrest and DNA damage inducible 34; HERPUD1, homocysteine-inducible, endoplasmic 
reticulum stress-inducible, ubiquitin-like domain member 1. 
 Introduction 
Hepatocellular carcinoma (HCC) represents a major health problem that causes over 700,000 
deaths annually worldwide [1]. Conventional chemotherapy is ineffective and targeted therapy 
for advanced HCC with sorafenib provides a limited and variable survival benefit [2]. Sorafenib 
was identified as a multi-kinase inhibitor, targeting Raf (serine/threonine-specific protein 
kinase), Fms-like tyrosine kinase 3,4 c-Kit, p38, stem cell growth factor receptor 1, vascular 
endothelial growth factor receptors, and platelet-derived growth factor receptor-β to induce 
growth arrest in a variety of tumors, including HCC [3]. Resistance may be either pre-existent 
(intrinsic resistance), or drug-induced (acquired resistance). So far, no clinical strategy has been 
found to overcome sorafenib resistance. Long-term exposure to sorafenib of HCC cells induces 
acquired resistance with epithelial-to-mesenchymal transition. The sensitivity for sorafenib 
after resistance development can partially be restored by inhibition of phosphatidylinositol 3-
kinase/Akt, BCRP/ABCG2 or NF-κB-upregulated CD47 [4]–[6]. In addition, Rudalska et al. 
(2014) identified by in vivo shRNA screening the p38/ATF2 pathway as a potential mechanism 
of acquired sorafenib resistance in HCC [7]. However, the molecular mechanisms by which 
sorafenib exerts its effect or how intrinsic resistance to sorafenib is facilitated remain unclear 
[2]. 
Certain chemotherapeutic drugs provoke apoptosis through the mitochondrial pathway, 
whereas others, most notably the proteasome inhibitors, induce cell death via endoplasmic 
reticulum (ER) stress. The ER consists of a membranous network in which proteins are 
synthesized, post-translationally modified and folded.  
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Therefore, the ER lumen houses a large array of chaperones, including glucose-regulated 
protein-78 (GRP78) and protein disulfide isomerase A4 (PDIA4) and contains quality-control 
systems that extract terminally misfolded proteins for degradation, a process known as ER-
associated protein degradation (ERAD) [8].  
Disturbances in ER homeostasis activate the unfolded protein response (UPR), which initially 
compensates for damage, but will activate apoptosis during intense or persistent ER stress [9]. 
Three major ER stress transducers have been identified: PKR-like ER kinase (PERK), inositol-
requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6) [8]. Following release 
of GRP78, PERK phosphorylates eukaryotic initiation factor 2α (eIF2α) leading to attenuation 
of global translation. Accompanying this translational control, phosphorylated eIF2α 
selectively enhances translation of activating transcription factor 4 (ATF4), a transcriptional 
activator of genes involved in protein quality control, amino acid biosynthesis as well as 
induction of apoptosis such as CCAAT/enhancer-binding homologous protein (CHOP) [8]. 
Upon ER stress, ATF6 is mobilized to the Golgi where it is cleaved, which releases the 
transcriptionally active fragment and induces chaperones such as PDIA4, unspliced X-box-
binding protein-1 (XBP1u) and ERAD components such as homocysteine-inducible, ER stress-
inducible, ubiquitin-like domain member 1 (HERPUD1) [10]. Activation of IRE1 results in 
splicing of XBP1u mRNA to generate a more active spliced XBP1 (XBP1s), which induces 
genes involved in protein folding such as ERDJ4 [10], [11]. Next to XBP1 mRNA, also other 
mRNAs can be cleaved by IRE1, a process known as regulated IRE1-dependent decay (RIDD) 
[8], [12]. The effect of sorafenib on the UPR in HCC is controversial; both UPR inhibition [13] 
as activation [14]–[16] have been reported. 
Besides canonical UPR activation, sustained ER stress can elicit autophagy, which allows cells 
to sequester cytoplasmic material by forming double-membrane vesicles and to target the 
material for degradation [17]. Interestingly, sorafenib was previously shown to generate 
cytoprotective autophagy in different types of tumor cells including HCC [16], [18]. 
We further investigated the effect of rationally designed combinations of clinically applicable 
UPR- and autophagy-modulating agents and human equivalent dose of sorafenib on HCC in 
vitro and validated these results in an orthotopic and xenograft mouse model. Our data indicate 
that the effect of sorafenib is in part mediated by proteotoxic stress, which activates 
compensatory mechanisms, such as adaptive protein refolding and autophagy. Inhibition of 
these survival mechanisms under amplified ER stress synergistically enhanced the antitumor 
efficacy. 
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 Materials and Methods 
Cell culture 
Human HepG2 cells (HB-8065; ATCC, Virginia, USA) were cultured with Dulbecco's 
Modified Eagle's medium supplemented with 10% fetal bovine serum (Life Technologies, 
Ghent, Belgium). Cells were incubated for 24 hours with sorafenib (5-20 μM; Bay43-9006, 
Nexavar®), tunicamycin (1 μg/ml), thapsigargin (50 ng/ml), PERK inhibitor (0.5 μM; 
GSK2656157, Chengdu novi biotechnology, Shandong, China), IRE1 RNase inhibitor (8 μM; 
4μ8C, Calbiochem, Massachusetts, USA), quercetin (25-100 μM), bacitracin (3 mM), 
nelfinavir (10 μM), chloroquine (10 μM), clarithromycin (50 μg/ml), bortezomib (50 nM; Santa 
Cruz, Heidelberg, Germany), tauroursodeoxycholic acid (1 mM), cycloheximide (5 μM) or 
MEK inhibitor PD98059 (30 minutes; 10 μM; Cell signaling) or equal volumes of solvent as 
control. All reagents were obtained from Sigma (Diegem, Belgium) unless stated otherwise. 
Each experiment was performed in quadruplicate. 
 
Animals 
Wild-type 129S2/SvPasCrl mice and athymic nude mice were purchased respectively from 
Charles River (L'Arbresle Cedex, France) and Harlan (Horst, The Netherlands) and maintained 
as previously described [19]. All protocols were approved by the Ethical Committee of 
experimental animals at the Faculty of Health Sciences, Ghent University, Belgium (ECD 11/52 
and 13/39). 
Orthotopic model. Five-week-old males received weekly intraperitoneal (IP) saline or 
diethylnitrosamine (DEN) (35 mg/kg, in saline). After 25 weeks, saline-treated mice were 
randomly divided into 2 groups: control (intragastric (IG) 100 μl of vehicle once daily) or 
sorafenib (IG 30 mg/kg once daily, as indicated by human equivalent plasma levels [20]); and 
DEN-treated into 5 groups (each n=12): control, sorafenib, sorafenib + clarithromycin (IG 50 
mg/kg bid), sorafenib + nelfinavir (IP 50 mg/kg bid), sorafenib + nelfinavir + clarithromycin 
(idem) and nelfinavir (IP 250 mg/kg bid) + clarithromycin (idem). After 30 weeks, blood was 
collected from the retro-orbital sinus under isoflurane anaesthesia, and the mice were 
euthanized. All organs were fixed in 4% phosphate-buffered formaldehyde (Klinipath) and 
embedded in paraffin or snap frozen in liquid nitrogen. Hematoxylin/eosin and reticulin staining 
were performed and the results were blindly evaluated by two independent observers. Mean 
intercapillary distance was measured on CD105-stained slides as previously described [19]. 
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Xenograft model. HepG2 cells (6x106) were mixed with 40% Matrigel (BD Biosciences, 
Bedford, MA, USA). The cell preparation was injected subcutaneously into the right ﬂank of 
8-week-old male athymic nude mice housed in filter-topped cages. Tumor dimensions were 
recorded three times per week with a digital caliper starting with the first day of treatment. 
Tumor volumes were calculated using the following formula: volume (mm³)= ab²/2, where b 
was the smaller dimension. When mean tumor volume reached 150 mm³, animals were 
randomized into eight groups (n=6): sorafenib (IG 30 mg/kg once daily), sorafenib + 
clarithromycin (IG 50 mg/kg bid), sorafenib + nelfinavir (IP 50 mg/kg bid), sorafenib + 
nelfinavir + clarithromycin (idem), nelfinavir (IP 50 mg/kg bid) + clarithromycin (idem), 
nelfinavir (IP 250 mg/kg bid) + clarithromycin (idem), nelfinavir (IP 250 mg/kg bid) and 
control group. Final tumor weights were recorded at the time of sacrification. 
Detailed information of total RNA extraction, quantitative real-time PCR, Western blotting, 
immunohistochemistry, MTT, bromodeoxyuridine (BrdU) incorporation and caspase-3 activity 
assays and positron emission tomography is provided in the Supplementary Materials and 
Methods. 
 
Statistics 
Statistical analyses were performed using SPSS 21 (SPSS, Chicago, USA). Data are presented 
as the mean ± SD or percentage relative to expression in controls. Variables were tested for 
normality using the Shapiro-Wilk test. Normally distributed data were subjected to the unpaired 
student’s t-tests. Data involving more than two groups were assessed by one-way analysis of 
variance (ANOVA) with Bonferroni's post-hoc test. Non-normally distributed data were tested 
using the Mann-Whitney-U test. The chi-squared test was used to compare mortality. 
Continuous data (xenograft tumor volume changes) were evaluated using linear mixed models. 
CompuSyn program (ComboSyn, NJ, USA) was used to compute a combination index for drug 
combinations studied with cell proliferation assays. Reported p-values were two-sided and 
considered significant when less than 0.05. 
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 Results 
Sorafenib activates the IRE1/XBP1/RIDD and PERK/eIF2α/ATF4/GADD34 pathways in 
vitro 
The effect of sorafenib on the UPR was assessed in HepG2 cells at concentrations achieved in 
clinical practice (between 1 and 10 μM [21], [22]). Sorafenib dose dependently increased the 
mRNA levels of chaperones GRP78 (5 μM: p<0.05; 10 μM: p<0.001) and PDIA4 (from 5 μM: 
p<0.001) compared to control (Fig. 1A). GRP78 protein levels were decreased by sorafenib, 
which is consistent with observations in sorafenib-treated human leukemia cells [14]. In 
contrast, sorafenib increased PDIA4 protein levels (Fig. 1A-B). In addition, sorafenib increased 
the mRNA levels of HERPUD1 (10 μM: p<0.01; Fig. 1A).  
Expression of total IRE1 mRNA (p<0.001, Fig. 1A) and protein (Fig. 1B) was markedly 
increased by sorafenib. Through the use of Phos-tag (a reagent that selectively binds to 
phosphorylated amino acids), we readily detected the active phosphorylated form of IRE1 in 
sorafenib-treated cells (Fig. 1B) [23]. Accordingly, the IRE1-mediated splicing of XBP1 and 
expression of a target of XBP1s, ERDJ4 [10], were increased by sorafenib (p<0.001, Fig. 1A). 
5 μM sorafenib decreased XBP1u mRNA levels (p<0.05). However, 10 μM sorafenib increased 
XBP1u mRNA (p<0.001; Fig. 1A). The IRE1 inhibitor attenuated induction of XBP1s and 
ERDJ4 mRNA and restored XBP1u levels (p<0.001; Fig. 1A). Surprisingly, the IRE1 inhibitor 
increased IRE1 mRNA (p<0.001), suggesting negative regulation of the sorafenib-induced 
IRE1 mRNA expression by the IRE1 RNase, possibly by RIDD [12]. 
Interestingly, liver-expressed transcripts which are known targets of RIDD were all 
downregulated by sorafenib (Fig. 1D) [24]. Addition of the IRE1 inhibitor abolished the 
sorafenib-mediated downregulation of the tested RIDD targets. These results confirm that 
sorafenib induced IRE1-mediated RIDD. Importantly, sorafenib-induced RIDD downregulated 
Glypican-3 (GPC3), which encodes a cell-surface heparan-sulfate proteoglycan expressed in 
HCC [25]. Chemical ER stress inducers, thapsigargin and tunicamycin [8], downregulated all 
tested RIDD targets, with exception of CYP2E1, which was upregulated by tunicamycin, 
although thapsigargin downregulated this transcript (Fig. 1D). 
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Next, we examined whether sorafenib also activates the PERK pathway. Sorafenib promoted 
phosphorylation of eIF2α and expression of PERK targets ATF4, CHOP and growth arrest and 
DNA damage inducible 34 (GADD34) (mRNA: Fig. 1A; protein: Fig. 1B). The PERK inhibitor 
decreased sorafenib-induced phosphorylation of eIF2α and expression of ATF4 and GADD34 
(Fig. 1B). However, addition of the PERK inhibitor to sorafenib further upregulated GRP78, 
PDIA4 and HERPUD1 transcripts (Fig. 1A), which are primary regulated by ATF6 [10], 
suggesting enhanced cytoprotective ATF6 signaling upon pharmacological blockade of the 
PERK pathway. Interestingly, IRE1 inhibition modestly decreased sorafenib-induced 
expression of CHOP (Fig. 1B). 
Since sorafenib is developed as an inhibitor of the RAF/MEK/ERK pathway, we examined the 
effect of the MEK inhibitor PD98059 on the UPR. Next to a slight decline in GRP78, PD98059 
was unable to alter the expression of the UPR-mediated proteins (Fig. 1B), suggesting sorafenib 
induces ER stress in HCC cells independent of MEK inhibition. 
Since sorafenib induces ER stress, we questioned whether pre-existent ER stress, as present in 
human HCC in vivo [26], modulates the effect of sorafenib on the UPR. Therefore, we examined 
the effect of sorafenib on the UPR in the presence of tunicamycin in HepG2 cells (Fig. 1C). 
Despite the presence of tunicamycin-induced ER stress, sorafenib was able to further enhance 
the expression of GRP78 (p<0.001), XBP1s (p<0.05), ERDJ4 (p<0.001), CHOP (p<0.05) and 
GADD34 (p<0.001) mRNA. At the protein level, addition of sorafenib to tunicamycin 
potentiated the PERK-mediated phosphorylation of eIF2α and expression of GADD34 and 
CHOP. 
 
Sorafenib-mediated reduction in tumor cell proliferation is dependent on proteotoxic stress and 
IRE1 RNase activity 
Sorafenib at 5-20 μM dose dependently reduced HepG2 cell viability and proliferation and 
triggered caspase-3 activation (Fig. S1A-C). Although tunicamycin alone did not affect cell 
viability, we observed slight enhancement of the sorafenib-mediated reduction in proliferation 
and induction of caspase-3 by addition of tunicamycin (p<0.05, Fig. S1A-C). In the next 
experiments, sorafenib was applied at 10 μM, since this was the lowest concentration 
significantly reducing cell viability in the range of the human intratumor concentration.  
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To demonstrate that proteotoxic stress caused by sorafenib originates during the synthesis of 
new proteins, cycloheximide (CX) was used to block protein synthesis. In addition, chemical 
chaperone tauroursodeoxycholic acid (TUDCA) was applied to reduce the load of misfolded 
proteins. Cell viability was reduced by CX and increased by TUDCA, confirming their effect 
on metabolic activity (p<0.01; Fig. 2A). Interestingly, CX increased the proliferation and 
TUDCA reduced the caspase-3 activity of sorafenib-challenged cells (p<0.01; Fig. 2B-C). 
Next, we assessed the effect of inhibition of the sorafenib-activated IRE1 or PERK pathway on 
cell viability. The IRE1 inhibitor counteracted sorafenib-mediated suppression of viability 
(p<0.05, Fig. 2A), proliferation (p<0.01, Fig. 2B) and induction of caspase-3 activity (p<0.001, 
Fig. 2C), possibly by downregulating CHOP and inhibition of pro-apoptotic RIDD (Fig. 1). 
Inhibition of IRE1-activated JNK [8] by SP600125 did not alter the effect of sorafenib (data 
not shown). The PERK inhibitor did not alter sorafenib-induced cell death (Fig. 2A-C). Thus, 
these data demonstrate that IRE1 is partly responsible for the cytotoxicity of sorafenib, likely 
through induction of CHOP and RIDD. 
 
Sorafenib induces autophagy in part via induction of IRE1 
Sorafenib at 10 μM induced autophagy-related genes ATG5, ATG7 and BECLIN1 (Fig. S3A), 
LC3 conversion and P62 degradation (Fig. S3B) in HepG2 cells. Addition of the IRE1 inhibitor 
attenuated the induction of ATG5 and -7 (p<0.01) and LC3 conversion in sorafenib-challenged 
cells. The PERK inhibitor did not affect sorafenib-induced LC3 II (Fig. S3B). Chloroquine 
inhibits autophagy by increasing lysosomal pH [17]. Sorafenib-induced conversion of LC3 and 
P62 degradation in HepG2 cells was inhibited by chloroquine (Fig. S3B), suggesting sorafenib 
promotes autophagic flux. Additionally, we confirmed that neomacrolide antibiotic 
clarithromycin [27] was able to inhibit sorafenib-induced autophagic flux (Fig. S3B). 
Further, we evaluated the effect of sorafenib in combination with autophagy inhibition. 
Surprisingly, chloroquine was unable to potentiate the effect of sorafenib (Fig. 3A-C). Addition 
of clarithromycin to sorafenib further reduced the proliferation rate (p<0.01; Fig. 3B) and 
enhanced the caspase-3 activity (p<0.01; Fig. 3C) compared to sorafenib alone. Again, this 
rather seems to be an additive effect because clarithromycin monotherapy was able to induce 
both effects compared to control (Table S1). Thus, combination of sorafenib with autophagy 
inhibitors did not induce synergistic effects to HCC cells.  
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Autophagy inhibition together with IRE1 hyperactivation enhanced the efficacy of sorafenib 
Because the activation of the IRE1 pathway was critical for the sorafenib-induced 
antiproliferative effect, we questioned whether IRE1 hyperactivity could enhance its efficacy. 
Therefore, we used the clinically applicable flavonoid quercetin which is known to directly bind 
and activate IRE1 [28]. Indeed, in HepG2 cells, quercetin dose dependently downregulated the 
RIDD targets (Fig. 1D) and induced XBP1 splicing without affecting ATF6 targets such as 
HERPUD1 (Fig. S2A). Surprisingly, quercetin decreased sorafenib-induced CHOP expression 
(Fig. S2A and 1B) and caspase-3 activity (p<0.001; Fig. S2B-D).  
In order to find a clinically applicable efficacy-enhancing combination with sorafenib, we 
evaluated the combination of sorafenib with general ER stress inducers. Therefore, we selected 
the proteasome inhibitor bortezomib [8], [29] and the HIV protease inhibitor nelfinavir [30]. 
Surprisingly, combination of sorafenib with bortezomib did not show additive effects, although 
both demonstrated in monotherapy significant antitumor effects (p<0.001; Fig. 3A-C). Addition 
of nelfinavir at a noncytotoxic but ER stress-inducing concentration of 10 μM (data not shown) 
to sorafenib reduced the proliferation rate (p<0.05; Fig. 3B) and increased the caspase-3 activity 
(p<0.001; Fig. 3C) compared to sorafenib alone, however, this did not represent a synergistic 
effect (Table S1). 
Since intensification of ER stress was insufficient to increase the efficacy of sorafenib, we 
questioned whether the observed induction of resistance mechanisms, such as autophagy and 
adaptive protein refolding by upregulating chaperones, such as PDIA4, which help in relieving 
ER stress, enables tumor cell survival under ER stress. To modulate protein refolding, we 
applied bacitracin, which is known to affect PDI activity [31]. Although the efficacy of 
sorafenib was unaltered by addition of bacitracin, the efficacy of sorafenib/bortezomib was 
enhanced by triple therapy with bacitracin (Fig. 3A-C), indicating that adaptive protein 
refolding is an essential response to proteotoxic stress induced by sorafenib/bortezomib. Similar 
results on cell viability were obtained by triple therapy with sorafenib/nelfinavir and bacitracin 
compared to sorafenib/nelfinavir (p<0.05; Fig. 3A). 
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The efficacy of sorafenib with autophagy inhibition was synergistically enhanced by addition 
of ER stress inducers nelfinavir or bortezomib (p<0.001; Fig. 3A-C and Table S1), confirming 
the need for a triple therapy approach tackling cellular adaptation. In contrast to the autophagy 
inhibitors, addition of bacitracin to sorafenib/nelfinavir was unable to change the antitumor 
effect, suggesting autophagy is a more important survival mechanism instigated by 
sorafenib/nelfinavir than adaptive refolding. In addition, triple therapy with sorafenib, 
quercetin, and autophagy inhibition synergistically decreased tumor cell proliferation (p<0.001; 
Fig. S2E and Table S1), suggesting a pivotal role for IRE1 in this strategy. 
In addition, testing of this combination in HepG2 cells with acquired sorafenib resistance 
obtained by slowly increasing sorafenib concentrations, as described in [4], is ongoing. 
Interestingly, UPR-regulated CHOP mRNA was significantly upregulated in the sorafenib-
resistant compared to sorafenib-sensitive HepG2 cells (p<0.001). 
 
The antitumor efficacy of sorafenib is potentiated by combination with nelfinavir and 
clarithromycin in mouse models of HCC 
Since triple therapy with sorafenib, nelfinavir and clarithromycin demonstrated the strongest 
synergistic effects in vitro (combination index: 0.63, Table S1), we tested this triple therapy in 
an orthotopic and a xenograft mouse model. 
In saline-treated and DEN-treated mice, sorafenib administration did not alter body weight or 
mortality (Table S2). In the DEN-treated mice, sorafenib reduced the hepatic tumor burden 
(p<0.01, Fig. 4A-B and S4A-B). Addition of nelfinavir, and not clarithromycin, to sorafenib, 
augmented the sorafenib-mediated antitumor effect (p<0.01). Moreover, triple therapy with 
sorafenib/nelfinavir/clarithromycin synergistically reduced tumor burden (p<0.001) and 
showed a tendency to reduce mortality (p=0.17, Table S2). Visualization of the cellular 
membrane biosynthesis by 18F-choline positron emission tomography demonstrated a decreased 
number of loci with high mean standardized uptake values after triple therapy compared to 
vehicle-treated mice (Fig. S4D). 
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Hematoxylin/eosin staining demonstrated intense cytoplasmic vacuolization, which is related 
to ER stress [32], by sorafenib and, even more, by triple therapy (Fig. S4A). Sorafenib 
decreased tumor angiogenesis (p<0.05), however, addition of nelfinavir or clarithromycin did 
not alter vessel density (data not shown). Triple therapy increased caspase-3 activity, measured 
in lysates of HCC-bearing livers compared to vehicle-treated mice (p<0.05; Fig. S4C). 
Analysis of HepG2 xenograft tumors from the control- and sorafenib-treated mice showed that 
30 mg/kg/day sorafenib did not significantly reduce HCC growth in vivo (Fig. 4C-D). However, 
triple therapy demonstrated strong antitumor efficacy (p<0.001, Fig. 4C-D). Taken together, 
tackling the interplay between sorafenib-induced adaptation mechanisms strikingly suppressed 
HCC growth (Fig. 4E). 
Finally, we tested the possibility to omit sorafenib, which can induce serious adverse events in 
clinical use [3], from the triple therapy of sorafenib, nelfinavir and clarithromycin. At the dose 
of 50 mg/kg bid of nelfinavir, omitting sorafenib dramatically reduced the antitumor effect in 
the HepG2 xenograft model, however, increasing the dose of nelfinavir to 250 mg/kg bid 
resulted in a comparable antitumor action compared to the triple therapy, while 250 mg/kg bid 
nelfinavir without clarithromycin did not suppress tumor growth (Fig. 4C-D). Based on these 
results, we evaluated the combination of 250 mg/kg bid nelfinavir and clarithromycin in the 
orthotopic model. Importantly, this combination was superior in inhibiting tumor progression 
compared to treatment with sorafenib monotherapy (p<0.001).  
These data indicate that the threshold for ER stress-induced cell death during autophagy 
inhibition in HCC cells is elevated by omission of sorafenib from the triple therapy, which can 
be overcome by increasing the dose of nelfinavir. 
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 Discussion 
While sorafenib heralded a major breakthrough in HCC therapy, the clinical benefit is at best 
modest and transient [3]. HCC is a complex disease which needs multi-targeting approaches 
for effective therapy. ER stress and autophagy are two basic cell survival mechanisms often 
occurring in concert. In this study, we assessed the effect of sorafenib on the UPR and 
autophagy and on HCC growth in combination with modulation of these cellular adaptation 
processes.  
Sorafenib activates the IRE1/XBP1/RIDD and PERK/eIF2α/ATF4/GADD34 pathways, but 
reduced GRP78 protein expression. Since IRE1 knockdown increased induction of apoptosis 
by 20 μM sorafenib in MHCC97-L and PLC/PRF/5 HCC cells [16], we hypothesized that IRE1 
inhibition could boost the effect of sorafenib. Surprisingly, a small molecule inhibitor binding 
the IRE1 RNase domain [33] attenuated the antiproliferative effect of sorafenib in HepG2 cells. 
In this experiments, IRE1 is still present, upregulated and able to mediate the well-known 
protein-protein interactions, such as the IRE1-TRAF2 interaction [8]. Another difference is the 
concentration used, we applied 1-10 μM sorafenib, which is in the range of mean intratumor 
concentration of 8 μM in case of the recommended oral dose of 400 mg bid [21], [22]. For 
example, XBP1u mRNA levels decreased from 1 to 5 μM sorafenib, probably by depletion via 
IRE1-mediated splicing. However, 10 μM sorafenib increased XBP1u mRNA, which might 
suggest that XBP1s-mediated induction of XBP1u mRNA overruled the IRE1 splicing capacity 
[9]. Next to the known cytoprotective effects of IRE1 signaling [8], sustained XBP1 splicing is 
able to induce CHOP expression, cell dysfunction and apoptosis [9], [34]. In addition, the IRE1 
RNase performs RIDD on specific target transcripts, a pro-apoptotic process activated by 
sorafenib [24]. 
Inhibition of protein synthesis increased cell survival of sorafenib-treated cells, while 
tunicamycin slightly increased the antiproliferative effect of sorafenib, suggesting ER stress 
plays a significant role in the effect of sorafenib. Next, we selected two clinically applicable 
ER stress inducers: the proteasome inhibitor bortezomib and the HIV protease inhibitor 
nelfinavir. Interestingly, only nelfinavir induces an additive effect in combination with 
sorafenib in HCC. This effect was also observed in leukemia cells [35]. Because sorafenib was 
shown to induce apoptosis through induction of growth arrest and DNA damage 45β 
(GADD45β) and mitochondrial fragmentation [36], which both can be induced by ER stress 
[37], [38], it would be interesting to investigate whether sorafenib-induced mitochondrial 
fragmentation and GADD45β expression is dependent on UPR activation. 
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Sorafenib promotes adaptive autophagy in HCC cells, as shown previously [39]. To inhibit 
autophagy, we used antimalarial chloroquine and neomacrolide antibiotic clarithromycin [27]. 
However, combination of sorafenib with these autophagy inhibitors again induces only 
additive, but no synergistic, effects. 
Since sorafenib activates the UPR and thereby induces adaptive protein refolding and 
autophagy, we evaluated whether triple therapies could improve the antitumor efficacy of 
sorafenib. Combination of sorafenib with an ER stress inducer and an inhibitor of the observed 
compensatory mechanisms, adaptive protein refolding or autophagy, synergistically potentiated 
the antitumor efficacy of sorafenib in vitro. Of these multiple combinations, we tested the 
combination with nelfinavir and clarithromycin in different HCC models, which showed the 
strongest antiproliferative effects in vitro. Nelfinavir and clarithromycin synergized with 
sorafenib to reduce tumor growth in vivo without toxicity. 
The p38/ATF2 pathway was recently identified as a mechanism of sorafenib resistance in HCC 
[7]. Investigating the effect of the proposed triple therapy modulating the induced 
UPR/autophagy on this sorafenib-resistance pathway may uncover downstream 
interconnections. For example, oligomerized IRE1 binds TNF receptor-associated factor 2 
(TRAF2), activating apoptosis signal-regulating kinase 1 (ASK1) and downstream kinases that 
activate p38 [8], [40]. Therefore, an altered IRE1 pathway activation pattern may modulate the 
p38/ATF2 pathway and thereby sorafenib resistance. 
A recent phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors showed 
an ER stress-inducing maximum tolerated dose of 6250 mg/day or, for a person of 70 kg, 89 
mg/kg/day, which is 2.5 fold over the doses typically used in HIV patients [41]. This human 
dose correspond to a dose of 1094 mg/kg/day in mice [42], which highly exceeds the dose used 
in this study. The threshold for ER stress-induced cell death during autophagy inhibition in 
HCC cells is elevated by omission of sorafenib, however, this can be counterbalanced by 
increasing the dose of nelfinavir without increased toxicity given its high maximum tolerated 
dose. Further investigation needs to determine whether daily administration of this dual therapy 
is feasible and sufficient for sustained antitumor response, as evidenced for sorafenib [3]. 
Clarithromycin and nelfinavir are inhibitors of cytochrome P450 CYP3A4, which is involved 
in the metabolism of sorafenib [20], and could thereby increase the tissue concentration of 
sorafenib in vivo. However, combination of clarithromycin with another CYP3A4 substrate and 
multi-kinase inhibitor sunitinib showed no effect on the pharmacokinetics of sunitinib [43]. 
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Combined therapy with multiple drugs is a common practice in cancer therapy and can achieve 
better therapeutic effects than a single drug. Furthermore, the utility of combining approved 
drugs by rational drug repositioning may be rapidly implemented in HCC patients. Therefore, 
clinical evaluation of the investigated combinations subverting ER stress towards apoptosis is 
indicated. 
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 Figures 
 
Fig. 1. Sorafenib activates the UPR in HepG2 cells irrespective of pre-existent ER stress. (A) Real-time 
PCR analysis of chaperones, IRE1 targets and PERK targets. (B) Cells receiving the indicated treatments were 
harvested for Western blot analysis, and probed for indicated UPR-mediated proteins. Quercetin concentration: 
100 μM. (C) Real-time PCR analysis of UPR-mediated genes in the presence of tunicamycin. (D) Real-time 
PCR analysis of RIDD targets. One way ANOVA test was applied for statistical analysis. Data are presented as 
mean ± SD of n=4. All experiments were repeated three times with similar results. Concentrations are indicated 
in μM. Sora= sorafenib. *p<0.05, **p<0.01, ***p<0.001 compared to control. #p<0.05, ##p<0.01, ###p<0.001 
compared to 5 μM sorafenib. 
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Fig. 2. Sorafenib-mediated reduction in tumor cell 
viability and proliferation depends on proteotoxic 
stress and the IRE1 RNase. (A) Cell viability as shown 
by MTT assay. (B) Cell proliferation was assessed by 
BrdU incorporation. (C) Caspase-3 activity of HepG2 
cells treated with the indicated compounds. Data are 
presented as mean ± SD. These experiments were 
repeated three times with similar results. One way 
ANOVA test was applied for statistical analysis. CX= 
cycloheximide. *p<0.05, **p<0.01, ***p<0.001. 
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Fig. 3. Combination of sorafenib with an ER stress inducer and 
an inhibitor of adaptive protein refolding or autophagy 
potentiates the antitumor activity in vitro. (A) Cell viability, (B) 
proliferation rate and (C) caspase-3 activity of HepG2 cells. 
*p<0.05, **p<0.01, ***p<0.001 compared to control; #p<0.05, 
##p<0.01, ###p<0.001 compared to 10 μM sorafenib alone; §p<0.05, 
§§p<0.01, §§§p<0.001 compared to the indicated group. Sora= 
sorafenib, BORT= bortezomib, NEL= nelfinavir, BAC= bacitracin, 
CQ= chloroquine, CLAR= clarithromycin. 
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Fig. 4. Combination of sorafenib with an ER stress inducer and an inhibitor of autophagy 
potentiates the antitumor activity in vivo. (A) Representative photographs of the DEN-treated 
livers. (B) Tumor burden as assessed by reticulin staining in randomly selected high-power 
fields. *p<0.05, **p<0.01, ***p<0.001. (C) Effect of indicated treatments on growth of HepG2 
xenografts in athymic nude mice (n=6). The tumor volume was measured three times per week 
for 4 weeks. Values represent the mean ± SD. (D) At the end of the treatment period, animals 
were sacrificed and xenograft tumor weights were recorded. (E) Schematic model outlining the 
modulation of sorafenib-induced resistance mechanisms. Sora= sorafenib, NEL 50= nelfinavir 
50 mg/kg bid, NEL 250= nelfinavir 250 mg/kg bid, CLAR= clarithromycin. 
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 Supplementary figures 
 
Fig. S1. Sorafenib induces apoptosis and reduces proliferation in human 
and murine HCC cells irrespective of pre-existent ER stress. (A) Cell 
viability, (B) caspase-3 activity and (C) proliferation assessment in HepG2, 
BWTG3 and Hepa1-6 cells. Data are expressed as the percentage of control 
and presented as the mean ± SD of three separate experiments, each of which 
was performed in triplicate. *p<0.05, **p<0.01, ***p<0.001 compared to 0 
μM sorafenib in control conditions. #p<0.05, ##p<0.01, ###p<0.001 compared 
to indicated sorafenib concentration. 
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Fig. S2. IRE1 activator quercetin induces no synergistic antitumor effects in sorafenib-treated 
HepG2 cells. (A) Effect of 25-100 μM quercetin on the mRNA expression of UPR-mediated genes 
with and without sorafenib. (B) Proliferation rate. (C) Caspase-3 activity. (D) Cell viability. (E) 
Proliferation rate. Concentrations are indicated in μM. *p<0.05, **p<0.01, ***p<0.001 compared to 
sorafenib. Sora 5=sorafenib 5 μM. CQ=chloroquine. 
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Fig. S3. Sorafenib dose dependently induces autophagy in part via ER stress modulation. (A) mRNA 
expression of autophagy-related genes and (B) Western blotting for LC3 and P62 in HepG2 cells. Blots are 
representative of three independent experiments. *p<0.05, **p<0.01, ***p<0.001 compared to saline. 
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Fig. S4. Antitumor efficacy of sorafenib is potentiated by combination with nelfinavir and 
clarithromycin in xenograft and orthotopic models for HCC. (A) Hematoxylin/eosin and (B) 
Reticulin staining of HCC-bearing livers. Scale bar: 100 µm. Arrows indicate cytoplasmic vacuolization. 
(C) Caspase-3 activity in lysates of HCC-bearing livers, *p<0.05. (D) 18F-Choline positron emission 
tomography visualizes cell membrane synthesis. 
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Therapeutic effects of artesunate in hepatocellular carcinoma: repurposing an ancient 
antimalarial agent 
 Abstract 
Objectives 
Artemisinins are antimalarial drugs that exert potent anticancer activity. We evaluated the 
effects of artesunate, a semisynthetic derivative of artemisinin, on tumor growth, angiogenesis, 
the unfolded protein response, and chemoresistance in hepatocellular carcinoma. 
Materials and methods  
The effect of artesunate was examined in HepG2 and BWTG3 cells under normoxic and 
hypoxic conditions and in a diethylnitrosamine-induced mouse model. Histology was 
performed with hematoxylin/ eosin and reticulin staining. The expression of chemoresistance-
related transporters and angiogenic and unfolded protein response factors was determined. 
Cytotoxicity was assessed by alanine and aspartate transaminase, lactate dehydrogenase, water-
soluble tetrazolium salt, and caspase-3 activity assays. Small animal imaging was performed 
using dynamic contrastenhanced MRI and choline PET to assess tumor progression. 
Results 
Artesunate dose dependently reduced cell viability (from 50 μmol/l; P< 0.05) and increased 
caspase-3 activity (P< 0.05) in HepG2 and BWTG3 cells. These effects were enhanced by 
hypoxia (from 12.5 μmol/l; P< 0.01). Moreover, artesunate downregulated vascular endothelial 
growth factor and placental growth factor expression in vitro (both P< 0.05) and in vivo (both 
P< 0.01). In mice, artesunate decreased vessel density and tumor burden (both P< 0.05). These 
in-vivo effects were enhanced by combination with sorafenib (P< 0.05 and P= 0.07, 
respectively), without apparent hepatotoxicity. Furthermore, artesunate modulated the unfolded 
protein response in vitro and in vivo, increasing proapoptotic signaling, and did not induce 
doxorubicin chemoresistance. 
Conclusion 
These findings indicate that artesunate could offer a new approach to the therapy of 
hepatocellular carcinoma. Clinical trials with artesunate as monotherapy or in combination with 
current hypoxia-inducing approaches are necessary.  
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 Introduction 
Hepatocellular carcinoma (HCC) remains a major health problem and is the third leading cause 
of cancer-related mortality worldwide. HCC is frequently associated with liver cirrhosis and 
dysfunction, complicating therapeutic strategies [1]. Resection and transplantation are the only 
curative treatments available. However, only ∼20% of patients with HCC are eligible for 
surgery, and recurrence rates are high [2,3]. Classical chemotherapy is ineffective because HCC 
cells are chemoresistant, partially because of the increased cellular efflux of cytostatic 
compounds, including doxorubicin, by transmembrane ATP-binding cassette (ABC) 
transporters [4–7]. To date, the antiangiogenic multikinase inhibitor sorafenib, which targets 
Raf and platelet-derived and vascular endothelial growth factor (VEGF) receptor tyrosine 
kinase signaling, and transarterial embolization are the only approved treatments for advanced 
disease. Unfortunately, both treatments provide only a limited survival advantage [3], 
necessitating the development of innovative compounds. A phase III trial of sorafenib showed 
prolonged survival but only minimal tumor shrinkage, thus increasing the use of functional 
imaging (e.g. PET) [8]. 
Artemisinins, compounds extracted from the herb Artemisia annua, are safe and effective 
antimalarial drugs. Recent studies have suggested that artemisinins also exert antiangiogenic 
and cytotoxic effects on cancer cells [9]. Dihydroartemisinin, the main active metabolite, exerts 
antitumor effects against various human cancers, including liver, lung, ovarian, and pancreatic 
cancer [9,10]. Artesunate (ART) is a water-soluble semisynthetic artemisinin with improved 
pharmacokinetic properties and is approved by the Food and Drug Administration for the 
treatment of malaria [11]. The mechanism through which artemisinins inhibit cancer growth is 
not fully understood, but ferrous iron is considered to induce cytotoxic radicals by reductive 
scission of the endoperoxide bridge of artemisinins [9]. Blocking the transferrin receptor by 
specific monoclonal antibodies abrogates the antitumoral activity of ART [9]. Because the liver 
serves as an iron storehouse, we expect ART to be active in hepatocytes. Moreover, continuous 
HCC cell growth requires high iron metabolism, and cancer cells show increased transferrin 
receptor expression. As transferrin receptors are responsible for the uptake and regulation of 
intracellular iron [12], ART may have greater efficacy in cancer cells. 
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In addition to oxidative stress, ART inhibits angiogenesis and causes calcium dysregulation 
[9,13]. These effects may induce the unfolded protein response (UPR), which stimulates 
cellular adaptation to stress or, if the stress is too severe, apoptosis. In addition, the UPR 
regulates chemoresistance and angiogenesis and is activated in HCC [14–16]. Three UPR 
transducers have been identified: PKR-like endoplasmic reticulum kinase (PERK), inositol-
requiring enzyme 1 (IRE1), and activating transcription factor 6 (ATF6) [17]. In the absence of 
misfolded proteins, these stress sensors exist in an inactive state in association with binding 
immunoglobulin protein (BiP). During endoplasmic reticulum stress, misfolded proteins 
sequester BiP, allowing sensor activation. PERK phosphorylates eukaryotic initiation factor 2α 
(eIF2α), leading to transcription factor 4 (ATF4) and C/EBP homologous protein transcription 
factor (CHOP) activation, growth arrest, and DNA damage-inducible protein (GADD34) 
expression [17]. Furthermore, dihydroartemisinin induces CHOP in HepG2 cells [9]. The 
effects of ART on HCC growth, angiogenesis, UPR induction, and chemoresistance in vitro 
and in vivo are unknown. 
In this study, we tested the hypothesis that ART has antitumor activity in HCC and elucidated 
potential modes of action, such as the induction of tumor hypoxia and endoplasmic reticulum 
stress. We then evaluated dual therapy with sorafenib (ART/Sora) and the effect of ART on 
chemoresistance. 
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 Materials and methods 
Cell culture 
The human HepG2 (HB-8065; ATCC, Manassas, Virginia, USA) and mouse BWTG3 [18] cell 
lines were cultured in DMEM supplemented with 10% FBS (Life Technologies, Ghent, 
Belgium) and incubated at 37°C in a water-saturated atmosphere of 5% CO2/95% air. Cells 
were seeded in six-well plates at 2.5×106 cells/well and incubated for 1 or 4 days with different 
ART concentrations (provided by Dafra Pharma Research, Turnhout, Belgium); equal volumes 
of PBS and ethanol were included as controls. Cell density was assessed daily. Selective PERK 
(Toronto Research Chemicals, Toronto, Canada) and IRE1 (4μ8C; Calbiochem, Billerica, 
Massachusetts, USA) inhibitors were applied at concentrations of 0.1 and 7 μmol/l, 
respectively. Each experiment was conducted in quadruplicate under normoxic and hypoxic 
conditions (1% oxygen in a hypoxia chamber, AnaeroGen; Oxoid, Basingstoke, UK). 
Subsequently, the cells were lysed for RNA extraction. 
 
Animals 
Wild-type 129S2/SvPasCrl mice were purchased from Charles River (Brussels, Belgium) and 
maintained as described previously [19]. Five-week-old males received weekly intraperitoneal 
saline or diethylnitrosamine (DEN) (35 mg/kg, in saline) injections [20]. After 25 weeks, the 
mice were divided randomly into six groups (each n=14) including two control groups 
[intraperitoneal injections with 100μl of saline once daily with or without ART (30mg/kg/day)] 
and four DEN-treated groups [saline, ART, intragastric sorafenib (Bayer, Diegem, Belgium) 
once daily (10 mg/kg/day) or ART/Sora]. After 30 weeks, blood was collected from the 
ophthalmic artery under isoflurane anesthesia and the mice were euthanized. Pimonidazole HCl 
(Hypoxyprobe-1; Natural Pharmacia International Inc., Burlington, Massachusetts) was 
administered intraperitoneally to four random mice per group at a single dose of 60 mg/kg 1 h 
before they were killed. After macroscopic and microscopic assessment, all organs were fixed 
in 4% phosphate-buffered formaldehyde (Klinipath, Olen, Belgium) and embedded in paraffin 
or snap frozen in liquid nitrogen. Hematoxylin/eosin and reticulin staining was performed to 
assess tumor burden (size×number) and evaluated by two independent observers. All animals 
received humane care, and all protocols were approved by the Ethical Committee of 
Experimental Animals at the Faculty of Health Sciences, Ghent University, Belgium (ECD 
11/52). 
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WST-1 and LDH cytotoxicity assays  
HepG2 cells were seeded in 96-well plates at 104 cells/ well in DMEM supplemented with 10% 
FBS and stimulated with an ART dilution series or 1% Triton X-100. After 24 h, 100 µl of 
supernatant was collected for lactate dehydrogenase (LDH) measurement according to the 
manufacturer’s protocol (Biovision, Milpita, California, USA). Cell viability was determined 
using water-soluble tetrazolium salt 1 (WST-1) (Roche Diagnostics, Mannheim, Delaware, 
USA). After supernatant collection, the reagent was added and cells were incubated for 4 h at 
37°C. The absorbance of the bioreduced WST-1 (formazan) was measured at 450 nm against a 
background control at 655 nm (Multiskan Ascent, Leuven, Belgium). Experiments were 
conducted in quadruplicate. 
 
Detailed information on the caspase-3 activity assay, total RNA extraction, quantitative real-
time PCR, western blotting, immunohistochemistry, enzyme-linked immunosorbent assay and 
dynamic contrast-enhanced MRI (DCE-MR), and choline PET imaging is provided in the 
Supplementary Materials and methods section. 
 
Statistics 
Statistical analysis was carried out using SPSS 21 (SPSS Inc., Chicago, Illinois, USA). Values 
are presented as the mean ± SEM or log 2[fold change (FC)] relative to the average expression 
in controls. Variables were tested for normality using the Shapiro–Wilk test. Normally 
distributed data were subjected to the unpaired Student’s t-test. Non-normally distributed data 
were tested using the Mann-Whitney U-test. Two-tailed probabilities were calculated; a P-value 
less than 0.05 was considered statistically significant. Survival was analyzed using the log-rank 
test. 
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 Results 
Dose-dependent and time-dependent inhibitory effects of ART on tumor cell viability 
To assess the effects of ART on HCC cells, cell viability, cytotoxicity, and caspase-3 activity 
were assessed in HepG2 and BWTG3 cells treated with different ART concentrations. The 
WST-1 assay indicated that ART dose dependently decreased HepG2 cellular metabolic 
activity and, thus, cell viability (Fig. 1a, P<0.05 at 50 μmol/l). Because liver tumors rapidly 
outgrow their vascular supply and become hypoxic, all experiments were conducted under 
normoxic and hypoxic conditions [21]. In HepG2 and BWTG3 cells, hypoxia enhanced the 
reduction in cell viability [Fig. 1b (P<0.05 at 12.5 μmol/l) and Fig. 1Sb (P<0.001 at 12.5 
μmol/l), respectively]. 
Dose-dependent cellular cytotoxicity was measured by LDH released into the supernatant and 
observed at 25 and 50 μmol/l ART in HepG2 cells (Fig. 1c; P<0.01 and P<0.001, respectively) 
and 50 μmol/l ART in BWTG3 cells (Fig. 1Sc, P<0.05). 
The activity of caspase-3, a downstream effector of the intrinsic and extrinsic apoptotic 
pathways, time dependently increased after 24 and 48 h of incubation with 50 μmol/l ART in 
HepG2 cells, indicating induction of apoptosis (Fig. 1e, P<0.05 after 24 h). All of these effects 
led to a significant reduction in the number of HepG2 cells by 25 and 50 μmol/l ART after 4 
days of incubation (P<0.01, Fig. 1f). 
ART monotherapy and ART/Sora show antitumor efficacy in a mouse model of HCC 
To confirm the antitumor activity of ART observed in our in-vitro studies, we evaluated its 
antitumor activity in an HCC mouse model. Twenty-five weeks of DEN administration reduced 
the body weight of mice when compared with controls (P<0.001). Subsequent treatment with 
ART or ART/Sora for 5 weeks did not significantly alter the average body weight when 
compared with vehicle (Table 1). ART did not increase mortality in saline-injected mice; in 
DEN-injected mice with HCC, survival rates were slightly, but not significantly, increased by 
ART or ART/Sora therapy (P>0.05, 71.43, 85.71, and 82.62%; Fig. 2a). Furthermore, neither 
ART nor sorafenib induced apparent hepatotoxicity as the serum alanine aminotransferase and 
aspartate aminotransferase levels were equally increased compared with vehicle-treated mice 
after administration of DEN (Fig. 2b). Macroscopic evaluation (Fig. 3a) and tumor burden 
quantification (size×number), as determined by reticulin staining (Fig. 2c), showed reduced 
tumor number (Fig. 2d) and burden (Fig. 2e) in ART-treated mice (both P<0.05).  
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In addition, although sorafenib did not enhance the ART-induced reduction in HCC nodules 
(P=0.76, Fig. 2c), a borderline significant additive effect on tumor burden was observed 
microscopically (P=0.07, Fig. 2e). Interestingly, 25 weeks of DEN administration significantly 
increased transferrin receptor mRNA levels (1.93 FC compared with 25 weeks of saline, 
P<0.01) and protein levels (Fig. 2Sg). 
Caspase-3 activity levels were increased by administration of DEN (Fig. 2f, P<0.05) and 
significantly increased in HCC livers after ART monotherapy compared with controls (P<0.01). 
Administration of sorafenib also increased caspase-3 activity (P<0.05) and an additive effect 
was observed after ART/Sora (P<0.001). 
Functional choline PET and DCE-MRI studies were used to visualize cellular membrane 
biosynthesis [22] and time-dependent contrast uptake, respectively. Choline PET showed a 
reduced number of loci with high mean standardized uptake values according to the PERCIST 
criteria [23] after the administration of ART and ART/Sora compared with saline (Fig. 3b). 
DCE-MRI showed smaller and reduced numbers of nodules with low vascularization following 
the administration of ART and ART/Sora (Fig. 3c). 
ART decreases tumor angiogenesis in HCC 
In addition to its direct effect on tumor cell viability, the antitumor efficacy of ART has been 
associated with antiangiogenic activity [9,13]. Therefore, we assessed the effects of ART on 
the expression of key angiogenic factors VEGF and placental growth factor (PlGF), 
intratumoral hypoxia, and vessel density in this HCC model. After 25 weeks of DEN 
administration, Vegf mRNA and protein levels were upregulated (P<0.001 and P<0.01, 
respectively; Fig. 2S and Fig. 4a). An increase in vessel density after the administration of DEN 
further led to neovascularization, as shown by CD105 immunohistochemistry (1.49 FC, 
P<0.001, Fig. 4b–d). However, pimonidazole binding showed reduced oxygen levels within the 
tumor nodules, suggesting the formation of dysfunctional vessels. 
Remarkably, Plgf and Vegf mRNA (P<0.01 and P<0.05, respectively; Fig. 2S) and protein 
levels (P<0.05 and P<0.01, respectively; Fig. 4a) were reduced after 5 weeks of ART treatment 
compared with controls. Moreover, ART decreased the vessel density in the tumor (Fig. 4b) 
and surrounding tissue (Fig. 4c) compared with vehicle (both P<0.05). ART/Sora reduced 
angiogenesis more than ART monotherapy, but the difference was significant only in the tumor 
tissue (P<0.05).  
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Reduced vascularization was associated with increased nodular hypoxia in ART-treated and 
ART/Sora-treated mice compared with vehicle-treated mice (Fig. 4e). Finally, the addition of 
25 μmol/l ART for 24 h to HepG2 cells under hypoxia reduced VEGF and PlGF secretion (both 
P<0.05) (Fig. 2Sb), suggesting that these effects are cell intrinsic. 
ART modulates the UPR and ABC transporter induction in vitro and in vivo 
Because the induction of endoplasmic reticulum stress is a proposed ART mechanism of action 
[9], we evaluated the expression of key markers of the three UPR pathways in vitro and in vivo. 
In HepG2 cells, ART upregulated ATF4 and CHOP mRNA (both P<0.05, Fig. 3Sa) and protein 
(Fig. 2Sf) under normoxia. In addition, induction of these PERK targets was observed in 
BWTG3 cells (Fig. 4Sa). In mice, ART increased the levels of Atf4 mRNA (P<0.01, Fig. 3Sa) 
and phospho-eIf2α (P<0.01, Fig. 3Sb), Atf4 (P<0.01), Chop (P<0.05), and Gadd34 (P=0.12) 
protein expression (Fig. 3Sc). No changes were observed in IRE1-mediated X-box-binding 
protein 1 (XBP1) splicing activity in vitro or in vivo. Remarkably, in HepG2 cells, 25 μmol/l 
ART reduced the mRNA levels of BiP and other ATF6 pathway targets, protein disulfide 
isomerase family A, member 4 (PDIA4), and unspliced XBP1. Western blot analysis showed 
reduction of BiP by ART therapy in vitro (Fig. 2Sf) and in vivo (Fig. 3Sc). Importantly, VEGF 
and PlGF expression and the reduced cell viability induced by ART were not altered by an IRE1 
or a PERK inhibitor in HepG2 cells despite their effective inhibition of XBP1 splicing and 
CHOP expression (Fig. 2Sb–f). Therefore, ART attenuates the expression of chaperones, 
including BiP and PDIA4, and the cytoprotective ATF6 pathway, and increases certain PERK 
targets (e.g. the proapoptotic protein CHOP). 
ABC transporters determine cell viability following chemotherapy, and doxorubicin is the most 
commonly used chemotherapeutic agent for HCC [6,24,25]. Because hypoxia is a well-known 
ABC transporter inducer and because reduced oxygen levels were observed after ART therapy, 
we examined the effects of ART on the chemoresistance profile in HCC, which is primarily 
determined by the ABCB1 and ABCG2 levels [24,26]. Furthermore, we examined the effects 
of the ART-induced expression pattern by exposing HepG2 cells to ART for 4 h before 
incubation with doxorubicin for 24 h. In HepG2 cells, ABCB1 and ABCG2 were decreased by 
ART under normoxia, but not hypoxia (P<0.01, Fig. 3Sd). In BWTG3 cells, only Abcg2 was 
decreased (P<0.05, Fig. 4Sb).  
In addition, the expression of other ABC transporters implicated in chemoresistance, for 
example ABCC10, was altered [6]. ART pretreatment did not alter doxorubicin cytotoxicity 
(Fig. 2Sc), excluding direct resistance induction. 
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In mice, ART decreased Abcg2 and did not alter Abcb1 at the mRNA (Figs 3Sd and 4Sb) and 
protein levels [ABCG2: P<0.05; ABCB1 (Fig. 3Se): NS]. Only Abcc6 mRNA was upregulated 
(P<0.05). 
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 Discussion 
To date, only sorafenib has provided limited benefits for advanced HCC. ART is an approved 
treatment option for malaria and is well tolerated by patients at therapeutic doses of ∼5 
mg/kg/day [27,28]. The antitumor activity of ART has been described [9,29,30], but its 
biological activity has not been completely elucidated. In this study, ART (30 mg/kg/day) 
exerted potent cytotoxic effects on HCC in vitro and in vivo without inducing body weight 
reduction, hepatotoxicity, or increased mortality in an orthotopic mouse model of HCC. 
The effects of ART on angiogenesis and VEGF downregulation have been reported in other 
cell types [31,32]. We showed that ART reduced the angiogenic factors VEGF and PlGF in 
vitro and in vivo and decreased tumor angiogenesis in a mouse model [19]. Because the UPR 
is crucial for angiogenesis regulation and hypoxia is a well-known endoplasmic reticulum stress 
inducer, we evaluated the effects of ART on the UPR and, consequently, angiogenic factors 
[33]. ART fortified the PERK pathway in HCC. However, the addition of a selective PERK 
inhibitor did not counteract the ART-mediated reduction of VEGF or PlGF. In addition, ART 
did not affect the IRE1 pathway, and in-vitro IRE1 inhibition did not alter its effects on 
angiogenic factors or cell viability. These data suggest that ART-induced reductions in tumor 
angiogenesis could be dependent on the UPR, but upstream selective pathway inhibition was 
insufficient, confirming the known functional redundancy of the UPR. Validation in knockout 
models of downstream UPR factors is required. 
Remarkably, the antitumor activity of ART was increased under hypoxia. In addition, because 
hypoxic conditions are more distinctly present in intratumoral regions than in healthy livers 
[34], this finding also allows for dual therapy with ART and conventional hypoxia-inducing 
therapeutic strategies, for example transarterial embolization [34] and sorafenib therapy [35]. 
Because we previously showed the antitumor efficacy of sorafenib in DEN-induced HCC [36], 
we investigated combined ART/Sora and showed that it exerted an additive effect on the 
microscopic tumor burden and further reduced tumor neovascularization compared with 
monotherapy. 
Notably, macroscopic tumor counting in the ART/Sora group could have been biased by 
difficulty in identifying smaller nodules in contrast to the quantification of tumor burden 
determined by reticulin staining. In addition, no significant alterations were observed in the 
vascularization of the nontumoral liver tissue by ART/Sora compared with ART monotherapy. 
Apparently, the different modes of action of ART and sorafenib allow them to act in parallel. 
Further investigation to determine downstream interactions is needed. 
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In the mouse model, ART decreased tumor neovascularization. Moreover, enhanced 
antiproliferative activity was observed under hypoxia in HCC cell lines. Consequently, we 
hypothesize that a positive feedback loop exists: repeated ART administration reduces 
angiogenesis, increasing intratumoral hypoxia and thus enhancing ART efficacy (Fig. 4f). 
Given the modest effects of ART on ABC transporters in the mouse model and the unaltered 
doxorubicin cytotoxicity after pretreatment with ART in vitro, there is no indication for 
combining ART with chemotherapeutics such as doxorubicin for HCC therapy or to presume 
enhanced chemoresistance after ART therapy. Moreover, although doxorubicin is a substrate, 
the relevance of the only in-vivo upregulated ABC transporter, Abcc6, to chemoresistance is 
questionable [4]. Finally, in line with findings in non-small-cell lung cancer [37], Abcg2 was 
significantly reduced by ART. In this study, the effect of ART on ABC transporter expression 
was examined. Future studies should also investigate efflux pump activity. 
 Conclusion 
ART, as a monotherapy or in combination with sorafenib, exerted antitumor effects in 
experimental HCC models, and ART/Sora therapy was more effective than sorafenib alone and 
did not show cumulative toxicity. Experience in the use of ART and sorafenib in clinical 
practice is a considerable advantage. Furthermore, as a safe and low cost drug, ART might be 
of particular interest for developing countries with a high incidence of HCC [3, 38]. These 
results collectively suggest that ART could be a promising candidate drug for HCC treatment. 
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 Figures 
 
Fig. 1 Artesunate (ART) reduces proliferation and increases cytotoxicity in HepG2 cells. Cells 
were incubated for 24 h with 6.25–50 µmol/l ART or PBS or ethanol as a control. (a) Assessment of 
cell viability by optical density (OD) under normoxia and (b) hypoxia in HepG2 cells. (c) Assessment 
of cytotoxicity by LDH release in HepG2 under normoxia and (d) hypoxia. 1% Triton X-100 
=positive control. (e) Assessment of caspase-3 activity over time in HepG2 cells treated with 50 
µmol/l ART. (f) Incubation of HepG2 cells with ART for 4 days with a daily assessment of cell 
density. *P< 0.05,**P <0.01, ***P <0.001. 
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Fig. 2 Artesunate (ART) shows antitumor activity in an hepatocellular carcinoma (HCC) mouse 
model. (a) Kaplan–Meier survival curve. (b) Alanine aminotransferase (ALT) and aspartate 
aminotransferase (AST) levels. (c) Tumor number and (d) tumor burden. (e) Caspase-3 activity in saline 
(S)-treated mouse liver tissue and tumor nodules from diethylnitrosamine (DEN)-treated mice. (f) 
Representative reticulin-stained slides showing the absence of reticulin in HCC. Following ART, smaller 
nodules with less defined tumor borders were observed. Scale bars =100 µm. *P < 0.05, **P <0.01, ***P 
<0.001. Sora, sorafenib. 
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Fig. 3 Structural and functional imaging of the hepatocellular carcinoma model. (a) 
Representative liver images. (b) Representative images of choline PET and (c) DCE-MRI. ART, 
artesunate; DEN, diethylnitrosamine; Sora, sorafenib. 
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Fig. 4 Artesunate (ART) shows antiangiogenic properties in the hepatocellular carcinoma (HCC) 
model. (a) Protein concentrations of Vegf and Plgf (pg/ml) in liver lysates. (b) Assessment of vessel density 
by CD105 staining in tumor nodules and (c) surrounding tissue. (d) Representative CD105 staining of liver 
tissue after different treatments. (e) Pimonidazole staining. Scale bars =100 µm; S, saline; *P < 0.05, **P 
<0.01 and ***P <0.001. (f) Schematic representation of the modes of action of ART related to modulation 
of the unfolded protein response and hypoxia. DEN, diethylnitrosamine; Sora, sorafenib. 
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 Supplementary figures 
 
Fig. 1S: ART dose dependently reduces proliferation and increases cytotoxicity in BWTG3 
cells. Cells were incubated for 24 hours with 6.25-50 μM of ART or PBS or ethanol as a control. 
(A) Assessment of cell viability under normoxia and (B) hypoxia. (C) Assessment of LDH release 
under normoxia and (D) hypoxia. 1% Triton-X100= positive control. *p<0.05, ***p<0.001. 
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Fig. 2S: The effect of ART on angiogenic factors and cell viability is independent of PERK 
and IRE1 signaling. (A) Relative VEGF and PlGF mRNA expression in the mouse model. (B) 
Protein concentrations of VEGF and PlGF in supernatant from HepG2 cells incubated with ART 
and a PERK or IRE1 inhibitor. (C) Assessment of cell viability. Relative mRNA levels of (D) 
XBP1s and (E) CHOP in HepG2 cells. (F) Western blotting of lysates from HepG2 cells with 
anti-BiP and anti-CHOP antibodies. ART=Artesunate; S=Saline; *p<0.05, **p<0.01 and 
***p<0.001. 
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Fig. 3S: The mRNA and protein levels of UPR- and chemoresistance-related 
proteins. (A) The mRNA log2(fold change) of UPR-related genes in HepG2 cells 
following 25 μM ART compared with saline treatment, and the mRNA log2(fold 
change) of UPR-related genes in the mouse HCC model following 5 weeks of 30 
mg/kg per day ART compared with saline administration. (B) Representative 
immunohistochemistry images of phospho-eIf2α, which was increased (p<0.01) by 
ART treatment. Positive controls received only intraperitoneal tunicamycin for 72 
hours. (C) Western blotting of lysates from liver tissue after saline administration or 
tumors after DEN administration, as described in the Materials and Methods. The 
outer right lane in the blot for BiP represents a positive control. The mean 
densitometric values are shown below each group. (D) mRNA log2(fold change) of 
chemoresistance-related genes compared with those following saline administration. 
(E) Abcb1 expression was unaltered, whereas Abcg2 expression was decreased 
(p<0.05) by ART. Scale bars: 100 µm. (F) Western blot of Abcc1. Experiments were 
repeated twice with similar results. *p<0.05 and **p<0.01. 
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Fig. 4S: The mRNA and protein levels of UPR- and chemoresistance-related proteins in BWTG3 
cells. (A) The mRNA log2(fold change) of UPR- and (B) chemoresistance-related genes following 25 
μM ART compared with saline treatment. *p<0.05, **p<0.01 and ***p<0.001. 
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 PlGF inhibition and the UPR in hepatocellular carcinoma. 
4.1. Placental growth factor inhibition modulates the interplay between 
hypoxia and the unfolded protein response in hepatocellular carcinoma. 
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Placental growth factor inhibition modulates the interplay between hypoxia and unfolded 
protein response in hepatocellular carcinoma 
 
 Abstract 
Background. Hepatocellular carcinoma (HCC) is a leading cause of cancer-related mortality. 
We previously showed that the inhibition of placental growth factor (PlGF) exerts antitumour 
effects and induces vessel normalisation, possibly reducing hypoxia. However, the exact 
mechanism underlying these effects remains unclear. Because hypoxia and endoplasmic 
reticulum stress, which activates the unfolded protein response (UPR), have been implicated in 
HCC progression, we assessed the interactions between PlGF and these microenvironmental 
stresses. 
Methods. PlGF knockout mice and validated monoclonal anti-PlGF antibodies were used in a 
diethylnitrosamine-induced mouse model for HCC. We examined the interactions among 
hypoxia, UPR activation and PlGF induction in HCC cells. 
Results. Both the genetic and pharmacological inhibitions of PlGF reduced the chaperone levels 
and the activation of the PKR-like endoplasmic reticulum kinase (PERK) pathway of the UPR 
in diethylnitrosamine-induced HCC. Furthermore, we identified that tumour hypoxia was 
attenuated, as shown by reduced pimonidazole binding. Interestingly, hypoxic exposure 
markedly activated the PERK pathway in HCC cells in vitro, suggesting that PlGF inhibition 
may diminish PERK activation by improving oxygen delivery. We also found that PlGF 
expression is upregulated by different chemical UPR inducers via activation of the inositol-
requiring enzyme 1 pathway in HCC cells.  
Conclusions. PlGF inhibition attenuates PERK activation, likely by tempering hypoxia in HCC 
via vessel normalisation. The UPR, in turn, is able to regulate PlGF expression, suggesting the 
existence of a feedback mechanism for hypoxia-mediated UPR that promotes the expression of 
the angiogenic factor PlGF. These findings have important implications for our understanding 
of the effect of therapies normalising tumour vasculature. 
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 Background 
Hepatocellular carcinoma (HCC) ranks as the second leading cause of cancer-related mortality 
worldwide [1]. Conventional chemotherapy is ineffective, and targeted therapy for advanced 
HCC with sorafenib, which targets Raf and platelet-derived and vascular endothelial growth 
factor (VEGF) receptor tyrosine kinase signalling, shows only a limited survival benefit [2]. 
The VEGF signalling pathways play central roles in angiogenesis [3]. VEGF-A binds to two 
tyrosine kinase receptors, VEGFR-1 and VEGFR-2. Most of the biological effects of VEGF-A 
are mediated by VEGFR-2 [3]. The placental growth factor (PlGF, four isoforms: PlGF-1-4) 
binds to VEGFR-1 and induces responses in endothelial, malignant, and immune cells [4]. 
VEGFR-1 has weak tyrosine kinase activity but a substantially higher binding affinity for 
VEGF-A than VEGFR-2. Although VEGFR-1 may act as a trap for VEGF-A, it also transmits 
signals in response to PlGF via its tyrosine kinase domains [4], [5]. A role for VEGFR-1 during 
tumour angiogenesis has been suggested [5], [6]. VEGFR-1 expression in HCC tissues is higher 
than that in peritumoural tissues and correlates with worse survival after resection [7], [8]. 
Importantly, genetic or pharmacological inhibition of PlGF reduces tumour growth and induces 
vessel normalisation in different preclinical models, including the diethylnitrosamine-induced 
HCC model [5], [9], [10]. Although anti-PlGF antibodies are controversial [11], evidence for 
the dose and specificity of the anti-PlGF-2 antibody clone 5D11D4 was previously provided 
[5]. Furthermore, disease stabilization for 12 months has been observed with anti-human PlGF 
monoclonal antibody TB403 in 2 out of 23 patients with advanced solid tumours refractory to 
standard therapy, confirming the need for a better understanding of the effect of PlGF inhibition 
on tumour biology [12]. 
The endoplasmic reticulum (ER) consists of a membranous network in which proteins are 
synthesised, post-translationally modified and folded. Therefore, the lumen houses chaperones, 
including protein disulfide isomerase A4 (PDIA4), calnexin (CANX), glucose-regulated 
protein-78 (GRP78) and -94 (GRP94) [12–14]. Several perturbations in the protein folding, 
such as hypoxia, glucose deprivation and oxidative stress, lead to the accumulation of unfolded 
proteins in the ER, a phenomenon called ER stress. ER stress triggers the unfolded protein 
response (UPR), which leads to an adaptive transcriptional response involved in protein quality 
control, redox homeostasis and angiogenesis. Paradoxically, the UPR also coordinates pro-
apoptotic responses to ER stress [13], [14]. Interestingly, ER stress is present in human and 
experimental HCC, and modulating the UPR could hold important therapeutic potential [16], 
[17]. 
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Three major ER stress sensors have been identified, as follows: PKR-like ER kinase (PERK), 
inositol-requiring enzyme 1 (IRE1) and activating transcription factor 6 (ATF6) [13]. The effect 
of ATF6 on cell fate is primarily cytoprotective, whereas the effect of IRE1 and PERK is 
presumed to be both pro-adaptive and pro-apoptotic [13], [14], [18]. However, inhibition of the 
PERK pathway induces antitumour effects in experimental HCC [14]. Following the release of 
GRP78, PERK phosphorylates the eukaryotic initiation factor 2α (eIF2α), leading to the 
attenuation of global translation. However, the translation of certain transcripts, such as 
activating transcription factor 4 (ATF4), is favoured. ATF4 induces genes involved in protein 
quality control, amino acid biosynthesis and the induction of apoptosis via C/EBP homologous 
protein (CHOP) [13]. IRE1 activation results in X-box-binding protein 1 (XBP1) mRNA 
splicing to generate a more active spliced XBP1 (XBP1s), which induces the genes involved in 
protein folding, such as endoplasmic reticulum DnaJ homolog 4 (ERDJ4) and CANX [19]. 
ATF6 is mobilised to the Golgi, where it is cleaved, releasing a transcriptionally active 
fragment, which in turn induces the expression of homocysteine-responsive ER-resident 
ubiquitin-like domain member 1 (HERPUD1), unspliced XBP1 (XBP1u) and chaperones 
including PDIA4 [12, 18]. 
In this study, we investigated whether vessel normalisation induced by PlGF blockade 
modulates the activation of the UPR or oxygen levels in experimental HCC and whether PlGF 
expression is regulated by ER stress. Collectively, we revealed that PlGF inhibition reduced 
hypoxia and the activation of the PERK pathway of the UPR in the tumour nodules of the 
carcinogen-induced mouse model. Furthermore, PlGF expression was upregulated by divergent 
ER stress stimuli in vitro. These results provide important insight into the reciprocal interactions 
between PlGF and the tumour microenvironment. 
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 Materials and Methods 
Animals 
Wild type 129S2/SvPasCrl mice were purchased from Charles River (Belgium), and PlGF-/- 
knockout (PlGFKO) 129S2/SvPasCrl mice were obtained from the laboratory of Angiogenesis 
& Neurovascular link (Leuven, Belgium). Both were maintained as previously described [5]. 
All mice were genotyped by PCR before the start of the experiments. PlGF-deficient mice are 
born at normal Mendelian ratios and do not show any obvious vascular anomalities [20]. Five-
week-old males received weekly intraperitoneal saline or diethylnitrosamine (DEN) (35 mg/kg, 
in saline) injections [21]. A murine anti-PlGF monoclonal antibody (validated clone 5D11D4 
[5]; referred to as aPlGF) was obtained from Thrombogenics (Leuven, Belgium). Wild type 
mice that received DEN for 25 weeks were subsequently treated for 5 weeks with aPlGF 
(intraperitoneally, 25 mg/kg; 2x/week) or IgG (same regimen, n=10 in each group). Wild type 
mice that received saline for 25 weeks were subsequently treated for 5 weeks with aPlGF (same 
regimen) or IgG (same regimen, n=10 in each group). Pimonidazole HCl (Hypoxyprobe-1 Inc., 
Burlington, MA, USA) was intraperitoneally administered to 4 random mice per group in a 
single dose of 60 mg/kg one hour before sacrifice. Male PlGFKO mice and their wild type 
littermates received DEN for 30 weeks (n=12 in each group). After 30 weeks, blood was 
collected from the retro-orbital sinus under isoflurane anaesthesia. After macroscopic 
evaluation and the quantification of the number of hepatic tumours with a minimum diameter 
of 2 mm, the livers were fixed in 4% phosphate-buffered formaldehyde (Klinipath) and 
embedded in paraffin or snap frozen in liquid nitrogen. Tumour nodules were isolated by 
microdissection (Carl Zeiss, Bernreid, Germany) for expression analysis. Haematoxylin/eosin 
and reticulin staining were performed to assess the tumour burden, and the results were assessed 
by 2 independent observers. All protocols were approved by the Ethical Committee of 
experimental animals at the Faculty of Health Sciences, Ghent University, Belgium (ECD 
11/52). 
 
Cell culture 
HepG2 cells (HB-8065; ATCC, Virginia, USA) were cultured in DMEM supplemented with 
10% foetal bovine serum (Life Technologies, Ghent, Belgium). 
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Cells were incubated for 24 h or 48 h with a PERK inhibitor (0.3 μM; GSK2656157, NoVi 
Biotechnology, Shandong, China), an IRE1 inhibitor (8 μM; 4μ8C, Calbiochem, 
Massachusetts, USA), tauroursodeoxycholic acid (TUDCA, 1 mM), tunicamycin (1 μM), 
thapsigargin (150 nM) or quercetin (100-300 μM) and compared to equal volumes of solvent. 
All reagents were obtained from Sigma (Diegem, Belgium) unless stated otherwise. Hypoxic 
atmosphere (1% oxygen) was established in a hypoxic chamber (AnaeroGen; Oxoid, 
Basingstoke, UK). Experiments were carried out in quadruplicate and independently repeated 
three times. 
 
Detailed information regarding total RNA extraction, quantitative real-time PCR, Western 
blotting, and immunohistochemistry is provided in the Supplementary Materials and Methods. 
 
Statistics 
Statistical analyses were performed using SPSS 21 (SPSS, Chicago, USA). Values are 
presented as the means ± SD or fold change relative to the mean expression in controls. 
Kolmogorov-Smirnov test was used to test for normality. Normally distributed data were 
subjected to the unpaired Student’s t-tests. Multiple groups were compared by one-way analysis 
of variance (ANOVA) with Bonferroni correction. Non-normally distributed data were tested 
using the Mann-Whitney U-test. Two-tailed probabilities were calculated; a p-value less than 
0.05 was considered statistically significant. 
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 Results 
PlGF inhibition induces antitumour effects and vessel normalisation in experimental HCC 
First, we validated the previously reported antitumour effects and vessel normalisation induced 
by PlGF blockage [5, 9]. When wild type mice with established HCC were treated with aPlGF 
(n=10) or IgG (n=10) from 25 weeks onward for 5 weeks, 20% of mice receiving control IgG 
died, whereas only 10% died in the aPlGF group. Additionally, aPlGF-treated mice developed 
fewer nodules per liver (all sizes: 17.6 ± 4.9 after IgG versus 12.7 ± 3.2 after aPlGF; p<0.05). 
After 30 weeks of DEN administration to wild type (n=12) or PlGFKO (n=12) mice, 25% of 
wild type mice compared to 16% of PlGFKO mice succumbed, and fewer tumour nodules per 
liver were observed in PlGFKO mice (22.4 ± 4.8 in wild type versus 15.8 ± 6.2 in PlGFKO; 
p<0.05). Furthermore, several capillaries in control HCC nodules had an abnormal shape and 
size (Fig. S1A). In PlGF-blocked tumours, fewer capillaries, as shown by endoglin staining, 
were tortuous (aPlGF: p<0.05 and PlGFKO: p<0.01; Fig. S1B). These results confirm that PlGF 
blockage induces antitumour effects and partially normalises the abnormal tumour vessel 
structure. 
PlGF inhibition reduced chaperone expression and activation of the Perk pathway in 
experimental HCC 
We among others previously described the UPR pattern in DEN-induced HCC [16]. Here, we 
evaluated the effect of PlGF inhibition on this pattern in isolated tumours. The administration 
of aPlGF downregulated the mRNA expression of the ER stress-induced chaperones Grp78 and 
Grp94 in the tumours, compared to the IgG group (p<0.05; Fig. 1A). Additionally, the PlGFKO 
mice that received DEN for 30 weeks showed reduced levels of Grp78 (p<0.05) and Grp94 
(p<0.05) in the tumours compared to their wild type littermates. Western blotting demonstrated 
reduced protein expression of Grp78 in the tumours of the aPlGF-treated and PlGFKO mice 
compared to those of the IgG-treated and wild type control group, respectively (Fig. 1B). 
The Ire1-mediated splicing of Xbp1 was unaltered by PlGF inhibition (Fig. 1C). Accordingly, 
the targets of Xbp1s, Canx and Erdj4, showed a similar expression level compared to the 
corresponding controls. 
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Western blot analysis showed that the Perk-mediated phosphorylation of eIf2α was reduced in 
the HCC tissues of aPlGF-treated and PlGFKO mice compared to IgG-treated and wild type 
controls resp. (Fig. 1B and S2). Atf4 mRNA (aPlGF: p<0.05 and PlGFKO: p<0.01; Fig. 1D) 
and protein (Fig. 1B) expression in the nodules were decreased by PlGF inhibition. Further, 
Chop mRNA (p<0.05; Fig. 1D) and protein (Fig. 1B) levels were decreased. Next, we assessed 
the expression of Growth arrest and DNA damage-inducible protein (Gadd34), which initiates 
eIf2α dephosphorylation leading to a negative feedback loop of the Perk pathway [13]. Gadd34 
levels were unaltered (Fig. 1B and 1D), indicating that PlGF inhibition did not enhance this 
negative feedback loop. Also, the mRNA and protein levels of the UPR sensor Perk itself were 
unaltered, excluding a direct effect of PlGF on Perk expression (Fig. S3A-B). Overall, these 
data indicate that PlGF inhibition indirectly diminished Perk signalling in HCC. 
To examine the Atf6 pathway, Pdia4 and Herpud1 mRNA expression was monitored (Fig. 1A). 
Only Pdia4 mRNA was downregulated in the tumours of PlGFKO mice compared to their wild 
type littermates (p<0.05). 
Importantly, wild type mice that received saline for 25 weeks and were subsequently treated 
with aPlGF for 5 weeks demonstrated no significant differences in the hepatic mRNA 
expression of the selected UPR targets compared to those receiving control IgG treatment (data 
not shown). Thus, these results demonstrate that PlGF inhibition reduces the intratumour 
expression of chaperones, such as Grp78, Grp94 and Pdia4, as well as the activation of the Perk 
pathway. 
PlGF inhibition reduces intratumour hypoxia 
We previously showed that PlGF inhibition induces vessel normalisation (Fig. S1; [5]). To 
investigate whether these vascular changes were functionally relevant or, in other words, 
whether PlGF inhibition effectively increased the oxygen levels in the hepatic tumours of the 
used mouse model, we applied pimonidazole, a molecule that binds only hypoxic areas in vivo 
and can be detected after sacrifice by immunohistochemistry (Fig. 2A). Indeed, administration 
of aPlGF significantly reduced tumoural pimonidazole binding (p<0.05; Fig. 2A-B). To 
improve the quantification method of the binding of pimonidazole, Western blotting for 
detection of pimonidazole adducts in isolated DEN-induced tumours was performed (Fig. 2C). 
Densitometry analysis confirmed that the liver tumours were characterized by increased 
pimonidazole binding and that administration of aPlGF reduced pimonidazole binding in the 
tumours (p<0.05; Fig. 2C-D).  
Chapter 3 
195 
 
Finally, aPlGF downregulated the expression of hypoxia-inducible genes Glut1 (p<0.05) and 
Pfk (p=0.07) in the DEN-induced HCC (Fig. 2E). Thus, aPlGF effectively tempered the 
induction of tumour hypoxia. 
Hypoxia activates the PERK pathway 
Because PlGF inhibition reduced tumour hypoxia and PERK activation in vivo, we questioned 
whether hypoxia mediates PERK activation in HCC cells. Therefore, we examined the effect 
of hypoxia (<1% O2 or 7.6 mmHg [24]) for 24 h or 48 h on the expression of PERK targets in 
HepG2 cells (Fig. 3A-B). Hypoxic exposure upregulated the mRNA expression of GRP78 
(p<0.001), ATF4 (p<0.05), CHOP (p<0.001) and GADD34 (p<0.001). Furthermore, hypoxic 
exposure also increased the phosphorylation of eIF2α (24 h: p<0.05 and 48 h: p<0.01; Fig. 3B-
C) and protein expression of ATF4 and CHOP (Fig. 3B). These data indicate that hypoxic 
exposure causes potent activation of the PERK pathway in HCC cells. 
Activation of the IRE1 pathway promotes PlGF expression 
Because the UPR is activated in HCC and PlGF inhibition is able to reduce activation of at least 
the Perk branch of the UPR, we next analysed the effect of ER stress on PlGF expression in 
vitro. Therefore, we used two different ER stress inducers: tunicamycin, an inhibitor of protein 
glycosylation, and thapsigargin, an inhibitor of sarcoplasmic/endoplasmic reticulum Ca2+ 
ATPases [13], [25]. Both significantly increased the mRNA levels of PlGF (Fig. 4A). As shown 
in Fig. 4B, an increase in the expression of faster-migrating unglycosylated PlGF was detected 
in HepG2 cells treated with tunicamycin.  
The addition of the chemical chaperone TUDCA to tunicamycin-treated cells attenuated the ER 
stress-mediated induction of PlGF mRNA (p<0.01), whereas the addition of TUDCA to 
untreated cells had no effect on the PlGF mRNA levels (Fig. 4A). Quercetin, an IRE1 activator 
[26] (Fig. S4A), induced PlGF expression (300 μM: p<0.01; Fig. 4A-B). Accordingly, the 
addition of a small-molecule inhibitor of the IRE1 pathway reduced the tunicamycin-mediated 
upregulation of PlGF mRNA (p>0,001, Fig. 4A) and protein (Fig. 4B) levels. In contrast, the 
addition of a small-molecule inhibitor of the PERK pathway did not affect PlGF expression. 
These data show that the ER stress-mediated upregulation of PlGF is primary regulated by the 
IRE1 pathway of the UPR. 
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 Discussion 
Growing tumours are often subjected to deficiencies in vital nutrients and oxygen. These 
inadequate extracellular conditions can adversely affect the environment of the ER and impinge 
on the maturation of nascent proteins. We recently reported that PlGF inhibition induces vessel 
normalisation, potentially supporting the delivery of nutrients and oxygen to tumour cells [5], 
[27]. 
In this study, we found that PlGF inhibition reduced intratumour hypoxia and ER stress levels 
(Fig. 5). In fact, PlGF inhibition attenuates the carcinogen-induced upregulation of chaperones, 
such as Grp78 and Grp94, and the activation of the Perk pathway without affecting Ire1 
activation. These chaperones and Perk activation are pro-survival and pro-proliferative 
modulators in tumour cells [13]–[15]. Probably, the aPlGF-mediated reduction of these UPR 
factors tempers the aggressive growth of HCC cells. 
Recently, hypoxia-inducible factor-1α (HIF-1α), a key transcription factor in the cellular 
response to hypoxia, was shown to be an important driver of HCC growth [28]. In this study, 
we showed that PlGF inhibition reduced tumour hypoxia and PERK activation in vivo and that 
hypoxia activates the PERK/phospho-IF2α/ATF4 cascade in HCC cells, suggesting that tumour 
hypoxia mediates the observed PERK activation in HCC. Possibly, tumour hypoxia is also 
involved in the pronounced activation of PERK in other tumour types, such as glioma [29]. 
Finally, because PERK is, next to hypoxia, able to stimulate tumour growth [13], [30], the 
normalisation of tumoural oxygen levels by PlGF inhibition is able to dually target pro-survival 
signalling via reduced activation of the HIF-1α and PERK pathway. 
Because PlGF inhibition was previously reported to reduce experimental liver fibrosis [31], the 
contribution of hypoxia and ER stress modulation, which both have been implicated in 
fibrogenesis [32], [33], to this outcome requires further investigation. 
Whereas the UPR has previously been shown to upregulate several angiogenic factors, 
including VEGF [34], this is, to our knowledge, the first report to demonstrate the induction of 
PlGF by ER stress in tumour cells. Because studies on transgenic mice have revealed that PlGF 
expression is restricted to pathological conditions [35], the further investigation of the role of 
ER stress in the selectivity of PlGF expression to pathological conditions, potentially 
characterised by ER stress, is indicated. Finally, the role of the UPR in vessel abnormalisation 
induced by excessive production of angiogenic factors requires further investigation [35]. 
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Vice versa, the effect of therapies modulating tumour angiogenesis on the UPR activation 
pattern, which affects tumour growth, is currently unknown. To our knowledge, this is the first 
study to provide evidence that vessel normalisation regulates the UPR in cancer cells. We 
speculate that anti-VEGF therapies may exert their therapeutic effect in part by UPR 
modulation. 
The promising preclinical findings of anti-PlGF in HCC but also in other tumour types such as 
medulloblastoma [36], together with the acceptable safety profile of anti-PlGF administration 
in Phase I clinical trials, have attracted attention to PlGF as a potential target for therapy. 
However, improved understanding of the effect on tumour biology is required. This study 
indicates that anti-PlGF modulates the tumour microenvironment and cell adaptation 
mechanisms, which have been linked to tumour behavior [13], [37]. 
 Conclusions 
In summary, we have shown that inhibition of PlGF tempers UPR activation in HCC, most 
likely by improved oxygen delivery via the induced normalisation of tumour vessels. Moreover, 
we revealed that the UPR, in turn, regulates the expression of PlGF in HCC cells. Thus, our 
study sheds light on the reciprocal interactions between PlGF, hypoxia and the UPR and 
suggests that the antitumour effects of angiogenesis-modulating therapy could be mediated by 
modifying the tumour microenvironmental stresses in HCC. 
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 Figures 
 
Fig. 1. PlGF inhibition tempers the activation of the UPR in an orthotopic mouse model of HCC. 
(A) Quantitative real-time PCR analysis of the ER chaperones Grp78, Grp94 and Pdia4 and Herpud1 
in aPlGF-treated and PlGFKO mice. Relative fold changes were calculated using the ΔΔCT method. 
(B) Immunoblotting for UPR-mediated proteins. (C) Quantitative real-time PCR analysis of ER 
chaperones of Ire1-mediated splicing of Xbp1 and Ire1 targets Canx and Erdj4, (D) Perk-related genes 
Atf4, Chop and Gadd34. *p<0.05, **p<0.01, ***p<0.001. IgG= 25w DEN + 5w IgG, aPlGF= 25w 
DEN + 5w aPlGF, WT= 30w DEN in wild type (WT) mice, PlGFKO= 30w DEN in PlGF-/- knockout 
mice. 
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Fig. 2. PlGF inhibition reduces intratumour hypoxia in experimental HCC. (A) Immunostaining 
for pimonidazole in mouse livers following the indicated treatment. Arrows indicate tumours. Scale 
bars: 100 µm. (B) Quantification of the immunostaining for pimonidazole. (C) Lysates of control liver 
tissue or isolated DEN-induced tumours were subjected to Western blotting for detection of 
pimonidazole adducts (Pimo). Blotting of β-actin is shown as a loading control. (D) Densitometry 
analysis of the pimonidazole blot in (C). (E) Real-time PCR analysis of Glut1 and Pfk mRNA levels in 
tumour tissues. IgG= 25w DEN + 5w IgG, aPlGF= 25w DEN + 5w aPlGF. Data are presented as the 
means ± SD. *p<0.05.  
  
Chapter 3 
204 
 
 
Fig. 3. Hypoxia activates the PERK pathway in HCC cells. (A) HepG2 cells were cultured in 
normoxia or hypoxia for 24 h or 48 h. The PERK targets, GRP78, ATF4, CHOP and GADD34 mRNA 
were detected by Real-time PCR analysis. (B) Expressions of phospho-eIF2α, eIF2α, ATF4, and 
CHOP protein were detected using Western blotting. All experiments were repeated three times with 
similar results. (C) Densitometry analysis of the ratio of phosphorylated eIf2α to total eIf2α bands 
normalised to tubulin and relative to the corresponding control. Quantitative results of the 
phosphorylation of eIf2α are presented as the mean ± SD. *p<0.05, **p<0.01, ***p<0.001. 
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Fig. 4. ER stress induces PlGF expression in HepG2 cells. (A) Relative PlGF mRNA levels in HepG2 
cells treated for 48 hours with the indicated treatments. *p<0.05, **p<0.01, ***p<0.001 compared to 
control. #p<0.05, ##p<0.01, ###p<0.001 compared to the indicated group. TUDCA: tauroursodeoxycholic 
acid. (B) Immunoblotting of cell lysates was performed to detect PlGF protein levels. All experiments 
were repeated three times with similar results. 
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Fig. 5. Schematic model outlining the interactions among PlGF, ER stress and 
hypoxia and their effects on HCC growth. 
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 Supplementary Figures 
 
Fig. S1. PlGF blockage induces vessel normalization. (A) Immunostaining for the endothelial 
marker endoglin (CD105). In HCC nodules, the capillary network is chaotically organized with 
tortuous vessels (indicated by red arrows) laying at large distances from each other. However, the 
capillaries in HCC after aPlGF treatment or in PlGFKO mice have a more normal appearance with 
regular pattern, size, and shape (indicated by green arrows). Black arrows and dashed lines indicate 
tumours. (B) Quantification of tortuous vessels per mm2; n= 5; *p<0.05, **p<0.01. 
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Fig. S2. Densitometry analysis of the 
phosphorylation of eIf2α in isolated HCC. (A) 
Densitometry analysis of the ratio of phosphorylated 
eIf2α to total eIf2α bands normalized to tubulin and 
relative to the corresponding control. Quantitative 
results of phosphorylation of eIf2α are presented as 
the mean ± SD. *p<0.05. 
 
 
Fig. S3. Effect of PlGF inhibition on the expression of the UPR sensor Perk. (A) Quantitative real-time 
PCR analysis of Perk. Relative fold changes were calculated using the ΔΔCT method. IgG= 25w DEN + 5w 
IgG, aPlGF= 25w DEN + 5w aPlGF, WT= 30w DEN in wild type (WT) mice, PlGFKO= 30w DEN in PlGF-
/- knockout mice. (B) Immunoblotting for Perk protein. 
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Fig. S4. Validation of quercetin as activator of the IRE1 RNase. (A) 
Quantitative real-time PCR analysis of unspliced and spliced XBP1 mRNA to 
evaluate the effect of 100-300 μM quercetin for 24 hours on HepG2 cells. Results 
are representative of 2 independent experiments. *p<0.05, **p<0.01, ***p<0.001. 
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Next-generation proteasome inhibitor oprozomib synergizes with modulators of 
endoplasmic reticulum stress in hepatocellular carcinoma 
 
 Abstract 
Background & Aims:  
Advanced hepatocellular carcinoma (HCC) responds poorly to conventional systemic therapies. 
The first-in-class proteasome inhibitor bortezomib has been approved in clinical use for 
hematologic malignancies and has shown modest activity in a variety of solid tumours including 
HCC. However, a considerable proportion of subjects fail to respond and experience adverse 
events. Recently, the next-generation orally bioavailable proteasome inhibitor oprozomib was 
developed. In this study, we assessed the efficacy of oprozomib and its effects on the unfolded 
protein response (UPR) in HCC.  
Methods:  
Oprozomib was evaluated in vitro and in diethylnitrosamine-induced and xenograft mouse 
models for HCC. Also, the role of the UPR in HCC cells treated with oprozomib was 
determined.  
Results: 
Oprozomib dose-dependently reduced the viability and proliferation of human HCC cells. 
Unexpectedly, oprozomib-treated cells displayed reduced cytoprotective ATF6-mediated 
transcription, whereas PERK and IRE1 pathway activation was not observed. However, 
oprozomib increased pro-apoptotic UPR-mediated protein levels, including CHOP, by 
prolonging their half-life. Supplementary boosting UPR activity improved the sensitivity of 
HCC cells to oprozomib, an effect that was blocked by inhibition of PERK. Oral oprozomib 
monotherapy displayed significant antitumour effects in the experimental HCC models, and 
importantly, the combination of oprozomib with different UPR activators further improved the 
antitumour efficacy in vitro and in vivo by stimulating UPR-induced apoptosis without 
cumulative toxicity.  
Conclusion: 
Next-generation proteasome inhibition by oprozomib significantly dysregulates UPR activation 
in HCC. This finding can be exploited to enhance the antitumour efficacy by combining 
oprozomib with UPR modulators for the treatment of advanced HCC. 
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 List of nonstandard abbreviations 
HCC, hepatocellular carcinoma; ER, endoplasmic reticulum; GRP78, glucose-regulated 
protein, 78 kDa; OZ, oprozomib; UPR , unfolded protein response; PERK, PKR-like 
endoplasmic reticulum kinase; IRE1, inositol-requiring enzyme-1; ATF6, activating 
transcription factor 6; eIF2α, eukaryotic initiation factor 2α; ATF4, activating transcription 
factor 4; CHOP, c/EBP-homologous protein; XBP1u, unspliced X-box-binding protein 1; 
XBP1s, spliced X-box-binding protein 1; ERDJ4, endoplasmic reticulum DnaJ homolog 4; RIP, 
intramembrane proteolysis; S1P, site-1 protease; S2P, site-2 protease; GRP94, glucose-
regulated protein, 94 kDa; PDIA4, protein disulfide isomerase A4; CALR, calreticulin; ERO1L, 
endoplasmic oxidoreductin-1-like protein; HERPUD1, homocysteine-inducible, ER stress-
inducible, ubiquitin-like domain member 1; DEN, diethylnitrosamine; NAC, N-acetyl-L-
cysteine; GADD34, growth arrest and DNA damage inducible 34; SREBP-1, sterol regulatory 
element binding protein-1. 
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 Introduction 
Hepatocellular carcinoma (HCC) is the second leading cause of cancer-related mortality 
worldwide [1]. Resection and transplantation are the only potentially curative treatments 
available following detection of a small HCC [2]. For the majority of patients with locally 
advanced disease, however, the multi-kinase inhibitor sorafenib and transarterial embolization 
are the only approved treatments. Unfortunately, both provide a limited survival benefit [2]. 
The ubiquitin-proteasome pathway is responsible for the degradation of misfolded proteins as 
well as short-lived mediators of signalling cascades regulating cell proliferation and survival 
pathways [3]. Proteasome inhibition leads to accumulation of these substrates, resulting in 
concomitant activation of pro- and anti-proliferative signals, disruption of cell-cycle regulation, 
and, ultimately, apoptosis. Bortezomib is a first-in-class proteasome inhibitor clinically used 
for the treatment of multiple myeloma. Bortezomib-induced cell death is related with induction 
of endoplasmic reticulum (ER) stress, inhibition of nuclear factor kappa B, activation of 
caspase-8 and generation of oxidative stress [3], [4]. Multiple clinical trials have demonstrated 
that this small-molecule possesses antitumour activity in a variety of human cancers [5], [6]. 
Despite promising preclinical results [5], a multicentre, single-arm, phase II trial assessing the 
activity of bortezomib in HCC has demonstrated modest antitumour effects, indicating intrinsic 
or acquired resistance [4], [7]. In addition, the majority of the patients developed adverse events 
including peripheral neuropathy [7]. However, the good clinical outcome of bortezomib in 
myeloma led to the development of next-generation proteasome inhibitors, such as carfilzomib, 
that selectively and irreversibly bind to the proteasome aspiring to enhance inhibition, improve 
antitumour activity and decrease toxicity by reducing off-target effects, such as peripheral 
neuropathy [8], [9]. A phase III trial showed that intravenously administered carfilzomib 
improved progression-free survival in myeloma with a favourable risk-benefit profile [10]. 
Recently, an orally bioavailable analogue of carfilzomib, called oprozomib (OZ), was 
developed [9]. 
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Proteasome inhibition is thought to trigger accumulation of misfolded proteins in the ER, which 
activates the unfolded protein response (UPR) [4]. Three major ER stress transducers have been 
identified: PKR-like endoplasmic reticulum kinase (PERK), inositol-requiring enzyme-1 
(IRE1) and activating transcription factor 6 (ATF6) [11]. Following release of chaperone 
glucose-regulated protein, 78 kDa (GRP78), PERK phosphorylates eukaryotic initiation factor 
2α (eIF2α) leading to attenuation of global translation. However, the phosphorylated form of 
this factor favours selective translation of activating transcription factor 4 (ATF4), which 
regulates genes involved in protein quality control, amino acid biosynthesis as well as apoptosis 
regulators such as c/EBP-homologous protein (CHOP) [11]. Activation of IRE1 results in 
splicing of unspliced X-box-binding protein 1 (XBP1u) mRNA to generate a more active 
spliced XBP1 (XBP1s), which induces genes involved in protein folding such as endoplasmic 
reticulum DnaJ homolog 4 (ERDJ4), protein degradation and redox homeostasis [11]. ATF6 is 
mobilized to the Golgi where it is cleaved by regulated intramembrane proteolysis (RIP), which 
involves the site-1 (S1P) and site-2 (S2P) proteases, releasing a transcriptionally active 
fragment, which in turn induces the expression of chaperones, such as GRP78, glucose-
regulated protein, 94 kDa (GRP94), protein disulfide isomerase A4 (PDIA4), calreticulin 
(CALR) and endoplasmic oxidoreductin-1-like protein (ERO1L), XBP1u and of proteins 
stimulating protein degradation, such as homocysteine-inducible, ER stress-inducible, 
ubiquitin-like domain member 1 (HERPUD1) [12]. 
In this study, we provide a molecular clue to the how OZ might work and identified the 
therapeutic potential of OZ in monotherapy or in combination with modulators of the induced 
interplay with the UPR in vitro and in mouse models for HCC. 
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 Materials and Methods 
Cell culture 
HepG2 (ATCC, Virginia, USA) and Huh7 cells (JCRB, Japan) were cultured in Dulbecco's 
Modified Eagle's medium supplemented with 10% foetal bovine serum (Life Technologies, 
Ghent, Belgium). Cells were incubated for 48 hours with oprozomib (100-400 nM; ApexBio, 
USA), tunicamycin (1 μg/ml; Sigma, Diegem, Belgium), PERK inhibitor (14 μM; 
GSK2656157, Chengdu novi, Shandong, China), salubrinal (50 μM; Sigma), IRE1 inhibitor 
(25 μM; 4μ8C, Calbiochem, Massachusetts, USA), cycloheximide (5 μM; Sigma), 1,10-
phenanthroline (5-50 μM; Sigma), ascorbic acid (50 μM; Sigma), nelfinavir (10 μM; Sigma) or 
pre-treated with N-acetyl-L-cysteine (2 hours; 5 μM; Sigma) and compared to equal volumes 
of solvent as control. Each condition was performed in quadruplicate. 
 
Animals 
Wild-type 129S2/SvPasCrl mice were purchased from Charles River, Belgium, and were 
housed as previously described [13]. The animals had free access to water and to a commercial 
chow (mice maintenance chow, Carfil Labofood, Pavan Service, Belgium). Five-week-old male 
mice received weekly intraperitoneal injections with saline or diethylnitrosamine (DEN) (35 
mg/kg, Sigma) for 25 weeks. Then, 4 DEN-treated groups (n=12) were treated for 4 weeks with 
oprozomib (intragastric 30 mg/kg/day for 3 consecutive days per week) alone or in combination 
with salubrinal (intraperitoneally 1 mg/kg/day) or nelfinavir (intraperitoneally 250 mg/kg/day) 
and compared to a similar volume of vehicle. Blood was collected from the retro-orbital sinus 
under isoflurane anaesthesia. After macroscopic evaluation and quantification of the number of 
hepatic tumours, all organs were fixed in 4% phosphate-buffered formaldehyde (Klinipath, 
Belgium) and embedded in paraffin or snap frozen in liquid nitrogen. Haematoxylin/eosin and 
reticulin stainings were performed to assess tumour burden and the results were blindly 
evaluated by two independent observers (YV and CC). 
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For the xenograft model, HepG2 cells (6x106) were resuspended in 100 µl serum-free media 
and mixed with 100 µl Matrigel (BD Biosciences, Bedford, MA, USA). Cell/Matrigel mixture 
was injected subcutaneously into the right ﬂank of 8-week-old athymic nude (Foxn1nu/Foxn1nu) 
mice housed in filter-topped cages. Tumour dimensions were recorded three times per week 
with a digital calliper starting with the first day of treatment. Tumour volumes were calculated 
using the following formula: volume (mm³) = ab²/2, where b was the smaller dimension. When 
tumours reached 150 mm³, animals were randomized into four groups (n=6) with the same 
treatment regime as the DEN-treated mice plus monotherapy with salubrinal (intraperitoneally 
1 mg/kg/day) or nelfinavir (intraperitoneally 250 mg/kg/day). The ethical committee of 
experimental animals at Ghent University, Belgium, approved the protocols (ECD 13/39). 
 
Detailed information of MTT, TUNEL, caspase-3/7 activity, bromodeoxyuridine (BrdU) 
incorporation assays, total RNA extraction, quantitative real-time PCR and Western blotting is 
provided in the Supplementary Materials and Methods. 
 
Statistics 
Statistical analyses were performed using SPSS 21 (SPSS, Chicago, USA). Data are presented 
as the mean ± SD or percentage relative to controls. Variables were tested for normality using 
the Shapiro-Wilk test. Normally distributed data were subjected to the unpaired student’s t-
tests. Data involving more than two groups were assessed by one-way analysis of variance 
(ANOVA) with Bonferroni's post-hoc test. Non-normally distributed data were tested using the 
Mann-Whitney-U test. The chi-squared test was used to compare mortality. The IC50 values 
were obtained using the Bliss method. Interpretation of combination index (CI) values, as 
calculated by the method of Chou and Talalay [14] using CompuSyn software (ComboSyn Inc., 
Paramus, NJ), is defined such that CI= 1 indicates an additive effect, and CI<1 and a CI>1 
indicate synergism and antagonism, respectively. Reported p-values were two-sided and 
considered significant when less than 0.05.  
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 Results 
Supplementary ER stress improves the sensitivity of HCC cells to proteasome inhibition 
In HepG2 cells, 48 hours of incubation with 100-400 nM OZ dose-dependently reduced cell 
viability, as shown by a tetrazolium MTT spectrophotometric assay (p<0.001; Fig. 1A and 
Table S1). Combination with the chemical ER stress inducer tunicamycin or with the recently 
developed small-molecules selectively inhibiting the IRE1 or PERK pathway or salubrinal, 
which inhibits eIF2α dephosphorylation, was evaluated. Addition of tunicamycin or salubrinal 
synergistically decreased cell viability (p<0.05, CI=0.71 and 0.60 respectively). As shown by 
BrdU incorporation, OZ decreased the proliferation rate (p<0.001; Fig. 1B), whereas the 
addition of tunicamycin or salubrinal further impeded cell proliferation (p<0.05). As revealed 
by activation of executioner caspase-3/7, OZ dose-dependently induced apoptosis in HepG2 
cells (p<0.001; Fig. 1C). Again, addition of tunicamycin or salubrinal further increased caspase-
3/7 activity (p<0.001). Although the IRE1 and PERK inhibitors were previously validated [15], 
these compounds did not affect the sensitivity of HCC cells to OZ. Since tunicamycin increased 
the sensitivity, but is not clinically applicable because of its toxicity, the HIV protease inhibitor 
nelfinavir, which represents one of the few clinically applicable ER stress-inducing agents [16], 
was tested. Interestingly, also addition of nelfinavir synergistically increased the sensitivity to 
OZ (CI=0.68). The MTT viability and BrdU incorporation experiments were repeated in Huh7 
cells with similar results (Fig. S1A-B and Table S1). 
Next, we questioned whether the efficacy of other proteasome inhibitors, such as the first-in-
class bortezomib, could also be enhanced by combination with UPR inducers. Interestingly, a 
similar synergistic increase in antiproliferative efficacy was observed with 25 nM bortezomib 
in combination with tunicamycin, nelfinavir or salubrinal in HepG2 cells (Fig. S2A-B). Finally, 
we assessed whether OZ or bortezomib altered the chemosensitivity of HepG2 cells to 25-100 
µM doxorubicin and observed that proteasome inhibition did not alter the chemosensitivity 
(data not shown). Together, these results indicate that the sensitivity of human HCC cells to 
proteasome inhibition is enhanced by ER stress. 
 
Antiproliferative effect of oprozomib depends on the build-up of proteotoxic stress 
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After 24 hours of incubation, no significant alteration in proliferation rate, caspase-3 activity or 
cell viability is induced by 400 nM OZ (data not shown). However, after 48 hours, as stated 
above, OZ displayed robust growth-inhibitory effects, suggesting sufficient time is required to 
build-up proteotoxicity induced by proteasome inhibition in HCC cells. To demonstrate that 
proteotoxic stress caused by OZ originates during the synthesis of new proteins, cycloheximide 
was used to inhibit protein synthesis. Interestingly, treatment with cycloheximide readily 
increased proliferation (p<0.001; Fig. S3A) and cell viability (p<0.01; Fig. S3B) and reduced 
caspase-3 induction (p<0.001; Fig. S3C) of OZ-challenged HepG2 cells. 
Since bortezomib generates oxidative stress, which is crucial for its antitumour activity [17] 
and is reported to induce ER stress [11], we investigated whether the antiproliferative effect of 
OZ is also dependent on oxidative stress. Therefore, we measured cell viability and proliferation 
after treatment with OZ only or in combination with the antioxidants N-acetyl-L-cysteine 
(NAC) or ascorbic acid in HepG2 cells. Surprisingly, addition of these antioxidants to OZ did 
not alter its antitumour action (Fig. S3A-C). Thus, these findings suggest that the build-up of 
proteotoxic, and not oxidative, stress is indispensable for the effects of OZ. 
 
Oprozomib upregulates UPR-mediated proteins without induction of the transcriptional 
UPR program 
First, we examined the induction of UPR targets at the mRNA level by 200 or 400 nM OZ in 
HepG2 cells. Surprisingly, incubation with 400 nM OZ downregulated the ATF6-mediated 
GRP78 and PDIA4 mRNA levels (p<0.05; Fig. 2A) [18]. In addition, incubation with 400 nM 
OZ repressed CHOP and ATF4 transcription (p<0.05) but did not alter the mRNA levels of 
IRE1-generated XBP1s and its target ERDJ4. Even in presence of ER stress induced by 
tunicamycin, OZ reduced the transcription of GRP78, PDIA4, XBP1u and CHOP compared to 
cells treated with tunicamycin alone. Intriguingly, the levels of growth arrest and DNA damage 
inducible 34 (GADD34) mRNA, a downstream target of ATF4 and CHOP protein, were 
increased by incubation with OZ and tunicamycin compared to tunicamycin alone (p<0.001). 
Collectively, these data indicate that OZ impeded the transcriptional induction of target genes 
of the ATF6 and PERK pathway without altering the IRE1 RNase activity. 
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In contrast to the mRNA levels, 400 nM OZ triggered increased expression of GRP78, PDIA4, 
ATF4 and CHOP protein (Fig. 2B). In line with its transcriptional activation, also GADD34 
protein levels were elevated. Based on these findings, we determined the protein half-life of the 
transcription factor CHOP in HepG2 cells by performing a time-course in the presence of 
cycloheximide blocking protein synthesis (Fig. 2C). The half-life of CHOP protein increased 
from 5.75 hours in vehicle-treated to 12.82 hours in OZ-treated cells (fold change: 2.23, 
p<0.001; Fig. 2D). Thus, OZ increased the UPR protein levels by inhibition of their proteasomal 
degradation and not by enhanced de novo synthesis following induction of the transcriptional 
UPR program. 
 
OZ inhibits cytoprotective ATF6 signalling by direct RIP inhibition 
Because OZ increased the levels of full ATF6 protein without any change in the levels of the 
transcriptionally active cleaved ATF6 fragment, consistent with inhibition of ATF6 activation 
(Fig. 2B), the effect of OZ on tunicamycin-induced ATF6 activation was evaluated (Fig. S4). 
First, we assessed the effect of OZ on the tunicamycin-mediated transcriptional induction of 
additional ATF6-regulated UPR targets, such as GRP94, ERO1L, CALR and HERPUD1 mRNA 
(Fig. S4A) [12], [18]. As expected, upregulation of all ATF6 targets by tunicamycin was 
evident. Interestingly, addition of OZ to tunicamycin downregulated these selected ATF6 
targets. To validate this hypothesis, the processing of another target of RIP, sterol regulatory 
element binding protein-1 (SREBP-1), was examined. Western blotting confirmed 
accumulation of precursor SREBP-1 in OZ-treated HepG2 cells (Fig. S4B). These results 
indicate that OZ inhibits ATF6 signalling by RIP inhibition. 
RIP inhibition could be either directly by inhibition of the S1P or S2P expression or activity or 
indirectly by upregulation of a repressor of protease-mediated ATF6 activation. OZ does not 
alter the S1P or S2P mRNA levels (Fig. S4C), suggesting OZ functions through post-
translational RIP inhibition without affecting S1P or S2P expression. Nucleobindin 1 is a 
reported ATF6 repressor [19]. While tunicamycin increased nucleobindin 1 expression, the 
expression in OZ-treated cells was indistinguishable from vehicle-treated cells (Fig. S4B). 
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Treatment of HepG2 cells with 25 μM 1,10-phenanthroline, a metalloprotease-specific S2P 
inhibitor [20], leads to accumulation of precursor SREBP-1 and to the absence of processed 
SREBP-1 detection and did not alter the nucleobindin 1 expression (Fig. S4B). In addition, 5 
to 50 μM of 1,10-phenanthroline dose-dependently reduced the HepG2 cell viability (Fig. S4D), 
phenocopying the effects of OZ (Fig. 1 and S4B, respectively). Thus, OZ at an effective dose 
of 400 nM inhibits cytoprotective ATF6 signalling by RIP inhibition, probably, via off-target 
protease inhibition. 
 
The PERK pathway regulates the nelfinavir-mediated increase in sensitivity to OZ 
OZ slightly increased the eIF2α phosphorylation, which could not be inhibited by the PERK 
inhibitor (Fig. 2B), suggesting other eIF2α kinases such as heme-regulated inhibitor are 
involved, as previously reported for eIF2α phosphorylation induced by proteasome inhibitor 
MG-132 [21]. Importantly, addition of salubrinal or nelfinavir profoundly increased the OZ-
induced eIF2α phosphorylation and pro-apoptotic CHOP protein levels (Fig. 2B), which may 
contribute to the increased sensitivity to OZ (Fig. 1). Indeed, addition of the PERK inhibitor 
increased the proliferation rate of HepG2 cells treated with the combination of OZ and 
nelfinavir (p<0.05; Fig. 2E), validating the role of the PERK pathway in the mechanism of this 
combination. Furthermore, addition of nelfinavir to OZ abolished the protein levels of the 
ATF6-dependent chaperones GRP78 and PDIA4 (Fig. 2B), possibly exacerbating the generated 
proteotoxicity. Interestingly, nelfinavir was previously reported to induce apoptosis in 
liposarcoma cells by direct S2P inhibition [22]. These data suggest that dysregulation of the 
transcriptional UPR program and decreased proteasomal degradation of short-lived pro-
apoptotic UPR proteins are involved in OZ-induced HCC cell death and the observed synergy 
with PERK inducers. 
 
OZ reduced tumour burden in orthotopic and xenograft mouse models for HCC 
Prior to evaluating the antitumour activity of OZ in the DEN-induced mouse model 
characterized by severe liver dysfunction [23], several dosing regimens for 2 weeks were tested 
in 25 weeks saline-treated and DEN-treated mice (n=3, Table 1). We observed 100% mortality 
in the mice with liver dysfunction treated with 50 mg/kg/day for 5 consecutive days per week. 
At 30 mg/kg/day for 3 consecutive days per week, no mortality occurred. Therefore, this dosing 
regimen was applied in the following experiments.  
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OZ for 4 weeks did not affect mortality in saline- or DEN-injected mice (n=12, Table 2). 
Average body weight of mice was decreased following 25 weeks of DEN compared to saline 
administration (p<0.001, Table 2). Subsequent treatment with OZ did not alter the average body 
weight compared to vehicle. Although serum ALT and AST levels were elevated by DEN 
administration (p<0.001), treatment with OZ did not alter these levels in the surviving mice 
(Fig. S5A). 
DEN-treated mice that received OZ developed fewer macroscopic nodules per liver (all sizes: 
16.2 ± 4.5 after vehicle versus 11.1 ± 3.9 after OZ; p<0.05). HCC burden, microscopically 
quantified by the loss of reticulin staining, was reduced in OZ-treated compared to vehicle-
treated mice (p<0.01, Fig. 3A-C). Hepatic caspase-3/7 activity levels ex vivo were elevated by 
DEN compared to saline administration (p<0.001, Fig. 3D). OZ monotherapy further increased 
these levels compared to vehicle-treated HCC-bearing mice (p<0.05), consistent with in vivo 
apoptosis induction. We previously reported the UPR pattern in the DEN-induced mouse model 
[15]. Here, OZ administration reduced the levels of Grp78 mRNA (p<0.05) and induced a 
tendency to reduce Pdia4 and Chop in the isolated tumours (Fig. 4A). However, 
immunoblotting of lysates of isolated tumours revealed that OZ promoted CHOP protein 
expression in vivo (Fig. 4B). Yet, UPR-regulated caspase-12 cleavage was only slightly 
increased by OZ. These observations provide evidence that the efficacy of OZ in inhibiting the 
growth of DEN-induced HCC is through similar mechanisms as those observed in vitro. 
Secondly, the effect of OZ was assessed in a HepG2 xenograft model. No signiﬁcant differences 
in body weight or appearance between control and OZ-treated animals were observed during 
the course of the xenograft study (data not shown). OZ administration suppressed the growth 
rate of the HepG2-derived tumours (p<0.05, Fig. 4E). Accordingly, TUNEL 
immunofluorescence demonstrated a significant increase of TUNEL-positive apoptotic HepG2 
cells following OZ administration (p<0.01, Fig. 4C-D). 
 
Nelfinavir and salubrinal potentiate the therapeutic efficacy of OZ in experimental HCC 
Administration of nelfinavir or salubrinal did not alter the mean body weight compared to 
vehicle (Table 1). Although hepatic caspase-3/7 activity was not significantly increased (Fig. 
3D), combining OZ with nelfinavir was more efficacious compared to OZ monotherapy in the 
orthotopic model (number of macroscopic nodules per liver: 11.1 ± 3.9 after OZ versus 7.2 ± 
5.2 after OZ and nelfinavir; microscopic tumour burden: p<0.05; Fig. 3A-C).  
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Addition of salubrinal at 1 mg/kg/24 hrs similarly improved the effect of OZ (number of 
macroscopic nodules per liver: 6.7 ± 4.8 after OZ and salubrinal; microscopic tumour burden: 
p<0.05; Fig. 3A-C). Interestingly, addition of nelfinavir or salubrinal to OZ promoted eIf2α 
phosphorylation and downstream Chop mRNA and protein levels (Fig. 4A-B), suggesting 
intensified pro-apoptotic UPR signalling. Caspase-12 cleavage was indeed markedly increased 
by addition of nelfinavir or salubrinal to OZ treatment (Fig. 4B). In contrast, salubrinal at 1 
mg/kg/72 hrs induced no detectable effects on the antitumour efficacy of OZ, eIf2α 
phosphorylation or Chop expression (data not shown). 
Accordingly, in the HepG2 xenograft model, dual therapy with OZ and nelfinavir or OZ and 
salubrinal strikingly inhibited tumour growth compared to vehicle-treated (both p<0.001) and 
to OZ-treated mice (both p<0.01), whereas nelfinavir or salubrinal monotherapy did not alter 
the xenograft growth (Fig. S5B-C). Furthermore, addition of nelfinavir or salubrinal augmented 
the number of TUNEL-positive HepG2 cells in the xenograft tumours (p<0.05 and p<0.01 
respectively, Fig. 4C-D), suggesting robust induction of apoptosis when UPR modulators are 
added. Thus, we identified that nelfinavir and salubrinal potentiate the therapeutic efficacy of 
OZ in different models for HCC, likely by increased UPR-mediated apoptosis via induction of 
Chop synthesis while OZ diminishes its proteasomal degradation. 
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 Discussion 
Proteasome inhibition could represent a novel therapeutic strategy for advanced HCC [5], [7]. 
The next-generation orally bio-available irreversible proteasome inhibitor oprozomib (OZ) is 
assumed to evoke less adverse events and improved antitumour activity compared to the first-
in-class bortezomib [3]. Recently, OZ was shown to exert antitumour activity on myeloma and 
head and neck cancer xenograft models [3]. In this study, OZ exerted potent anti-tumour effects 
in vitro and in different in vivo models for HCC, supporting the potential value of irreversibly 
targeting the proteasome in the treatment of HCC. Moreover, we revealed a strategy to further 
enhance the efficacy of OZ by modulation of the UPR. 
When unfolded proteins accumulate in the ER, the UPR is initiated to allow the cells to restore 
homeostasis by proteasomal degradation of unfolded proteins, translational arrest and 
increasing protein folding capacity [11]. The association between UPR activity and therapeutic 
efficacy of proteasome inhibition was first illustrated in myeloma, in which patient serum levels 
of XBP1 correlated with the clinical response towards bortezomib [24]. Theoretically, 
decreased protein degradation by proteasome inhibition could lead to oxidative stress and UPR 
activation. However, the effect on the UPR is not well understood. We showed that the 
cytotoxic effect of OZ depends on the build-up of proteotoxic stress without an important 
contribution of oxidative stress. Although OZ did not induce the transcriptional UPR program 
and even inhibited the protease-dependent activation of the cytoprotective ATF6 pathway, OZ 
increased the protein levels of different UPR markers. Notably, OZ increased the protein 
stability of the pro-apoptotic transcription factor CHOP and did induce CHOP-mediated 
transcription of GADD34. Thus, OZ increased the levels of the UPR-regulated proteins by 
abrogated proteasomal degradation of these rather than a general activation of the UPR program 
by increased unfolded protein load. Apparently, rapid proteasomal degradation of UPR proteins 
is a pivotal negative feedback mechanism following recovery of the ER proteostasis. 
Consistent with the effect of OZ on the UPR, PERK or IRE1 inhibition did not alter its effect, 
whereas ER stress inducers, such as tunicamycin or nelfinavir, or an inhibitor of eIF2α 
dephosphorylation enhanced the growth-inhibitory effects of OZ in HCC cells. Interestingly, a 
similar synergy was observed with bortezomib, suggesting this concept can also be applied to 
other proteasome inhibitors. Since the maximum serum levels attained in patients are much 
higher (bortezomib: 0.16 μM (1.3 mg/m2 intravenous); oprozomib: 3.8 μM (30 mg per os) [25]), 
the concentrations used in vitro are clinically relevant. 
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Based on these results, we evaluated the in vivo effects of the combination of nelfinavir or 
salubrinal and OZ in HCC. Both nelfinavir and salubrinal enhanced the growth-inhibitory effect 
without cumulative toxicity, suggesting this rational combination presents a safe strategy to 
potentiate the antitumour effects of proteasome inhibition in HCC. Experience in the use of 
proteasome inhibitors and nelfinavir in clinical practice and the oral bio-availability are 
considerable advantages for implementation.  
Bortezomib resistance in myeloma cells was shown to be induced by attenuated eIF2α 
phosphorylation [26]. Salubrinal typically provides for enhanced resistance to stress conditions, 
such as those triggered by oxidizing or UPR-inducing agents [27], [28]. However, here we 
provide evidence that salubrinal renders HCC cells more susceptible to proteasome inhibition 
by activating the PERK/phospho-eIF2α/CHOP pathway. Of note, human HCC, in contrast to 
unaffected adjacent liver tissue, is characterized by increased CHOP staining [29]. 
Although a recent phase I trial with OZ demonstrated that OZ has an acceptable safety profile 
when given daily for 5 consecutive days every 2 weeks in patients with solid tumours [30], 
significant toxicity occurred when OZ was administrated for several consecutive days in mice 
with DEN-induced liver dysfunction. However, identification of sensitivity enhancers by UPR 
modulation could allow for dose and, possibly, toxicity reduction. 
Because ER stress potentiates the antitumour efficacy of OZ, we assume a stronger effect on 
hypoxic ER-stressed tumour cells compared to the normal liver tissue [15]. Consequently, OZ 
could be more efficacious in combination with antiangiogenic treatments increasing tumour 
hypoxia-induced UPR [11], [31]. 
In conclusion, dysregulation of the transcriptional UPR program and reduced proteasomal 
degradation of pro-apoptotic UPR-mediated proteins are involved in OZ-induced cell death. 
Furthermore, modulation of the interplay between OZ and the UPR enhances its antitumour 
efficacy without cumulative toxicity. Therefore, OZ monotherapy or in combination with UPR 
modulators may present a novel and clinically applicable therapeutic strategy for HCC. 
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 Tables 
Table 1. Mortality at different dosing regimens (n=3 in each group). 
Consecutive-day dosing in 
weekly cycle 
Mortality in saline-treated 
mice 
Mortality in DEN-treated 
mice 
50 mg/kg/day for 5 days 2/3 3/3 
30 mg/kg/day for 5 days 1/3 1/3 
30 mg/kg/day for 4 days 0/3 1/3 
30 mg/kg/day for 3 days 0/3 0/3 
 
Table 2. Average body weight (g) ± SD and survival of mice (n=12 in each group). 
Group 
Average body weight 
25 weeks (g) 
Average body weight 
29 weeks (g) 
Survival 
(%) 
Saline => vehicle 27.22 ± 1.32 26.03 ± 1.61 100 
DEN => vehicle 19.75 ± 1.76*** 18.30 ± 2.92 58.33 
DEN => OZ 20.86 ± 1.45 19.17 ± 2.10 NS 58.33 
DEN => OZ + nelfinavir 22.96 ± 3.65 17.92 ± 3.19 NS 66.67 
DEN => OZ + salubrinal 21.23 ± 5.89 18.09 ± 6.23 NS 66.67 
***p<0.001: 25 weeks DEN vs. saline, NS= not significant compared to vehicle. 
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 Figures 
 
Fig. 1. Antiproliferative and pro-apoptotic effects of oprozomib in monotherapy or in 
combination with modulators of ER stress in human hepatoma HepG2 cells. (A) MTT 
assay (B) BrdU incorporation (C) Caspase-3/7 activity. OZ: oprozomib. *p<0.05, **p<0.01, 
***p<0.001 compared to oprozomib 0 nM; #p<0.05, ##p<0.01, ###p<0.001 compared to 
respective concentration of oprozomib alone. 
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Fig. 2. Oprozomib modulates the UPR pattern in HepG2 cells. (A) Real-time PCR analysis of 
relative mRNA levels of UPR-mediated genes after 48 hours of incubation with the indicated 
treatments. (B) Immunoblotting of UPR-mediated proteins. (C) To measure the half-life of CHOP 
protein in HepG2 cells, cells were pre-treated for 1 hour with 1 μg/ml tunicamycin and a time-course 
in the presence of 50 μg/ml cycloheximide, which blocks protein synthesis, was performed. Band 
intensities were quantified using ImageJ software. (D) Half-life of CHOP protein was determined by 
plotting optical density (arbitrary unit) calculated from densitometric analysis of bands in panel C 
versus hours of treatment. Data represent the mean ± SD of three independent experiments. (E) BrdU 
incorporation of HepG2 cells incubated with indicated treatments for 48 hours. OZ: 400 nM 
oprozomib. *p<0.05, **p<0.01, ***p<0.001. 
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Fig. 3. Impact of oprozomib in monotherapy or in combination with ER stress modulators 
on an orthotopic and a xenograft model for HCC. (A) Photographs of representative livers 
after different treatments. (B) Reticulin staining. Scale bar: 100 µm. (C) Assessment of tumour 
burden in the carcinogen-induced mouse model in randomly selected high-power fields. (D) 
Hepatic caspase-3/7 activity ex vivo. (E) Evolution of tumour volume in mice bearing HepG2-
derived xenograft tumours. (F) Final tumour weights. Values represent the mean ± SD. *p<0.05, 
**p<0.01, ***p<0.001. 
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Fig. 4. Oprozomib and UPR modulation in experimental HCC. (A) Real-time PCR analysis and 
(B) Immunoblotting of UPR targets in isolated DEN-induced tumours following the indicated 
treatments. (C) TUNEL immunofluorescence in HepG2 xenografts and (D) quantification of TUNEL-
positive index (n=6). OZ: oprozomib. *p<0.05, **p<0.01, ***p<0.001. 
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Fig. 5. Schematic model outlining the mechanisms of oprozomib with 
indication of the point of action of the applied products. Persistent ER stress 
activates the tripartite UPR-mediated transcriptional program followed by 
translation of these UPR proteins, which leads to proteotoxicity-mediated tumour 
cell death. Although oprozomib did not induce the UPR and even inhibited ATF6-
mediated transcription, it increased the UPR-mediated protein levels by 
prolonging their half-life. This UPR dysregulation allows for enhanced 
proteotoxicity by supplementary boosting PERK activity by tunicamycin, 
nelfinavir (also inhibits ATF6) or salubrinal. 
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 Supplementary Figures 
 
Fig. S1. Growth-inhibitory effects of oprozomib in Huh7 cells. (A) Assessment of cell viability 
by MTT assay. (B) Cell proliferation rate as assessed by BrdU incorporation in Huh7 cells. One-
way ANOVA was applied for statistical analysis. *p<0.05, **p<0.01, ***p<0.001 compared to 
oprozomib 0 nM; #p<0.05, ##p<0.01, ###p<0.001 compared to respective concentration of oprozomib 
alone. OZ: oprozomib. Results are representative of 2 independent experiments. 
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Fig. S2. Bortezomib and ER stress modulation in HepG2 
cells. (A) Cell viability as assessed by MTT assay. (B) Cell 
proliferation rate as assessed by BrdU incorporation. 
*p<0.05, **p<0.01, ***p<0.001. BZ: bortezomib 25 nM. 
Results are representative of 3 independent experiments. 
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Fig. S3. Modulation of proteotoxic, not oxidative, stress affects antitumour activity of 
oprozomib in HepG2 cells. (A) Cell proliferation rate. (B) Cell viability. (C) Caspase-3/7 
activity. Values represent the mean ± SD. *p<0.05, **p<0.01, ***p<0.001 compared to 
oprozomib alone. OZ: oprozomib 400 nM. CX: cycloheximide. NAC: N-acetyl-L-cysteine. 
Results are representative of 2 independent experiments. 
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Fig. S4. OZ inhibits cytoprotective ATF6 activation in HepG2 cells. (A) Quantitative real-
time PCR analysis of the ATF6 targets GRP94, ERO1L, CALR and HERPUD1. (B) Western 
blotting for RIP-dependent SREBP-1 cleavage and the ATF6 repressor Nucleobindin 1. RIP 
inhibitor 1,10-phenanthroline was applied at a dose of 25 μM. (C) Quantitative real-time PCR 
analysis of S1P and S2P. OZ: oprozomib 400 nM. (D) Effect of 5 to 50 μM 1,10-phenanthroline 
on the MTT cell viability of HepG2 cells. Results are representative of 2 independent 
experiments. *p<0.05, **p<0.01, ***p<0.001. 
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Fig. S5. Effect of nelfinavir and salubrinal on the serum levels of liver enzymes in the 
DEN-induced model and on HepG2 xenograft growth. (A) Liver damage was assessed by 
measuring ALT and AST levels in the serum of surviving mice after the indicated treatments. 
Values represent the mean ± SD (n=7). ***p<0.001. (B) Evolution of tumour volume in mice 
bearing HepG2-derived xenograft tumours. (C) Final tumour weights. Values represent the 
mean ± SD of the tumour volumes of each group. 
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1. Conclusions and future perspectives 
1.1. Introduction 
Hepatocellular carcinoma (HCC) is a common cancer worldwide with a very poor prognosis 
[1]. Few therapeutic strategies have been proven efficient, particularly for those patients not 
indicated for curative resection or transplantation [2]. To date, sorafenib remains the only 
approved, targeted molecule for the treatment of advanced HCC. Although a small survival 
benefit was demonstrated, it remains only true in the population of patients with Child-Pugh A 
liver disease [3]. Moreover, sorafenib has distinct side effects that require close monitoring [2]. 
Recently, newer but similar tyrosine kinase inhibitors (TKIs) and angiogenesis inhibitors have 
been evaluated in clinical trials with disappointing results [4]. Therefore, innovative therapeutic 
strategies are urgently required. 
Cancer cells survive the self-created hostile microenvironmental conditions, such as 
hypoglycaemia, hypoxia, acidosis and nutrient scarcity by activation of adaptive processes [5]. 
These processes render cancer cells resistant to stress-induced cell death allowing for 
continuous proliferation. However, elucidation of these adaptive processes makes it possible to 
exploit this characteristic feature to selectively target the cancer cells. The aim of the present 
thesis is to explore this hypothesis in the setting of HCC. 
The unfolded protein response (UPR) and autophagy are two fundamental adaptive 
mechanisms [6]. As a consequence of the already engaged ER stress system, fewer 
contingencies may be left to accommodate additional intensities of ER stress in cancer cells. In 
comparison, normal cells without chronic ER stress may harbour greater reserves to withstand 
intervention with agents aimed at aggravating the pro-apoptotic UPR signalling. Thus, 
manipulation of the UPR could provide a novel strategy to treat HCC. 
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1.2. The unfolded protein response is dynamically fine-tuned during murine 
multistep hepatocarcinogenesis 
Animal models can provide essential knowledge about the pathogenesis of cancer, particularly 
when they mimic the natural environment in which human tumours develop. 
Diethylnitrosamine (DEN) has been shown to induce hepatic tumours, which are similar to 
human HCC with poor prognosis [7]. In our study, weekly intraperitoneal injections with 35 
mg/kg DEN gave rise to HCC formation in a background of inflammation and fibrosis, thus 
mimicking the human setting. By monitoring the UPR in this model, we provided the, to our 
knowledge, first evaluation of the UPR dynamics in a long-term cancer model [8]. 
Surprisingly, we observed that the UPR is not an all-or-nothing system. Activation of the UPR 
pathways is dynamically fine-tuned during the different phases of hepatocarcinogenesis. In fact, 
each phase of hepatocarcinogenesis is characterized by a specific pattern of UPR signalling. 
For example, a peak in Ire1 signalling was observed during tumour initiation, while the Perk 
pathway was activated during tumour progression. Possibly, the dynamic regulation of the UPR 
is mediated by variations in tissue oxygen levels, which is influenced by the interactions 
between the UPR and angiogenesis [9]. 
How the shift from pro-survival to pro-apoptotic UPR signalling is regulated remains unclear 
with both IRE1 and PERK signalling associated with pro-survival as well as pro-apoptotic 
signalling [10], [11]. A recent study indicated that the relative dynamics of IRE1/XBP1 and 
PERK/ATF4 signalling rather than a switch between branches determine cell survival [11]. 
Moreover, the exact role of cell apoptosis [12] and, more specifically, UPR-induced cell 
apoptosis in the different steps of hepatocarcinogenesis is also unclear. Counterintuitively, 
recent studies have demonstrated that hepatocyte apoptosis is a pathogenic event in several liver 
diseases [13], [14]. Chronically increased hepatocyte apoptosis in genetic mouse models is 
carcinogenic and leads to compensatory liver regeneration, oxidative stress and DNA 
hypermethylation [13], [15]. However, once tumours are established and develop resistance 
against cell death signaling pathways, pharmacological or genetic induction of tumour cell 
apoptosis slows down the tumour growth [12]. Again, the timing of the event determines its 
outcome. 
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It is important to note that the hepatic expression of major ER stress markers is age-dependent. 
For example, we observed a decrease in Grp78 mRNA levels and an increase in Chop mRNA 
levels in the control mice of 5 weeks of age compared to those of 35 weeks of age (fold change: 
0.57 and 1.43 respectively). Apparently, there is a shift in the balance between the adaptive 
response of the UPR and pro-apoptotic signalling during aging; where the protective arm is 
reduced and the apoptotic arm is more robust [16]. Hence, we decided to use age-matched 
controls during the monitoring of the UPR dynamics in hepatocarcinogenesis. 
Carrara et al. (2015) revealed that transient conversion from a dimeric to a previously unknown 
and more active tetrameric state of PERK is an important regulatory mechanism in PERK 
signalling [17]. Therefore, analysis of the state and effect of tetramerization of PERK in HCC 
may offer important insights in the downstream effects of this UPR pathway. 
We strengthened the manuscript by performing transmission electron microscopy of the 
tumours in the mouse model at week 30 revealing an extensive expanded ribosome-bound 
ER in a lamellar pattern and the presence of remarkable ER reorganization in HCC cells [18]. 
Additional investigation of the temporal pattern of these changes in size, preferably measured 
quantitatively, and organization of the ER in experimental and human HCC is indicated. 
Also, exploration of the UPR dynamics in the multistep process of human 
hepatocarcinogenesis from low-grade to high-grade dysplastic nodules, dysplastic nodules with 
HCC foci to HCCs and comparison to the UPR dynamics in experimental HCC is indicated. 
During the progress of our work on the UPR in the DEN model, we encountered the need for 
functional assessment of the tumour burden in this model. Therefore, we validated innovative 
small animal imaging techniques for the functional assessment of the experimental HCC 
burden, including 18F-Fluoro-deoxyglucose (FDG) positron emission tomography–computed 
tomography (PET/CT), 18F-Choline PET/CT and (dynamic contrast-enhanced) magnetic 
resonance imaging ((DCE-)MRI), and compared these different imaging techniques evaluating 
the tumour burden in the DEN-induced mouse model (in collaboration with Infinity Lab, Ghent 
University). We concluded that 18F-Choline PET/CT, which visualizes the increased cell 
membrane synthesis requiring choline uptake in tumour cells, was the optimal imaging 
technique providing high spatial resolution and 3D image reconstructions to assess tumour 
burden in this model. Furthermore, we validated the quantification of this technique by using 
the left kidney as reference density and calculating the standardized uptake values of the voxels 
within the mouse liver [19]. This technique is and will be of uttermost importance in the setting 
of testing new pharmacological or genetic tools minimizing the number of animals needed, 
creating smaller standard deviations and eliminating possible confounders between animals. 
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1.3. Role of the unfolded protein response in the pathogenesis of hepatocellular 
carcinoma 
1.3.1. Modulation of the unfolded protein response impedes tumour cell adaptation to 
proteotoxic stress: a PERK for hepatocellular carcinoma therapy 
In an effort to better understand the underlying mechanisms of HCC cell survival under ER 
stress, we demonstrated that under ER stress, Perk inhibition and not Ire1 inhibition reduced 
HCC cell viability and proliferation via escalating proteotoxic stress, and that the small-
molecule inhibitor of PERK leads to HCC regression in the orthotopic mouse model [8]. 
However, important drawbacks to clinical application of Perk modulation were identified 
and need to be discussed. 
First, we observed only a modest antitumour effect in vivo compared to the dramatic effects on 
cell viability under chemically induced ER stress in vitro. Our preliminary validation studies of 
the Perk inhibitor used (GSK2656157 [20] at 100 mg/kg bid) showed that the tunicamycin-
mediated activation of the Perk pathway in hepatocytes was inhibited for only 6 hours following 
administration (data not shown), explaining the use of twice a day dosing. Consequently, 
tumoural Perk signalling was probably not completely and continuously inhibited during the 
treatment. Development of sustained release formulations containing GSK2656157 could solve 
this issue. 
Secondly, the Perk inhibitor-treated mice exhibited hyperglycaemia compared to the vehicle-
treated mice. Induction of diabetes in cancer patients could be an important limitation of 
therapeutic Perk inhibition. Possibly, the development of a targeted drug delivery system could 
reduce the toxicity of this compound. A recent study showed that nanoparticles conjugated with 
an antibody against GRP78 promote drug delivery of 5-fluorouracil into human HCC cells with 
high expression of surface-exposed GRP78 [21]. Nanoparticles increase the stability of 
chemical agents by encapsulation, protecting these agents from the extracellular environment 
and regulating the drug release in a prolonged and controllable manner. The technical feasibility 
of Perk inhibitor-loaded nanoparticles conjugated with anti-Grp78 and the effect of Perk 
inhibition on the surface Grp78 expression of HCC cells require further investigation. Taken 
together, although our results are promising, pharmacological efforts to establish a drug 
formulation with sustained release and tumour-targeted drug delivery are required. 
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Recently, the small-molecule N,N'-trans-(cyclohexane-1,4-diyl)-bis-(2-(4-chlorophenoxy) 
acetamide (integrated stress response inhibitor, ISRIB), which prevents translational inhibition 
downstream of the Perk/phospho-eIf2α pathway, was developed [22]. Interestingly, this small-
molecule partially restores global translation without adverse effects on the pancreas, such as 
induction of diabetes. In prion disease, restoration of global protein synthesis using the Perk 
inhibitor was profoundly neuroprotective [23]. However, in line with our results, this also 
occurred at the cost of toxicity to the pancreas. Recently, the effect of ISRIB was tested in this 
model and conferred similar neuroprotection in prion-diseased mice but without the pancreatic 
toxicity [24]. Whether the ISRIB-mediated modulation of translational control could mimic the 
antitumour effects of the Perk inhibitor in the DEN-induced mouse model without the observed 
deleterious effects is currently unknown. 
 
1.3.2. Tauroursodeoxycholic acid dampens oncogenic apoptosis induced by 
endoplasmic reticulum stress during hepatocarcinogen exposure 
 
To assess the role of ER stress in the biology of tumour initiation and progression, we applied 
the chemical chaperone TUDCA in preventive and therapeutic settings of experimental HCC 
[25], [26]. We discovered that TUDCA attenuates hepatocarcinogenesis by suppressing 
carcinogen-induced ER stress-mediated cell death and inflammation without stimulating 
tumour progression [25]. Therefore, this chemical chaperone could represent a novel 
chemopreventive agent. An important limitation of these interpretations is that the effect of 
TUDCA was assessed in a model induced by the carcinogen DEN. Although this is a commonly 
used and well-known carcinogen for experimental HCC, it is noteworthy that assessment of the 
effects of TUDCA on hepatocarcinogenesis induced by human-relevant carcinogens, such as 
chronic HCV replication or alcohol exposure, could further support the clinical application of 
this putative chemopreventive strategy. Regarding HCV, preliminary experiments with HCV-
infected humanized livers in Fah-/-/Rag2-/-/Il2rg-/- (FRG) mice [27] and with transgenic mice 
expressing the full HCV protein repertoire at levels corresponding to the natural human 
infection [28] were initiated in collaboration with Prof. Ph. Meuleman, Ghent university, Ghent, 
Belgium and Prof. H. Lerat, INSERM U955, Créteil, France. Assessment of the tumour-
promoting effects of chronic HCV infection and effects of targeted UPR modulation in these 
models is planned. 
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The mechanism of action of chemical chaperones is complex and their application is hindered 
by limited knowledge of their molecular activities [29]. It is thought that chemical chaperones 
are typically poor solvents for a protein backbone and hence facilitate native structure formation 
[30]. However, it is unknown whether different chemical chaperones can act differently to 
modulate folding energy landscapes. Recently, a classification of chemical chaperones based 
on their thermodynamic effect on protein folding landscapes was proposed [29]. The canonical 
chemical chaperones, trimethylamine-N-oxide and trehalose, accelerate refolding by 
decreasing the flexibility of the refolding intermediate, thereby decreasing the entropic barrier 
of refolding (i.e. reduced disorder of the refolding intermediate), while other small-molecules 
stabilize the transition state enthalpically (i.e. reduced sum of the internal energy of the 
refolding intermediate). Additional studies on the exact chaperone mechanism of TUDCA are 
required. 
Next to TUDCA, assessment of the effects of other established and safe chemical chaperones, 
such as 4-phenylbutyric acid (4-PBA) or the novel 4-PBA derivatives with a greater chemical 
chaperone activity than 4-PBA [31], on hepatocarcinogenesis, is indicated to better understand 
the exact role of chemically improved protein folding capacity in carcinogenesis during 
carcinogen exposure. 
TUDCA has next to its chaperone properties other direct or indirect downstream effects [32]. 
For example, the reported mechanisms involved in the antiapoptotic properties of TUDCA 
include targeting of mitochondrial function and integrity and interactions with survival signals 
in the cAMP, Akt, NF-κB, mitogen-activated protein kinase and phosphatidylinositol 3-kinase 
signalling pathways [33]. Next to the reduced pro-apoptotic UPR signalling, these 
cytoprotective effects could attribute to the observed chemopreventive action of TUDCA. 
The cellular and molecular pathways involved in metastasis have been studied in many models; 
however, the link between ER stress signaling and invasion/metastasis is poorly understood 
[34]. Because ER stress was previously linked to cell invasion [29,30], we assessed the effect 
of TUDCA on cell invasion in a hepatocyte growth factor-induced invasion assay in which 
spheroids of Hepa1-6 HCC cells embedded in collagen matrix were observed over time. 
Additionally, we assessed its effect in a Boyden chamber assay.  
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In the spheroid assay, the perimeter of the TUDCA-treated spheres increased compared to 
controls after 24 and 48 hours of incubation, suggesting an altered invasive phenotype. 
However, in the Boyden chamber assay, addition of TUDCA induced no significant alterations 
in the hepatocyte growth factor-stimulated invasion of these HCC cells over a 48 hour period. 
These differential results could possibly be explained by the different experimental set-up to 
assess cell invasion. In the spheroid assay, cells at the border of the spheroid directly invade the 
surrounding collagen without a chemoattractant force. In contrast, in the Boyden chamber 
assay, plated HCC cells migrate in the direction of the source of chemoattractants (i.e. added 
serum in the lower chamber) through the microporous filter membrane and subsequently invade 
into the attached basement membrane extract. Indeed, adequate in vivo evaluation of 
invasion/metastasis could solve this issue. Despite recent advances in this field [34], systematic 
studies on the role of the UPR in cancer invasion and metastasis and its effects on the 
degradation of the extracellular matrix by matrix metalloproteinases are required. 
In conclusion, improved cellular coping with carcinogen-induced stress by assisting protein 
folding holds great potential to prevent tumourigenesis. However, validation in other 
models and identification of the best chemical chaperone in this context is required prior to 
clinical evaluation. 
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1.4. Sorafenib interacts reciprocally with the unfolded protein response in 
hepatocellular carcinoma 
While the multi-kinase inhibitor sorafenib heralded a major breakthrough in HCC therapy, 
the clinical benefit is at best modest and transient [3]. Biomarkers determined at diagnosis to 
identify the patients who will have the best tumour response and/or survival benefit are 
currently lacking and efforts to attenuate the sorafenib resistance or toxicity were hitherto 
disappointing [37]. Numerous clinical trials have been conducted to evaluate a large number of 
molecularly targeted drugs for treating HCC, but most drugs exhibited less efficacy and/or 
higher toxicity compared to sorafenib. Therefore, considering that this ‘specific’ inhibitor could 
target unexpected molecules depending on the biological context [38], defining the mechanisms 
underlying sorafenib resistance of HCC cells is critical for treating HCC by maximizing its 
treatment efficacy, while minimizing adverse effects [39]. 
We found that sorafenib dose-dependently activates the IRE1/XBP1/RIDD and 
PERK/eIF2α/ATF4/CHOP/GADD34 pathways leading to adaptive protein refolding, but 
reduced the GRP78 protein expression. Since IRE1 knockdown increased induction of 
apoptosis by sorafenib in MHCC97-L and PLC/PRF/5 HCC cells [40], we hypothesized that 
IRE1 inhibition could boost the effect of sorafenib. Unexpectedly, a small-molecule inhibitor 
binding the IRE1 RNase domain [41] attenuated the antiproliferative effect of sorafenib in 
HepG2 cells. In our experiments, IRE1 is still present, upregulated and able to mediate the well-
known protein-protein interactions, such as the IRE1-TRAF2 interaction [10]. In addition, the 
IRE1 RNase performs RIDD on specific target transcripts, a pro-apoptotic process 
unexpectedly but significantly activated by the multi-TKI sorafenib [42]. Mechanistically, 
further characterisation of the mRNA targets of sorafenib-activated RIDD in HCC cells could 
offer important insights into its mechanism of action. 
Recently, So et al. (2015) showed that the IRE1/RIDD pathway could mediate the inhibitory 
effects of ER stress on global protein translation by decay of the mRNA of CReP/Ppp1r15b, 
a regulatory subunit of eIF2α phosphatase, which is similar to the PERK-mediated 
GADD34/Ppp1r15a. Therefore, analysis of the effects of sorafenib on this 
IRE1/RIDD/CReP/eIF2α/translation-axis could provide additional information on the 
mechanism of action of sorafenib. 
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Interestingly, GRP78 protein expression, a chaperone protein classically induced during the 
UPR [10], was decreased in sorafenib-treated cells, whereas no major change was observed in 
the protein levels of PDIA4, another chaperone protein. In view of evidence that GRP78 
overexpression confers resistance to sorafenib in HCC cells [43] and that GRP78 plays a 
cytoprotective role in the setting of ER stress [44], these findings raise the possibility that the 
decrease in GRP78 levels contribute to the pro-apoptotic effects of sorafenib and that additional 
blockade of GRP78 induction may enhance the sorafenib-mediated lethality. To elucidate the 
underlying mechanism of the selective decrease in GRP78 protein expression by sorafenib, 
analysis of the protein half-life of GRP78 in the presence of sorafenib is indicated to 
differentiate between decreased production and increased degradation. 
Next, we selected two clinically applicable ER stress inducers: the proteasome inhibitor 
bortezomib and the HIV protease inhibitor nelfinavir [45]. Interestingly, only nelfinavir induces 
an additive effect in combination with sorafenib in HCC, suggesting that the effect of UPR 
activation depends on the used ER stress inducer. By analysis of the effect of proteasome 
inhibition in HCC, we found that the proteasome inhibitor oprozomib did not activate the 
canonical UPR signalling pathway but rather increased the protein levels of UPR proteins by 
reduced proteasomal degradation. This observation could possibly explain the differential 
impact of the used ER stress inducers. Finally, further elucidation of clinical applicable 
pharmacological ER stress inducers is ongoing and a recent study confirmed that several 
commonly used drugs modulate the UPR pathways [46]. Evaluation of the effects of 
combination with these newly identified ER stress inducers is optional. 
Sorafenib also promotes autophagic flux in HCC cells, as shown previously [47]. However, 
combination of sorafenib with these autophagy inhibitors again induces only additive, but no 
synergistic, effects in HCC cells. The role of autophagy in sorafenib resistance was previously 
investigated in other HCC cell lines [48], [49]. These studies indicate that the autophagic 
responsiveness to sorafenib is distinct between Hep3B and Huh7 cells and that resistance of 
Hep3B cells to sorafenib may be associated with altered autophagy signalling pathways. 
Accordingly, in our study we used HepG2 cells, but further research in other HCC cell lines 
could improve our understanding of the exact role of autophagy in sorafenib resistance. 
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Since sorafenib activates the UPR and thereby induces adaptive protein refolding and 
autophagy, we assessed whether triple therapies could improve the antitumour efficacy of 
sorafenib. It was striking that combination of sorafenib with an ER stress inducer and an 
inhibitor of the observed compensatory mechanisms, i.e. adaptive protein refolding or 
autophagy, synergistically potentiated the antitumour efficacy of sorafenib in vitro. Of these 
multiple combinations, we assessed the combination with nelfinavir and clarithromycin in 
different models for HCC, which showed the strongest antiproliferative effects in vitro. Of note, 
nelfinavir and clarithromycin synergized with sorafenib to reduce tumour growth in vivo 
without significant toxicity. 
In the last section of our study, we assessed whether it is possible to omit sorafenib in this 
strategy. Interestingly, the threshold for ER stress-induced cell apoptosis during autophagy 
inhibition in HCC cells is elevated by omission of sorafenib, however, this can be 
counterbalanced by increasing the dose of nelfinavir without increased toxicity given its 
relatively high maximum tolerated dose (MTD) [50]. Further investigations need to determine 
whether daily or cyclic administration of this dual therapy is feasible and sufficient for sustained 
antitumour response, as evidenced for sorafenib [3]. In line with these results, a patent 
application involving the use of ER stress inducers together with autophagy inhibitors in HCC 
with or without sorafenib was filed (P2014/060, Ghent University, in collaboration with 
Bimetra). Prior to clinical evaluation of these combinations, further investigations including the 
determination of the optimal dose and ratio of the involved compounds and the efficacy in 
sorafenib-resistant HepG2 cells [51] is required. 
Rudalska et al. (2014) elegantly identified by in vivo shRNA screening the p38/ATF2 pathway 
as a mechanism of sorafenib resistance in HCC [52]. Investigating the effect of the proposed 
triple therapy modulating the induced UPR/autophagy on this presumed sorafenib-resistance 
pathway may uncover downstream interconnections. For example, oligomerized IRE1 binds 
TNF receptor-associated factor 2 (TRAF2), activating apoptosis signal-regulating kinase 1 
(ASK1) and downstream kinases that activate p38 [10], [53]. Therefore, we speculate that an 
altered IRE1 pathway activation pattern modulates the p38/ATF2 pathway and thereby 
sorafenib resistance. 
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The complex, highly heterogeneous nature of HCC makes it unlikely that targeting only one 
pathway will achieve optimal disease control. Moreover, the efficacy of multi-TKIs including 
sorafenib and the recently tested compounds, such as sunitinib, also appears to be insufficient 
[4] to meaningfully prolong the overall survival of the patients. However, the strategy of 
combining targeted disruption of the cellular protein homeostasis with inhibition of the cellular 
“waste disposal” via autophagy (and/or proteasomal degradation) alone or added to the multi-
TKI could offer new perspectives in HCC therapy. Combined therapy with multiple drugs is a 
common practice in cancer therapy and can achieve better therapeutic effects than a single drug. 
Furthermore, the utility of combining approved drugs by rational drug repositioning may be 
rapidly clinically implemented in patients. Therefore, clinical evaluation of the investigated 
combinations subverting ER stress in HCC cells towards apoptosis is indicated. 
1.5. Therapeutic effects of Artesunate in hepatocellular carcinoma: repurposing 
an ancient antimalarial agent 
The antimalarial Artesunate exerts potent cytotoxic effects on HCC in vitro and in vivo without 
inducing body weight reduction, hepatotoxicity or increased mortality in experimental HCC 
[54]. Furthermore, we found that Artesunate fortified the PERK pathway but did not affect the 
IRE1 pathway. However, the relevance of this effect on the UPR in the cytotoxic effects of 
Artesunate requires further investigation. 
Of note, the antitumour activity of Artesunate was increased under hypoxia and dual therapy 
with Artesunate and sorafenib exerted an additive effect on the microscopic tumour burden and 
further reduced tumour neovascularization compared to sorafenib monotherapy, the current 
standard-of-care [2], without cumulative toxicity. Again, whether the altered UPR signalling is 
involved in the efficacy of this dual therapy remains to be elucidated. 
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Experience in the use of both Artesunate and sorafenib in clinical practice is a considerable 
advantage. However, in contrast to sorafenib, the safety of Artesunate in HCC patients with 
mild impaired liver function is currently unknown. Therefore, we recently initiated the 
DESPARTH trial (NCT02304289; in collaboration with Prof. Dr. L. Van Bortel, clinical 
pharmacology, Ghent University, Belgium and the “Anticancer Fund”), a phase I dose-
escalation trial, to assess the safety and determine the MTD of oral Artesunate in HCC patients 
with mild impaired liver function. This trial is approved and now recruiting. In parallel, the 
effect of DEN-induced liver dysfunction on Artesunate metabolization and pharmacokinetics 
following intragastric administration will be investigated (in collaboration with Prof. Dr. B. De 
Spiegeleer. Lab of Drug Quality & Registration, Ghent University, Belgium). We consider the 
present studies as an important step forward in moving our understanding of Artesunate 
mechanisms into the clinical stage. 
1.6. PlGF inhibition modulates hypoxia and the unfolded protein response in 
hepatocellular carcinoma 
Our group previously showed that the inhibition of PlGF exerts antitumour effects and induces 
vessel normalisation [55]. Our most recent study indicates that PlGF inhibition significantly 
suppresses UPR activation, potentially by tempering hypoxia in HCC and that the UPR, in 
turn, is able to induce PlGF, suggesting the existence of a feedback mechanism of hypoxia-
mediated UPR that stimulates PlGF-mediated angiogenesis. Thus, anti-angiogenic therapies, 
including the blockade of the PlGF pathway that ‘normalise’ the abnormal blood vessels in 
tumours, seem to effectively temper tumour hypoxia and hypoxia-induced adaptation 
processes, such as the UPR, in experimental HCC. However, whether the diminished activation 
of these adaptation processes accounts for the observed reduction in tumour growth remains 
elusive. 
Our present work in HCC models confirmed the excellent safety profile of monoclonal 
antibodies against PlGF. Because previous studies on transgenic mice have revealed that PlGF 
expression is mainly restricted to pathological conditions [56], characterisation of the role of 
ER stress in the selectivity of PlGF expression to pathological angiogenesis, potentially 
characterised by ER stress, is indicated. Finally, the role of the UPR in vessel abnormalisation 
induced by excessive production of angiogenic factors [57] remains to be elucidated. The UPR 
induces angiogenic factors [9], possibly resulting in an excessive production and hence vessel 
abnormalisation. 
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Because we observed that the chemotherapeutic doxorubicin promotes PlGF production and 
that PlGF inhibition leads to hypoxia-reducing vessel normalisation, potentially decreasing 
hypoxia-mediated chemoresistance and improving tumoural drug delivery, we questioned 
whether the inhibition of this angiogenic factor was able to increase the antitumour effect of 
doxorubicin in vivo. However, addition of anti-PlGF to doxorubicin did not alter the weight, 
survival or tumour burden compared to mice treated with doxorubicin and IgG (data not 
shown). Thus, we were not able to detect any improvement, suggesting the inhibition of this 
specific angiogenic factor was insufficient to improve the efficacy of doxorubicin. Possibly, the 
lack of PlGF can be bypassed by increased production of other angiogenic factors or the 
tumoural drug delivery may be still impaired despite the observed vessel normalisation. Further 
investigation is needed to support these hypotheses. 
1.7. Proteasome inhibition and the unfolded protein response in hepatocellular 
carcinoma: an unexpected pathway dysregulation provides an opportunity to 
boost its efficacy 
At its most simple level the ubiquitin-proteasome system (UPS) is composed of an E3 ligases-
mediated tagging factor in the form of ubiquitin which marks unwanted or damaged proteins 
for degradation, and the proteasome, a large molecular shredder that degrades proteins into 
smaller peptides for use in other anabolic processes [58]. The multifaceted role of the UPS 
includes the degradation of misfolded and damaged proteins, cell cycle regulators, oncogene 
and tumour suppressor proteins, as well as the regulation of antigen processing and control of 
transcription factor activity [59]. 
The next-generation orally bio-available irreversible proteasome inhibitor oprozomib (OZ) is 
assumed to have less adverse events and improved antitumour activity compared to the first-in-
class proteasome inhibitor bortezomib [60]. Recently, OZ was shown to exert antitumour 
activity on myeloma and head and neck cancer xenograft models [60]. Our study showed for 
the first time that OZ exerted potent anti-tumour effects in vitro and in different in vivo models 
for HCC, supporting the therapeutic potential of irreversibly targeting the proteasome. 
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Theoretically, decreased protein degradation by proteasome inhibition could lead to oxidative 
stress and UPR activation. However, the mechanism of action and links with the UPR pathways 
are not well understood. We showed that the cytotoxic effect of OZ depends on the build-up of 
proteotoxic stress without an important contribution of oxidative stress. Although OZ did not 
induce the transcriptional UPR program and even inhibited the protease-dependent activation 
of the cytoprotective ATF6 pathway, OZ elevated the protein levels of different UPR markers. 
Notably, OZ increased the protein stability of the pro-apoptotic transcription factor CHOP. 
Thus, decreased proteasomal degradation of pro-apoptotic UPR proteins leads to elevated 
levels of these proteins rather than a general UPR activation by increased unfolded protein load 
in the ER. Apparently, rapid proteasomal degradation of UPR proteins is a pivotal negative 
feedback mechanism following recovery of the ER protein homeostasis.  
Identification of the specific components of the UPS regulating degradation of these UPR 
proteins is indicated. Therefore, we initiated a research project investigating the role of 
deubiquitinases (DUBs) in the regulation of the UPR and autophagic flux in HCC. DUBs are 
components of the UPS that catalyse the removal of ubiquitin moieties from target proteins or 
polyubiquitin chains, resulting in altered signalling or changes in protein stability. Analysis of 
the human genome shows the presence of ~80 functional DUBs [61]. A number of DUBs 
regulate processes associated with cell proliferation and apoptosis, and as such represent 
candidate targets for cancer therapeutics [62]. Interestingly, the majority of DUBs are cysteine 
proteases and are more "druggable" compared to the E3 ligases. 
Intriguingly, addition of ER stress inducers nelfinavir or salubrinal enhanced the growth-
inhibitory effects of OZ in both models without cumulative toxicity, suggesting that this rational 
combination could represent a safe strategy to potentiate the antitumour effect of proteasome 
inhibition in HCC. Finally, assessment of the role of autophagy in OZ effect and of the effect 
and toxicity of a triple strategy consisting of oprozomib, an autophagy inhibitor (i.e. 
clarithromycin) and an ER stress inducer (i.e. nelfinavir), a concept that may retain the unfolded 
proteins in the ER by blocking the major degradation pathways while inducing additional ER 
stress, provides great opportunities for future research. 
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Of note, human HCC, in contrast to the unaffected adjacent liver tissue, is characterized by 
extensive CHOP staining and, assuming the cellular threshold for CHOP-induced apoptosis is 
similar in hepatocytes and HCC cells, CHOP-promoting therapy could selectively drive the 
HCC cells toward apoptosis [63]. Because ER stress potentiates the antitumour efficacy of OZ, 
we assume a stronger effect on the hypoxic ER-stressed tumour cells compared to normal liver 
tissue. Consequently, we speculate that OZ could be more efficacious in combination with 
antiangiogenic treatments, presumably increasing tumour hypoxia-induced UPR [9], [10], 
[25]. 
In conclusion, modulation of the interplay between OZ and the UPR enhances the antitumour 
efficacy of OZ in vitro and in experimental HCC models without cumulative toxicity. 
Therefore, OZ monotherapy or in combination with UPR modulators may represent a novel and 
clinically applicable therapeutic strategy for advanced HCC. 
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2. General conclusions 
Although extensive HCC research is in progress, to this date, the results are unsatisfactory with 
limited long-term survival. In the fight against this lethal disease, there is still a long way to go. 
New therapeutic tools need to be not only therapeutically effective but also tolerable and 
economically within the reach of the neediest people. The potential impact of the UPR in many 
human diseases makes UPR signalling a promising target for therapeutic intervention. In this 
thesis, the role and translational potential of the UPR in HCC biology were explored. 
The UPR protects cells against defects in protein folding in the ER. Because many mechanisms 
come into play, the cell carefully balances various means at its disposal to protect against 
proteotoxicity while also providing adequate protein synthesis to sustain cellular fitness. 
Tumour cells continuously divide and grow under oncogenic stress caused by hypoxia, nutrient 
deprivation, metabolic stress and oxidative stress, leading to UPR activation as a central cellular 
adaptation strategy. The role of the UPR in malignancy has inspired great interest in exploring 
the therapeutic potential of targeting UPR components. Because most normal cells are not 
subjected to stress and the UPR pathways remain inactive in these cells, this difference between 
tumour and normal cells might offer the advantage of achieving specificity in cancer therapy 
by UPR targeting. If tumour cells are exposed to another form of ER stress in addition to the 
pre-existent ER stress, the intensity of ER stress might exceed a threshold, thereby inducing 
cell death specifically in tumour cells. Therefore, it is of considerable importance to understand 
the impact and dynamics of the UPR in HCC. 
As a general conclusion, this thesis provides evidence that the UPR plays a pivotal role in the 
multistep process of hepatocarcinogenesis. Furthermore, this work indicates that modulation of 
the UPR could potentially be applied as an innovative strategy against HCC initiation and 
progression and as a method to enhance the efficacy of certain drugs acting on these adaptive 
signalling pathways. Based on the novel concepts discussed here, the future challenge is to 
integrate our understanding of how the UPR regulates distinct aspects of cancer biology as a 
global network integrating the different cellular stress responses. Although the obtained results 
hold great potential, several questions remain and require further fundamental and clinical 
research in the near future. 
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Belgium. Oral presentation 
 
 Yves-Paul Vandewynckel, Debby Laukens, Lindsey Devisscher, Annelies Paridaens, 
Eliene Bogaerts, Xavier Verhelst, Anja Van den Bussche, Sarah Raevens, Christophe Van 
Steenkiste, Marleen Van Troys, Christophe Ampe, Benedicte Descamps, Chris Vanhove, 
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Oral presentation 
 
 Yves-Paul Vandewynckel. Young BASL Forum. introduction as Young BASL President. 
27th Belgian Week of Gastroenterology, 25/02/2015, Brussels, Belgium. Oral presentation 
 
 Yves-Paul Vandewynckel, Debby Laukens, Lindsey Devisscher, Annelies Paridaens, 
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International Liver Congress of EASL, 24/04/2013, Amsterdam, The Netherlands. Poster 
presentation 
 
 Yves-Paul Vandewynckel, Debby Laukens, Eliene Bogaerts, Annelies Paridaens, Anja Van 
den Bussche, Xavier Verhelst, Christophe Van Steenkiste, Benedicte Descamps, Chris 
Vanhove, Louis Libbrecht, Riet De Rycke, Bart N. Lambrecht, Anja Geerts, Sophie 
Janssens, Hans Van Vlierberghe. The unfolded protein response in HCC. EASL 
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chemoresistance through PlGF inhibition in a mouse model of hepatocellular carcinoma. 
Interuniversity ER stress conference Ghent University/VIB, 10/09/2012, Ghent, Belgium. 
Oral presentation 
 
 Awards and patents 
 22/04/2015: EASL Vienna, Austria: “Top 10% abstract” award for “TUDCA dampens 
oncogenic apoptosis induced by endoplasmic reticulum stress during hepatocarcinogen 
exposure”. 
 10/03/2015: Patent application: invention of a novel treatment option for HCC. 
 27/02/2015: “Belgian Week of Gastroenterology (BWGE) Research Grant” based on 
evaluation by external referees of previous work, CV and research project proposal 
(TUDCA in HCC). 
 14/10/2013: “National Award” for best Belgian UEG abstract 2013 of the “United 
European Gastroenterology” (UEG) week in Berlin, Germany. 
 30/05/2005: Finalist international "Flemish Biology Olympiad". 
 
 Research skills 
 qRT-PCR 
 Western blotting, IHC and ELISA 
 Cell culture techniques 
 Cell viability and proliferation assays and colony formation assays 
 Mouse models for HCC and cirrhosis 
 Clinical trial design 
 
 Reviewer for journals 
Reviewed manuscripts for the following international scientific journals: 
 20/05/2015:  Journal of Hepatology (IF: 10.4) 
 13/04/2015: Apoptosis (IF: 3.6) 
 16/03/2015: World Journal of Gastroenterology (IF: 2.4) 
 02/05/2013:  Carcinogenesis (IF: 5.7) 
 01/02/2014:  European Journal of Gastroenterology and Hepatology (IF: 2.2) 
 
 Participation in popular media 
 10/11/2014: Interview regarding the foundation of Young BASL in “Artsenkrant” 
 
 Active memberships 
 EASL: European association for the study of the liver 
 AASLD: American association for the study of liver diseases 
 ECCO: European cancer organisation 
 VVGE: Vlaamse vereniging van Gastro-enterologie 
 Jong-VVGE: Jong Vlaamse vereniging van Gastro-enterologie 
 BASL: Belgian association for the study of liver diseases 
 Young BASL: Young Belgian association for the study of liver diseases (President: 2014- 
up till now) 
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